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PROGNOSIS IN CHILDREN WITH OTITIS MEDIA WITH EFFUSION 
 
Joshua Titmus, M.S. 
University of Pittsburgh, 2007
 
 
The public health significance of this study is to provide researchers and clinicians interested in 
the study and treatment of Otitis Media with effusion (OME) with a better understanding of the 
associations between covariates and antibiotic treatment with the resolution of OME, which in 
turn will inform the decision-to-treat process.  In a secondary analysis of the data from a series of 
three efficacy trials, we focus on the roles of laterality (unilateral vs. bilateral disease) and 
sidedness (right vs. left ear) as prognostic factors.  The D&A trial compared the efficacy of 
decongestant and antihistamine (D/A) to placebo, the ABI trial was similar but compared 
amoxicillin (with and without to D/A) to placebo, and the ABII trial compared the efficacy of 2 
promising antibiotics to amoxicillin.  Each trial assessed subjects for OME at baseline, 2 weeks, 
and 4 weeks. 
The prevalence of OME at each time point was described by laterality and sidedness.  
McNemar’s test showed no evidence that left and right ears differ with respect to prevalence 
rates at 2 or 4 weeks (OR = 1.106 and OR = 0.858, respectively).  Transition matrices of changes 
in OME status from 0 to 2 weeks and 2 to 4 weeks described the dependence of prior effusion 
status on a subject’s current OME status.  Multinomial regression was used to assess baseline 
covariates associated with prevalence and transitions of effusion status at each time point.  We 
identified statistically significant prognostic factors of OME, including duration of effusion.  Our 
analyses showed no differences in either prevalence of OME or in transitions of effusion status 
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attributable to sidedness.  A Chi Square Goodness-of-Fit test at each timepoint rejected the 
hypothesis of independence, p < 0.001.  An ear-level GEE analysis demonstrated that effusion 
status of a contralateral ear was a significant predictor of effusion in the other ear (OR = 1.44, p 
< 0.001).  There was no significant effect of sidedness (p = 0.86) and bilateral disease does not 
resolve at the rate predicted by unilateral resolution.  This reanalysis using correlated data 
methods augments the initial findings by further examining sidedness and documenting 
transitions over time. 
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1.0  INTRODUCTION 
Otitis media (OM) is one of the most common childhood infections, the second most common 
diagnosis made by pediatricians at sick patient visits, and the leading cause of physician visits by 
children; costs in the United States alone are estimated to be 3 to 5 billion dollars annually 
(Rovers, 2004).  In light of the fact that antibiotics and surgery have only moderate efficacy for 
OM and because antibiotics present an associated risk that may outweigh the potential benefit, 
management of OM, in general, remains controversial (Glasziou, 2002).   
Otitis media with effusion (OME) is particularly difficult in terms of the questions 
regarding the decision to treat because it represents a stage of OM that is different than acute 
otitis media (AOM), one absent the signs, symptoms, and some of the associated threats of an 
acute infection (Daly, 1999).  OME also is characterized by a high rate of spontaneous recovery.  
Because of increasing antibiotic resistance and the call for judicious use of antibiotics, antibiotics 
are not recommended for routine treatment of OME.  In actuality only the most severe 
manifestations of OME need to be treated. However, due to the convoluted nature of the disease, 
prediction of the onset and resolution of the disease have proven difficult over the years.  Despite 
the general interest of the scientific community and advances in all areas of the study of OM, 
evidenced by the increasing number of publications listed on PubMed (from 250 in 1967 to 740 
in 2005), much of the disease’s etiology and pathogenesis remains uncertain (Rovers, 2004).  An 
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investigation of the influence of specific covariates may contribute to a better overall 
understanding of OME, which, in turn, could inform the decision-making process.   
1.1 REVIEW OF LITERATURE 
1.1.1 The Nature of OME 
OM is a multi-factorial disease that has stages of severity and variant viral and bacteriological 
intensity over time (Tran, 2005).  Due to the absence of many of the more obvious symptoms of 
AOM, which make it easier to define clearly and observe an outcome of interest, future 
investigations into OME may need to take better care to account of the stages of disease, its 
clinical course, and, most importantly for our purposes, the context under which the various 
manifestations occur, i.e. the variables that relate to a particular expression of the disease and 
that may influence outcome.  
1.1.2 Prognostic Factors and OME 
Several covariates have been found to be statistically significant predictors of outcome in 
efficacy trials of pharmacological treatments for OME.  Mandel et al., over the course of the 
three studies that provide the data for the present investigation, showed varying degrees of 
efficacy of the treatments under study.  Laterality of OME (unilateral versus bilateral) was the 
most significant predictor of resolution of effusion, with bilateral cases taking longer to resolve. 
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1.1.3 Laterality 
Because laterality of disease is commonly acknowledged to be related to disease severity, it is 
one of the most important prognostic variables to consider in the diagnosis and proper 
management of OME.  Bilaterality, in particular, has been reported to be one of the most 
important risk factors in chronic OME and has been understood to reflect a “more difficult 
disease process than a unilateral one” (Jero, 1997a).  Some clinical investigators believe that 
bilateral and unilateral cases of OME represent different manifestations of the disease, i.e. 
whether the disease is systemic, or, contrarily, whether specific local factors of individual ears, 
such as Eustacian tube dysfunction, contribute independently to the development of the condition 
in a child (van Heerbeek, 2003).  By contrast, even if a bilateral ear were the same, biologically, 
as a unilateral ear and had the same probability of becoming effusion-free, we would expect a 
child with bilateral disease to have a lesser chance of becoming effusion-free in a specified time 
interval simply because there are two affected ears.  Laterality is a controversial topic in the 
study of OME.  
1.2 DESCRIPTION OF THE ORIGINAL STUDIES 
The data are taken from a series of efficacy studies conducted at the Children’s Hospital of 
Pittsburgh between July 1, 1978 and December 31, 1987.  Infants and children from seven 
months to 12 years of age with suspected OME were referred to the studies from the ambulatory 
care center of the hospital and from private practices throughout the surrounding community.  
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1.2.1 Decongestant and Antihistamine (D & A) Trial (Cantekin et al., 1983) 
Six hundred eleven children were enrolled in the study, which took place between July 1, 1978 
and June 30, 1981.  Five hundred fifty-three children (91%) completed the study.  Of the 553 
subjects. 393 (71%) had bilateral OME at entry; the remaining 160 (29%) had unilateral disease 
(10 of these 160 had to be excluded at the 4-week follow-up because one ear could not be 
checked satisfactorily).  The investigators compared the efficacy of a 4-week course of an oral 
decongestant-antihistamine (D/A) combination with that of a placebo.  
Children were evaluated at 2 weeks and again at 4 weeks for the presence or absence of 
middle-ear effusion (MEE).  MEE is commonly the endpoint of interest in studies of OME, since 
its presence is often associated with the inflammation of the middle ear indicative of the disease. 
 The study concluded that the standard D/A treatment was not efficacious relative to 
placebo.  The p-values were 0.74 for subjects with unilateral disease at entry and 0.67 for 
subjects who had bilateral disease at entry.  When treatment and placebo groups were compared 
in regard to the proportions who had bilateral, unilateral, or no effusion at the 4-week endpoint, 
no statistically significant difference was observed for either the unilateral or bilateral groups (p 
= 0.51 and p = 0.38, respectively).  Comparisons made within each treatment group showed that 
those children who had unilateral effusion at entry were twice as likely to become effusion-free 
as those who had entered with bilateral effusion (30 of 80 [37.5%] compared to 36 of 195 
[18.5%] for the placebo group and 27 of 80 [33.8%] compared to 41 of 198 [10.3%] for the D/A 
treatment group; p <0.001) and those children who had had bilateral effusion at entry were three 
times as likely to have experienced bilateral effusion at 4 weeks (32 of 160 [20%] compared to 
247 of 393 [62.9%] unilateral children).  
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Subject characteristics such as age, previous use of antimicrobials, duration of effusion, 
sex, race, socioeconomic status, season at entry, upper-respiratory-tract infection, history of 
middle-ear disease, diagnosed allergy, and adenoid size were balanced over all treatment groups.  
None of these variables appeared to diminish the efficacy of the drug relative to that of the 
placebo.  No interactions between treatments and the stratification variables (age, previous use of 
antimicrobials, and duration of effusion) were identified when the data were analyzed using 
logistic regression.  In addition to laterality, duration of effusion and prior history of OM 
appeared to be related to effusion at the 4-week timepoint (p < 0.05), as did a time-dependent 
covariate, upper-respiratory-tract infection (p < 0.01).  Of the subjects with unilateral disease at 
entry, the proportion who were effusion-free at 4 weeks was twice that of subjects who had had 
bilateral disease at entry (57 of 160 [35.6%] and 77 of 393 [19.6%]).   
1.2.2 Antibiotic (AB) I Trial (Mandel et al., 1987) 
Five hundred eighteen children with OME, of whom 148 were unilateral and 326 were bilateral, 
were enrolled in the study between July 1, 1981 and October 30, 1984.  The investigators 
compared the efficacy of a 2-week course of amoxicillin, with and without a 4-week course of an 
oral D/A combination, with that of placebo (two separate placebo groups, one for antibiotic and 
one for D/A). 
Children were evaluated at 2-week and 4-week endpoints for the presence or absence of 
MEE.  Of the 488 children who entered the study, 94% were evaluated at the 2-week timepoint, 
4-week timepoint, or both.  The rate of resolution of MEE of the 474 children who were 
observed at the 4-week endpoint was twice as high in those treated with amoxicillin, either with 
or without the D/A, compared to those who received the placebo (50 of 158 [31.7%] in 
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amoxicillin and D/A; 46 of 160 [28.8%] in amoxicillin/placebo; and 22 of 156 [14.1%] in 
placebo/placebo, p < 0.001).  Outcomes were consistently better in children who received 
amoxicillin.  The investigators concluded that amoxicillin treatment increased the likelihood of 
resolution of MEE to some extent.  
Subject characteristics such as age, previous use of antimicrobials, duration of effusion at 
entry, sex, race, laterality of MEE, season at entry, upper-respiratory-tract infection, history of 
middle-ear disease, allergy diagnosed, and socioeconomic status appeared balanced over the 
treatment groups.  No statistically significant interaction between the treatment and any of these 
variables was identified using logistic regression methods.  Among both the amoxicillin-treated 
subjects and placebo-treated subjects, resolution was more likely in those who entered the study 
with unilateral effusion, those who had had effusion for eight weeks or less, and those without an 
upper-respiratory-tract infection at the 4-week timepoint.  As in the D & A trial, laterality of 
disease was the strongest prognostic variable (p < 0.001).  Subjects with unilateral effusion at 
entry were nearly twice as likely to have no effusion at 4 weeks as those who had entered the 
study with bilateral effusion.   
1.2.3 AB II Trial (Mandel et al., 1991) 
Three hundred thirty-one children were enrolled in the study, of whom 85 (26%) were unilateral 
and 246 (74%) were bilateral, between July 1, 1984 and December 31, 1987.  Three hundred 
fourteen (95%) children were evaluated at the 2-week timepoint and 310 (94%) were evaluated 
at the 4-week timepoint.  The investigators were interested in whether either erythromycin-
sulfisoxazole (E-S) or cefaclor, both “second-line” antibiotics, would have greater short-term 
efficacy than that found for amoxicillin in the original AB trial. 
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The trial was terminated early due to an interim analysis conducted after half of the 
estimated number of children required for the trial had reached both the 2-week and 4-week 
timepoints.  At that time, the two treatments hypothesized to be more efficacious than 
amoxicillin were actually less so, as indicated by the study’s primary outcome measure of the 
proportions of children who were effusion-free at the 2-week and 4-week endpoints.  It was 
determined that the likelihood of detecting “true” differences between the treatments in the 
direction hypothesized a priori was not sufficient to continue subject accrual.  Though not the 
original intent of the trial, the researchers regarded the results of the amoxicillin versus placebo 
comparisons of the present study a valuable continuation of the data gathered in the previous AB 
trial.  Amoxicillin continued to show promise in terms of its efficacy relative to placebo. 
Subject characteristics such as age, sex, race, previous middle-ear disease, laterality, 
duration of effusion, speech-recognition threshold (SRT) in worse ear, season at entry, upper-
respiratory-tract infection, allergy diagnosed, parent with history of ear disease, and occupation 
of primary wage earner were included in logistic models to ascertain their association with 
prognosis and whether statistical interaction with treatment was evident.  In no case were the 
results of the analysis of primary endpoints of the trial substantially altered by adjustment for any 
of these variables.  The percentages of subjects who were effusion-free at both the 2-week and 4-
week timepoints were lower in children with bilateral effusion, in those with SRT greater than or 
equal to 25 dB HL in at least one ear at entry (compared to those who had SRT < 25 dB HL 
bilaterally), and in females.  Interaction between sex and SRT may explain the poorer outcome in 
females.   
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Table 1 summarizes the number of evaluated subjects at baseline, 2 weeks, and 4 weeks 
by study, laterality, and treatment group in these three trials.  In most subgroups, at least 90% of 
the subjects were followed at the 2 week and 4 week timepoints. 
Table 1. Number of Subjects by Study, Laterality, and Treatment 
Study Treatment Laterality of 
OME at entry 
Baseline 2 Week Observed 4 Week Observed 
N % N % 
D & A 
 
 
 
 
 
Placebo 
(N=302) 
Unilateral R 40 36 90 38 95
Unilateral L 43 39 91 39 91
Bilateral 219 202 92 197 90
D&A 
(N=306) 
Unilateral R 39 36 92 35 90
Unilateral L 52 45 87 43 83
Bilateral 215 206 96 199 93
AB I 
 
 
 
 
 
 
 
 
Amoxicillin 
(N=167) 
Unilateral R 26 24 92 24 92
Unilateral L 31 29 94 29 94
Bilateral 110 104 95 106 96
Placebo 
(N=169) 
Unilateral R 23 22 96 22 96
Unilateral L 19 17 89 18 95
Bilateral 127 111 87 113 89
Amox / 
D&A 
(N=174) 
Unilateral R 30 25 83 24 80
Unilateral L 27 24 89 24 89
Bilateral 117 110 94 107 91
AB II 
 
 
 
 
 
 
 
 
 
 
 
Amoxicillin 
(N=82) 
Unilateral R 8 7 88 7 88
Unilateral L 12 11 92 10 83
Bilateral 62 60 97 59 95
Placebo 
(N=81) 
Unilateral R 12 12 100 11 92
Unilateral L 8 8 100 8 100
Bilateral 61 58 95 56 92
      E-S 
(N=84) 
Unilateral R 14 12 86 11 79
Unilateral L 9 8 89 8 89
Bilateral 61 60 98 61 100
Cefaclor 
(N=83) 
Unilateral R 10 9 90 10 100
Unilateral L 11 9 82 9 82
Bilateral 62 59 95 59 95
1.3 STUDY DESIGNS 
All studies were approved by the Human Rights Committee of the Children’s Hospital of 
Pittsburgh and written informed consent was obtained for all subjects.  In each of these three 
studies, a careful preliminary examination, which included a standardized history for each 
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subject and the findings of a standardized ear, nose, and throat examination, including a detailed 
description of observations on pneumatic otoscopy, was conducted after subjects met specific 
eligibility requirements.  Subjects were deemed ineligible if they had any of the following: 
D & A Trial: congenital craniofacial malformations; Down’s syndrome; systemic 
illnesses such as asthma, cystic fibrosis, or diabetes mellitus; a history of tonsillectomy, 
adenoidectomy, or tympanostomy-tube insertion; a structural middle-ear abnormality such as 
tympanic-membrane perforation or adhesive OM; a sensorineural hearing loss or a conductive 
loss not attributable to the middle-ear effusion; severe upper-airway obstruction; acute 
suppurative otitis media; purulent rhinitis; acute or chronic sinusitis: or a history of having 
received sympathomimetic amines or antihistamines during the preceding 30 days. 
AB I Trial: same as the D & A trial but also history of hypersensitivity to any form of 
penicillin. 
AB II Trial: same as the AB I trial but also hypersensitivity to erythromycin, 
sulfonamides or cephalosporins. 
Subjects who met the selection criteria were stratified according to age (7 to 23 months, 2 
to 5 years, or 6 to 12 years), duration of effusion (less than 4 weeks, 4 to 8 weeks, or more than 8 
weeks), and whether or not an antimicrobial drug had been used for OM in the preceding 60 days 
in the D & A Trial; according to age (7 to 23 months, 2 to 5 years, or 6 to 12 years), duration of 
effusion (less than 4 weeks, 4 to 8 weeks, or more than 8 weeks), and whether an antimicrobial 
drug had been administered during the preceding two months for the OM present at entry in the 
AB I Trial; and according to duration of MEE (less than 4 weeks, 4 to 8 weeks, or more than 8 
weeks) and laterality of MEE (unilateral or bilateral) in the AB II Trial.  Subjects were then 
randomly assigned to treatment groups (D/A or Placebo in the D & A trial; Amoxicillin/Placebo, 
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Amoxicillin/D/A, or Placebo/Placebo in the AB I trial; and Erythromycin-Sulfisoxazole, 
Cefaclor, Amoxicillin, or Placebo in the AB II trial).  Antibiotic or its placebo was administered 
for 2 weeks; D/A or its placebo was administered for 4 weeks.  All subjects were to be followed 
over a 4-week period, which consisted of two follow-up visits (one at the end of 2 weeks and the 
other at the end of 4 weeks).  All medication was dispensed in a double-blind fashion and all 
observations at follow-up visits were made by blinded observers.  The primary outcome measure 
in each trial was the prevalence of MEE, as determined by an algorithm combining otoscopy and 
tympanometry, 2 and 4 weeks after entry. 
1.4 OBJECTIVES 
We postulate that covariates, laterality in particular, have a strong association with outcome 
based upon the literature and the results of the original series of efficacy trials.  Specifically, 
these analyses address the question whether the bilateral condition is simply a more intense case 
of unilateral disease or, alternatively, whether bilateral disease represents a novel condition to 
each ear of the individual child (Johnson, 1997).  If the latter case is true, it is possible that the 
ears of the individual are biologically different and provide varying environments within which 
OME is allowed to thrive to greater or lesser degrees.  To address these and other related 
questions, the following aims shall be addressed: 
(1) a)  Assess whether the prevalence of effusion is similar in right ears and left ears at each 
time point, and b) the extent to which prevalence in right ears and left ears is associated 
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with other baseline covariates such as age, duration of effusion, treatment arm and 
gender.   
(2) a)  Describe the transitions in laterality status of effusion at 2 weeks and 4 weeks, and b) 
assess the extent to which the transitions in effusion status are associated with other 
baseline covariates such as age, duration of effusion, treatment arm and gender.   
(3) Assess whether the outcomes of left ears and right ears are independent by analyzing the 
responses of contralateral ears at each timepoint. 
 
We expect that these analyses will demonstrate that laterality is a risk factor, confirming 
the findings of many previous studies.  However, our question of interest, one we believe has not 
been asked before, is whether a bilateral ear represents a tougher disease.  By “tougher disease,” 
we mean that bilateral disease may represent an increased influence, or more complex 
interaction, of local factors not observed in the unilateral condition.  The novel aspect of this 
investigation is to gain insight as to whether this occurrence relates simply to the fact that there 
are two ears that must be “cured” before the child is considered effusion-free or whether there 
are biological differences between bilaterally and unilaterally involved ears. 
2.0  LITERATURE REVIEW OF STATISTICAL METHODS 
2.1 CORRELATED DATA   
The original studies were randomized, double-blinded, and placebo-controlled efficacy trials 
involving infants and children ages seven months to 12 years who had OME.  The trials 
measured the association between treatment and outcome using odds ratios, and by comparing 
the proportions of subjects without effusion at each timepoint using chi square statistics.  Subject 
characteristics that could influence outcome, such as age, race, sex, laterality, duration of 
effusion and season of the year, were balanced over treatment groups and were tested for their 
association with outcome using logistic regression.  In order to investigate higher-order 
interactions and to control for confounders, analyses of children at 2 and 4 weeks also were  
conducted using logistic regression. 
One shortcoming of the original trials was that both the longitudinal nature of the data 
and correlation between ears was not addressed in the analysis.  It is reasonable to assume that 
the repeated measures of individual subjects are likely to be correlated and, thus, in this 
investigation we will account for the correlation in the data from baseline over the time points of 
2 and 4 weeks.  One option would be to use generalized estimating equations (GEEs) at the 
subject level; however, due to two levels of correlation, one between ears of the individual 
subject and the other between time points, the correlation matrix structure is difficult to define.  
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We will define a composite outcome variable and use transition matrices to describe the data, 
and model the transition probabilities in left and right ears in subjects with unilateral or bilateral 
manifestations of disease at entry.   
2.2 TRANSITION MODELS 
Transitional models can be used to model a discrete-time stochastic process. If there are 
countable states, at each time point the system may have changed states from the previous time 
point or the system may have stayed in the same state. The changes of state are called transitions. 
For example, if a state set includes (No Effusion, Unilateral Right, Unilateral Left, Bilateral or 
Missing), a child may be a bilateral case at baseline and change into a unilateral right case at 2 
weeks. Let be the state of ith subject at time t (t = 0, 2 and 4 weeks) and  
be the complete observation vector of the ith subject. The process  is a Markov chain if given 
the present state, the future and past states are independent. Formally, 
itY )',,,( 21 iniii YYY K=Y
iY
)|(),,|( )1(1)1( ittiiitti YyYPYYyYP === ++ K  
A Markov chain of order q where q is finite satisfies 
),,|(),,|( )()1(1)1( qtiittiiitti YYyYPYYyYP −++ === KK  
Denote as a vector of covariates for the ith subject at time t and β as the associated 
vector of regression coefficients. Let the set of states be . Define 
, the history of ith subject at visit t. The 
itX
),2(ti −
},,{ 0 Kaaa ,1 K
),,,,,( )(),2()1()()1( qtititiqtitiit XXXYYY −−−−−= KKH
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conditional transition probabilities ),,|( )()1( qtitikit YYaYP −−= K
')|
1
q
l
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=
+== θβ
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are parameterized by the time 
series model proposed by Zeger and Qaqish (1988), 
)(( log itlfP H  , 
where  are functions of the past q outcomes and θl is the coefficient corresponding to . A 
special case would be when 
lf lf
itlf =)(H  and the model is the time series of order q, 
∑
=
+==
q
l
ititkit aY
1
')|( βXH
')|( 
−ltil yP )( log θ . 
Additionally, when q=1, this model reduces to the first-order Markov model 
)1(log −+== ititkit aYP θβXH
itY
)|( )1( mYlY tiit
tiy . 
Namely, the log of the probability of current state  is a linear function of covariate and the 
previous state . Denote 
itX
)1( −tiY PPlm === −
∑ ∑
= =
⎢⎣
⎡ +=
1 2
11 (log)
i t
lmi tPPYnY
. The likelihood  
== ⎥⎦
⎤− )()(
1
)1(),,,( mYIlYI ittiL 2YY K  
will be maximized to obtain the estimates of the βs and θs.  
2.3 MULTINOMIAL REGRESSION 
Multinomial regression of a K-level outcome can be considered as simultaneously estimating (K-
1) generalized binary logits for chosen comparison groups. Other comparisons can be computed 
from the current model.  For example, with five nominal outcomes {Unilateral Right, Unilateral 
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Left, Bilateral, No Effusion, Missing}, if “No Effusion” is chosen as the baseline level, the 
model will be constructed based on 
,
)|Effusion NoPr(
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)|BilateralPr(log
)|Effusion NoPr(
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where β0 is the intercept and β1 is the slope.   For each equation there is a unique intercept and 
slope.  The comparison between other levels is a linear combination of the above formula, for 
example 
x
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In STATA, this model is implemented by the function mlogit. 
2.4 GENERALIZED ESTIMATING EQUATIONS 
The GEE approach was introduced by Liang and Zeger (Liang and Zeger, 1986). It allows 
regression modeling of longitudinal data by specifying only the mean and variance of the 
outcome variables and a “working” correlation structure.  GEE is defined as the solution of the 
estimating equation 
{ } ,0);();(
1
1 =−∑
=
−n
i
icd μYαXβX iii  
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where Xi is the vector of independent variables for subject i , µi=h(Xiβ) is the estimated mean of 
observation Yi, and h is a link function. The T×T matrix c(Xi; α) is the “working” parametric 
model for the covariance matrix var(Yi|Xi). It is chosen by the investigator. The p × T matrix 
d(Xi; β) is a fixed function of  Xi and β with { }ββXβ Xi; ∂∂=) /);(d( ih .  
The important feature of GEE is that under mild regularity conditions, GEE has a 
solution that is consistent for estimating β and asymptotically normal, regardless of the 
misspecification of the working correlation matrix. A robust sandwich-type estimator can be 
adopted to obtain a consistent estimate of the variance even when the working correlation matrix 
is mis-specified (Huber, 1967; White, 1982). 
ˆ
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3.0  METHODS 
3.1 DATA STRUCTURE 
These data provide information on laterality at each time point as well as the effusion status of 
individual ears of the subject.  A subject-level predictor is unilateral or bilateral status.  Using the 
information on individual ears, the unilateral group can be split into left and right categories to 
assess differences in prevalence related to sidedness.  A new variable, category of effusion, will 
be created to assess whether left ears and right ears in unilateral left, unilateral right, and bilateral 
ears behave differently over time.  
The data are in “wide” format and will need to be converted into “long” form to assess 
the transition probabilities of effusion at 2 weeks and 4 weeks used to address objective 2).  The 
first 4 records will be checked to make sure that the data were restructured correctly and all 
variables involved in the conversion are properly displayed.  In addition to unilateral-right ears, 
unilateral-left ears and bilateral ears, missing observations at the ear-level and ears that become 
effusion-free at 2 weeks can be tracked over time.  Category of effusion will be a 5-level 
variable.  The previous category of effusion (lag1) will link present effusion status with prior 
effusion status from 0 to 2 weeks and 2 to 4 weeks. 
To address aim 3) the data will be kept in long form.  At each timepoint 2 records will be 
created, one for each ear.  For example, subject 1 at baseline has separate records for the left and 
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right ears.  A variable denoting the effusion status of each contralateral ear also is created.  Data 
will be sorted by subject, time point, and ear.    For a record of left-ear status, contralateral ear 
status is defined as the status of the right ear in the same subject at a specified time.  Likewise, 
for a record of right-ear status, contralateral ear status is defined as the status of the left ear in the 
same subject at a specified time.   
3.2 DATA INVESTIGATION AND CODE CHECKING 
Measures to ensure data security and to verify code include basic checks of whether the numbers 
of subjects in each trial match those used for the original analyses.  Replications of a few of the 
findings of the original trials, particularly those related to effusion status at each time point, will 
provide reassurance that further analyses are based on accurate data.  Counts will be tabulated to 
assess whether the distributions of individual variables were similar for each of the 3 original 
trials.  Frequency tables will be created for baseline demographics and prognostic factors by 
study.  The frequency of the outcome of subject-level effusion at each time point, by study and 
treatment, will be checked against the results of the original studies.  Redundant variables will be 
removed. 
Variable xoccup will be created to reduce the original 8-level parental occupation 
variable to only 4 levels: combining executive, small business and skilled occupations into one 
group; clerical and semiskilled occupations into a second group; welfare, unemployed, or other 
occupations into a third group; and unknown occupations into the fourth group.  Treatment 
effects across the 3 trials will be compared to determine whether some treatments can be 
combined.  The variable subject effusion, denoted sbjom, refers to a subject who has OME, 
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coded as 1 when subject has effusion in at least one ear, or coded as 0 when the subject does not 
have effusion at all, at a specified timepoint.  The laterality the disease is not indicated by the 
variable sbjom.  The variables ome1r1, ome1l1, and so forth do not specify laterality of disease; 
instead, each specifies the condition of an ear at a specified timepoint.  The variables to be 
included in this analysis are defined in Table 2. 
Table 2. List of Variables 
variable 
name 
storage 
type 
display 
format variable label 
durgrp byte %8.0g Duration of OME at entry 
season byte %8.0g Season at entry 
ome1r1 byte %11.0g OME (R ear) at entry visit 
ome1l1 byte %11.0g OME (L ear) at entry visit 
sbjom11 byte %11.0g OME (subject) entry visit 
ome1r2 byte %11.0g OME (R ear) at 2 wk visit 
ome1l2 byte %11.0g OME (L ear) at 2 wk visit 
sbjom12 byte %11.0g OME (subject) at 2 wk visit 
ome1r4 byte %11.0g OME (R ear) at 4 wk visit 
ome1l4 byte %11.0g OME (L ear) at 4 wk visit 
sbjom14 byte %11.0g OME (subject) at 4 wk visit 
rtrt byte %11.0g Treatment 
study byte %8.0g Study 
gender byte %8.0g Gender 
xlat byte %10.0g Laterality of OME at entry 
xrace byte %8.0g Race 
xpreab byte %11.0g Antimicrobials rec'd in past 8 weeks 
xage byte %8.0g Age at entry 
xhxdx byte %10.0g History of ear disease 
xuri1 byte %8.0g Upper respiratory infection at entry 
xhear byte %8.0g Average hearing (SRT/SAT) at entry 
id int %8.0g ID 
xoccup float %21.0g Occupation of primary wage earner 
 
In total, 1448 subjects from the 3 trials were included in this study.  Overall, 7.25% (105 
of 1448) of outcome variables were missed at the 2-week endpoint and 8.36% (121 of 1448) 
were missed at the 4-week endpoint.  We feel this is a relatively low number of missing 
observations and therefore no missing data analysis is planned other than to include “missing” as 
a separate category in the analysis.  A check of missing observations revealed that only 4 
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subjects at the 2 week time point and only 5 subjects at the 4 week time point had a missing 
observation for one ear and were treated as completely missing. 
3.3 DESCRIPTIVE ANALYSIS 
3.3.1 Aim 1 
A table will be constructed to show prevalence of effusion at baseline, 2 weeks, and 4 weeks.  
Frequencies will be calculated for each laterality group as well as for subgroups of unilateral 
subjects who experienced either variant of unilateral disease, right-ear effusion or left-ear 
effusion.  These descriptives will be shown overall, and separately for each treatment arm. 
3.3.2 Aim 2 
Transition matrices will be constructed to provide a description of the data over time.  The 
progress of individual ears of subjects will be tracked from 0 to 2 weeks and from 2 to 4 weeks.  
The 3X5 transition matrix created for the baseline to 2-week time period will assign all subjects 
to unilateral right, unilateral left, or bilateral effusion groups at baseline, as all subjects coming 
into the study had some type of effusion and could not have had a missing outcome.  At two 
weeks it was possible for subjects to experience no effusion or be missing in addition to having 
effusion in right or left ear only or in both ears.  A 5X5 transition matrix will summarize 
transitions from the 2 to 4 week time points  
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3.3.3 Aim 3 
The baseline to 2-week transition matrix will summarize the conditional probabilities of effusion 
at the 2-week timepoint. The 2 to 4-week matrix will summarize the corresponding conditional 
probabilities for the 4-week timepoint.  The dependence of subjects’ current effusion status on 
prior status can be viewed using this method; this information cannot be discerned from 
prevalence measures.  
3.4 STATISTICAL MODELING 
In preliminary analyses, we will assess whether some of the treatment arms from the 3 studies 
can be combined in the present analysis.  Using data on the ear-level, a GEE analysis will be 
conducted with outcome OME and covariates including treatment and week.  The working 
covariance structure is assumed to be exchangeable.  A robust estimate of standard error will be 
used.  Non-significant treatments will be combined with placebo.  Among the treatments found 
to be significantly different from placebo, pair-wise comparisons will be conducted to check 
whether any can be grouped together. 
3.4.1 Aim 1 
McNemar’s test will be used to assess whether there are differences in prevalence associated 
with unilateral-right and unilateral-left manifestations of OME at 2 weeks and 4 weeks.  A 2 × 2 
table of left versus right ear will summarized the data for the matched pairs at each timepoint.  
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The test focuses on discordant pairs and each ear is expected to have the same probability of 
OME under the null hypothesis.  The null hypothesis of prevalence unilateral-right = prevalence 
unilateral-left, which is to say similar numbers of discordant pairs occur in both off-diagonal 
cells, will be rejected if p < 0.05.  Separate tests will be conducted at 2 weeks and 4 weeks.  
Multinomial regression will be used to assess baseline covariates associated with 
prevalence at each time point.  Category of effusion will be regressed on prognostic variables 
and baseline demographic characteristics of interest.  Selection will begin with the inclusion of 
all variables in the model.  Those variables without a p-value of less than 0.20 will be dropped 
and the remaining variables will be regressed successively at the alpha = 0.10 level until only 
statistically significant covariates remain.  Once a final model is obtained, Wald tests comparing 
the unilateral-left and unilateral-right ears will be conducted at the alpha = 0.05 level for each of 
the statistically significant covariates to assess whether prevalence differs by sidedness of OME.   
3.4.2 Aim 2 
The variable, category of effusion at previous time point, in addition to the other covariates of 
interest, will be regressed on current category of effusion using multinomial regression to assess 
status of effusion over time.  Selection will begin with all variables found to have had a 
statistically significant association on prevalence at baseline, 2 weeks, or 4 weeks.  Category of 
effusion will be regressed on covariates in the data set at the alpha = 0.20.  Model selection will 
continue until a final model contains only variables significant at alpha = 0.10.  Variables like 
age, if not found significant at alpha = 0.10, may be included in our final model if deemed to 
have biological importance.  For example, we choose, a priori, to look more carefully at the 
variables season of entry, upper respiratory tract infection, or duration of effusion, in addition to 
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age, as involvement of the Eustacian tube may be a confounder on laterality and MEE.  Once we 
have identified the most statistically significant covariates, our aim is to describe associations 
between levels of these variables and effusion in unilaterally and bilaterally affected children.   
3.4.3 Aim 3 
Under an assumption of independence, the proportion of bilateral children who become effusion-
free in both ears is expected to approximately equal the multiplied proportions of those who had 
resolution in one ear only.  By separating the bilateral subjects into 3 categories (no ears 
resolved, unilateral, and both ears resolved) and doubling the total to account for all ears in the 
subsample, expected frequencies in each of the above 3 categories can be calculated by summing 
the number of ears experiencing effusion and dividing by total number of ears.  For example, if 
at 2 weeks 149 subjects are effusion-free, 84 subjects have right-ear effusion, 75 subjects have 
left-ear effusion, and 660 subjects have bilateral effusion, the total number of ears is 1936, 
among which 1479 have effusion, then Pt = 1479/1936 = .764.  If, then, the marginal probability 
of effusion in all ears is (Pt), then the expected probabilities of bilateral effusion, unilateral 
effusion, and no effusion are Pt2, 2Pt(1-Pt), and (1-Pt)2, respectively.  A chi-squared goodness of 
fit test, with alpha set at 0.05, will then be conducted to assess whether the data matched what we 
expected under the null hypothesis of independence, 
)1(~)( 2
2
χ∑ −EEO  
A rejection of this hypothesis, in a manner where fewer bilateral children than expected were 
effusion-free, may indicate more severe disease in bilateral ears.  This process yields a time-
specific measure of independence between ears at the 2-week and 4 week time points.  This 
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approach assumes no difference between the probabilities of effusion by sidedness, although it 
could be adapted to account for such differences.  
Modeling of contralateral ears of the entire sample using GEE on the ear-level will 
quantify the extent of dependence one ear has relative to the effusion status of the other within 
each subject.  The outcome is OME and covariates include sidedness, contralateral ear status, 
and categorical variables for time.  The working covariance structure is assumed to be 
exchangeable.  A robust estimate of standard error is used. 
Table 3. Contralateral Ear Status Data Structure 
id week ear OME cs 
1 0 Right Effusion Effusion 
1 0 Left Effusion Effusion 
1 2 Right Effusion    No Effusion 
1 2 Left   No Effusion Effusion 
1 4 Right Effusion Effusion 
1 4 Left Effusion Effusion 
2 0 Right Effusion Effusion 
2 0 Left Effusion Effusion 
2 2 Right . . 
2 2 Left . . 
2 4 Right . . 
2 4 Left . . 
4 0 Right Effusion    No Effusion 
4 0 Left    No Effusion Effusion 
4 2 Right    No Effusion Effusion 
4 2 Left Effusion    No Effusion 
4 4 Right   No Effusion   No Effusion 
4 4 Left No Effusion    No Effusion 
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4.0  RESULTS 
Table 4 shows the results of the preliminary GEE analysis of the prevalence of effusion by 
treatment group over time, which justified a combining of treatments.  Based on efficacy of the 
various treatments, the 6 treatments were combined into 2 groups by combining E-S, D/A, and 
Placebo (coded as “0”) and by combining Amoxicillin, Amoxicillin and D/A, and Cefaclor 
(coded as “1”).  D/A and E-S were not statistically significantly different from placebo.  
Amoxicillin, Amoxicillin and D/A, and Cefaclor all were significant in reducing effusion.  Pair-
wise comparisons shown below the table show that these 3 effective treatments are not 
significantly different from one another.  
Table 4. Estimated Log Odds of Effusion by Treatment and Time 
 
Log 
Odds 
Semi-
robust 
Std. Err. z P>|z| [95% Conf. Interval] 
D/A -0.138 0.108 -1.28 0.199 -0.350 0.073
Amoxicillin -0.528 0.109 -4.83 0.001 -0.743 -0.314
Amoxicillin/D/A -0.507 0.128 -3.96 0.001 -0.757 -0.256
E-S -0.221 0.180 -1.23 0.219 -0.573 0.132
Cefaclor -0.403 0.181 -2.22 0.026 -0.757 -0.048
Week 2 -1.066 0.056 -19.05 0.001 -1.176 -0.957
Week 4 -1.320 0.058 -22.8 0.001 -1.434 -1.207
_cons 2.027 0.076 26.77 0.001 1.879 2.176
• Test for Amoxicillin=Amoxicillin/D&A, chi2(1) =0.02, Prob> chi2 = 0.878;  
• Test for Amoxicillin=Cefaclor,   chi2( 1) =    0.44,   Prob > chi2 =    0.506 
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4.1 BASELINE DEMOGRAPHIC CHARACTERISTICS IN THE COMBINED 
STUDY POPULATION 
There were 1034 bilateral subjects, 202 unilateral-right subjects, and 212 unilateral-left subjects 
at baseline (Table 5).  Baseline characteristics were similar for unilateral-right and unilateral-left 
subjects. Bilateral subjects were generally similar to subjects with unilateral OME except for 
having relatively more subjects with longer durations of effusion and/or upper-respiratory tract 
infections at baseline.   
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Table 5. Baseline Demographics by Laterality of OME at Study Entry 
 % 
Unilateral Right 
(N=202) 
Unilateral Left 
(N=212) 
Bilateral 
(N=1034)
Overall  14.64 13.95 71.41 
Study    
D & A 44.8 39.1 42.0 
AB I 36.3 39.1 34.2 
AB II 18.9 21.8 23.8 
Treatment    
Placebo/D&A/E-S 63.4 61.8 66.0 
Amoxicillin/Amox D&A/Cefaclor 36.6 38.2 34.0 
Gender    
Female 40.6 37.6 40.4 
Male 59.4 62.4 59.6 
Race    
White 73.1 71.3 75.1 
Black 25.9 27.7 24.3 
Unknown 0.9 1.0 0.6 
Age at entry    
>=2yrs 69.3 66.3 70.5 
< 2yrs 30.7 33.7 29.5 
Occupation of primary wage earner    
Exec/Sm.bus/Skld 45.3 37.1 38.1 
Clerical/Semiskld 17.0 20.3 22.5 
Welfare/Unempld/Other 33.5 39.1 37.4 
Unknown 4.2 3.5 1.9 
Duration of OME at entry    
0-3 wks 18.4 22.8 14.5 
4-8 wks 19.8 20.3 14.1 
> 8 wks 33.5 25.7 35.7 
Unknown 28.3 31.2 35.7 
Antimicrobials received in past 8 wks    
No Ab received 28.8 32.2 38.7 
Ab received 71.2 67.3 61.3 
Unknown 0.0 0.5 0.0 
History of ear disease    
No history 11.8 9.4 14.5 
History 88.2 90.1 85.2 
Unknown 0.0 0.5 0.3 
Season at entry    
Winter 35.8 33.7 36.8 
Spring 28.8 28.2 29.8 
Summer 14.2 16.3 12.6 
Fall 21.2 21.8 20.9 
Upper respiratory infection at entry    
(-) URI 70.3 69.8 61.7 
(+) URI 16.0 20.3 27.7 
Unknown 13.7 9.9 10.6 
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4.2 PREVALENCE OF EFFUSION BY LATERALITY OVER TIME 
Table 6 shows the prevalence of effusion at baseline, 2 weeks, and 4 weeks.  Effusion is 
summarized on laterality defined at the subject level.  Subjects who had unilateral disease in 
right ears and left ears at baseline were almost equally likely to have no effusion at 2 weeks, 
24.3% (49 of 202) and 26.4% (56 of 212), respectively (Odds Ratio [OR] = 1.14, p = 0.56).  Of 
414 subjects who had unilateral effusion at baseline, 25.1% had effusion in the right ear and 
22.7% had left ear effusion at 2 weeks.  Right ears with effusion at baseline were slightly more 
likely than left ears to remain unilateral and have effusion in the same ear at the first follow-up 
visit, 49% (99 of 202) and 42% (89 of 212), respectively.  Each group of unilateral subjects had 
very few instances of disease moving ear to ear, i.e. as the originally affected ear became 
effusion free the contralateral ear rarely developed effusion at the 2-week timepoint.  These 
subjects (only 2.5% of 202 in those entering with unilateral effusion in the right ear alone and 
2.4% of 212 in those entering with effusion exclusively in the left ear) ceased to have effusion in 
the originally affected ear but experienced an incident case of unilateral disease in the 
contralateral ear.   
Table 6.  Prevalence of Effusion by Timepoint and Laterality (N = 1448 subjects) 
Timepoint Baseline OME N No Effusion Unilateral 
Right 
Unilateral 
Left 
Bilateral Missing 
Baseline Total  1448 --- 14.0 14.6 71.4 --- 
2 week Bilateral 1034 14.4   8.1  7.3 63.8  6.4 
Unilateral   414 25.4 25.1 22.7 16.7 10.1 
R only    202 24.3 49.0  2.5 14.9  9.4 
L only    212 26.4  2.4 42.0 18.4 10.9 
4 week Bilateral  1034 19.1  8.3  8.8 56.1  7.7 
Unilateral    414 33.6 17.4 20.3 18.1 10.6 
R only   202 35.2 33.2  3.5 18.3  9.9 
L only    212 32.1  2.4 36.3 17.9 11.3 
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Subjects with unilateral disease in right ears and left ears at baseline were about equally 
likely to have no effusion at 4 weeks, 35.2% (71 of 202) and 32.1% (68 of 212).  Of 414 subjects 
who had unilateral effusion at baseline, 17.4% had effusion in the right ear and 20.3% had left 
ear effusion at 4 weeks.  At 4 weeks, unilateral effusion remained in left ears slightly more often 
than in right ears, 36.3% (74 of 202) and 33.2% (71 of 212), respectively.  Once again, incidence 
of effusion in the contralateral ear is quite uncommon in those subjects whose originally affected 
ear had become free of effusion (2.4% of the 202 subjects with unilateral effusion in the right ear 
at baseline and 3.5% of the 212 subjects entering with unilateral effusion in the left ear at 
baseline). 
McNemar tests were conducted 2 weeks and 4 weeks to confirm that there were not left-
right differences between ears, which could have accounted for differing rates of effusion among 
unilateral effusion groups in the original trials.  Among unilateral subjects, the numbers who had 
effusion in the right ear (104) and in the left ear (94) were not significantly different at 2 weeks, 
(OR = 1.106; 95% CI [0.829, 1.478]).  At 4 weeks, the numbers of subjects with unilateral-right 
effusion (72) and unilateral-left effusion (84) were not significantly different, (OR = 0.858; 95% 
CI [0.617, 1.188]).  These odds ratios are the ratios of unilateral left over unilateral right.  
Prevalence of effusion was described by treatment arm in Table 7.  McNemar tests also 
were carried out by treatment arm at 2 and 4 weeks.  In the Placebo/D/A/E-S treatment arm, the 
OR = 1.25 for unilateral-left relative to unilateral-right and the 95% CI is (0.889, 1.765).  The 
Amoxicillin/Amox. and D/A/Cefaclor arm had OR = 0.65 for unilateral-left relative to unilateral-
right and the 95% CI is (0.297, 1.373).  These results showed no significant difference in 
prevalence of effusion either between right and left ears in either treatment arm. 
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Table 7.  Prevalence of Effusion by Timepoint, Laterality, and Treatment 
a) Placebo/D/A/E-S 
Timepoint Baseline OME N No Effusion Unilateral 
Right 
Unilateral 
Left 
Bilateral Missing 
Baseline Total  942 --- 13.6 13.9 72.5 --- 
2 week Bilateral 683 10.4 6.7 7.8 68.1 7.0 
Unilateral 259 20.5 28.6 22.8 18.5 9.7 
R only  128 21.1 53.9 2.3 14.8 7.8 
L only  131 19.9 3.8 42.8 22.1 11.4 
4 week Bilateral  683 16.5 8.6 7.5 58.7 8.6 
Unilateral  259 30.9 18.9 19.7 20.5 10.0 
R only 128 32.0 37.5 1.6 20.3 8.6 
L only  131 29.8 0.8 37.4 20.6 11.5 
 
b) Amoxicillin/Amoxicillin and D/A/Cefaclor 
Timepoint Baseline OME N No Effusion Unilateral 
Right 
Unilateral 
Left 
Bilateral Missing 
Baseline Total  506 --- 14.6 16.0 69.4 --- 
2 week Bilateral 351 22.2 10.8 6.3 55.6 5.1 
Unilateral 155 33.6 19.4 22.6 13.5 11.0 
R only  74 29.7 40.5 2.7 14.9 12.2 
L only  81 37.0 0.0 40.7 12.4 9.9 
4 week Bilateral  351 23.9 7.7 11.4 51.0 6.0 
Unilateral  155 38.1 14.8 21.3 14.2 11.6 
R only 74 40.5 25.7 6.8 14.9 12.2 
L only  81 35.8 4.9 34.6 13.6 11.1 
 
Separate multinomial logistic models were run at baseline, 2 weeks, and 4 weeks to 
identify covariates associated with increased prevalence of effusion.  Unilateral effusion in the 
right ear was the reference category for the analyses of baseline effusion (Table 8).  At baseline, 
duration of effusion and upper-respiratory tract infection were significant predictors of category 
of effusion.  Subjects who had upper-respiratory infection at entry had an increased relative risk 
(RR) compared to subjects who had unilateral-right effusion disease (RR = 1.62, p = 0.012).  
Likewise, subjects who had longer (>8 weeks) or unknown duration of effusion at entry were 
more likely to have bilateral effusion.  There were no significant predictors that distinguished 
between left-ear and right-ear unilateral effusion at baseline (p > 0.24 for each). 
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Table 8.  Predictors of OME at Baseline Based on Multinomial Logistic Regression Model 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Left Effusion       
Upper-
respiratory tract 
inf. -0.239 0.261 -0.91 0.361 -0.750 0.273
Duration group 
4-8 weeks 0.219 0.332 0.66 0.510 -0.432 0.869
> 8 weeks 0.350 0.304 1.15 0.250 -0.246 0.945
unknown 0.135 0.299 0.45 0.652 -0.451 0.721
_cons -0.131 0.240 -0.55 0.586 -0.601 0.340
       
Bilateral       
Upper-
respiratory tract 
inf. 0.484 0.193 2.51 0.012 0.105 0.862
Duration  
4-8 weeks 0.066 0.262 0.25 0.801 -0.448 0.580
> 8 weeks 0.736 0.237 3.11 0.002 0.272 1.201
unknown 0.606 0.229 2.64 0.008 0.157 1.055
_cons 1.050 0.187 5.62 0.001 0.684 1.416
   
(cat1==R Effusion is reference outcome) 
Chi square test with df = 6      Duration of Effusion      P = 0.002 
Chi square test with df = 2      Upper-respiratory tract infection      P < 0.001 
 
The multinomial model for effusion status at 2 weeks is summarized in Table 9.  “No 
Effusion” is the reference category for this model.  The significant predictors of 2-week 
prevalence are treatment, male gender, occupation of primary wage-earner, upper-respiratory 
tract infection at baseline, and duration of effusion.  The overall test statistics for these variables 
are summarized in the Table 9 footnote.  Treatment significantly reduces the relative risk of 
effusion in unilateral-right, unilateral-left and bilateral groups (RR = 0.55, RR = 0.54, RR = 0.42; 
respectively).  Subjects who had longer (>8 weeks), or unknown duration of effusion had 
significantly increased relative risk of having bilateral effusion at 2 weeks (RR = 2.90 and RR = 
1.82, respectively).   
Missing effusion status at 2 weeks was less common in male subjects and in those who 
received the treatment.  Subjects whose primary wage-earner category was not executive/small 
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business/skilled were more likely to be missing at 2 weeks (P = 0.045 and P = 0.001 for 
Clerical/Semiskilled and Welfare/Unemployed/Other groups, respectively).  Duration of effusion 
longer than 8 weeks or unknown was much more common for subjects with missing effusion 
status at 2 weeks.  
Table 9.  Predictors of OME at 2 Weeks Based on a Multinomial Logistic Regression Model 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Right Effusion       
Treatment  
Amox/Amox 
D&A/Cefaclor -0.603 0.206 -2.92 0.003 -1.007 -0.199
Gender  
Male -0.091 0.210 -0.44 0.662 -0.503 0.319
Occupation 
Clerical/semiskilled -0.488 0.281 -1.74 0.083 -1.040 0.063
Welfare/Unemployed 
/other 0.218 0.231 0.94 0.346 -0.235 0.670
  unknown 0.514 0.943 0.55 0.585 -1.333 2.362
Upper-respiratory  
tract inf. 0.029 0.232 0.13 0.899 -0.426 0.485
Duration Group 
4-8 weeks 0.673 0.333 2.02 0.044 0.019 1.326
Duration > 8 weeks 0.805 0.303 2.66 0.008 0.212 1.398
unknown 0.298 0.295 1.01 0.314 -0.281 0.877
_cons -0.420 0.314 -1.34 0.181 -1.034 0.195
       
Left Effusion       
Treatment  
Amox/Amox 
D&A/Cefaclor -0.621 0.217 -2.87 0.004 -1.046 -0.197
Gender  
Male -0.288 0.218 -1.32 0.186 -0.714 0.139
Occupation 
Clerical/semiskilled -0.510 0.300 -1.7 0.089 -1.100 0.078
Welfare/Unemployed 
/other 0.271 0.241 1.12 0.261 -0.201 0.742
  unknown 0.299 1.027 0.29 0.771 -1.714 2.313
Upper-respiratory  
tract inf. -0.447 0.265 -1.69 0.09 -0.965 0.071
Duration Group 
4-8 weeks 0.573 0.348 1.65 0.099 -0.108 1.255
Duration > 8 weeks 0.602 0.318 1.90 0.058 -0.021 1.224
unknown 0.260 0.304 0.86 0.392 -0.335 0.855
_cons -0.273 0.320 -0.85 0.394 -0.899 0.354
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Table 9 continued 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Bilateral       
Treatment  
Amox/Amox 
D&A/Cefaclor -0.871 0.158 -5.51 0.001 -1.181 -0.562
Gender  
Male -0.083 0.162 -0.51 0.607 -0.401 0.234
Occupation 
Clerical/semiskilled 0.002 0.200 0.01 0.993 -0.391 0.395
Welfare/Unemployed 
/other 0.262 0.183 1.43 0.153 -0.097 0.621
  unknown -0.521 0.900 -0.58 0.562 -2.286 1.243
Upper-respiratory  
tract inf. 0.295 0.178 1.66 0.096 -0.053 0.643
Duration Group 
4-8 weeks 0.326 0.263 1.24 0.216 -0.190 0.842
Duration > 8 weeks 1.066 0.229 4.65 0.001 0.616 1.515
unknown 0.596 0.217 2.75 0.006 0.171 1.022
_cons 0.671 0.239 2.81 0.005 0.202 1.139
        
Missing        
Treatment  
Amox/Amox 
D&A/Cefaclor -0.815 0.254 -3.2 0.001 -1.314 -0.317
Gender  
Male -0.770 0.248 -3.1 0.002 -1.257 -0.284
Occupation 
Clerical/semiskilled 0.680 0.338 2.01 0.045 0.016 1.343
Welfare/Unemployed 
/other 1.064 0.305 3.49 0.001 0.466 1.663
  unknown 1.205 1.057 1.14 0.255 -0.868 3.277
Upper-respiratory  
tract inf. -0.004 0.280 -0.02 0.987 -0.554 0.545
Duration Group 
4-8 weeks 0.525 0.473 1.11 0.267 -0.401 1.451
Duration > 8 weeks 1.355 0.398 3.4 0.001 0.574 2.136
unknown 0.890 0.388 2.29 0.022 0.129 1.650
_cons -1.552 0.429 -3.62 0.001 -2.393 -0.711
       
(cat1==No Effusion is the reference outcome) 
Chi square test with df = 4  Treatment   P < 0.001 
Chi square test with df = 4  Gender   P = 0.019 
Chi square test with df = 12  Occupation   P = 0.014 
Chi square test with df = 4  Upper-respiratory infection P = 0.016 
Chi square test with df = 12  Duration of effusion  P < 0.001 
 
The multinomial model for effusion status at 4 weeks is summarized in Table 10.  The 
reference category is “No Effusion.”  Subjects who participated in the AB II trial had a decreased 
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relative risk (RR = 0.53) of unilateral effusion in the right ear at 4 weeks, p = 0.052.  Subjects 
who received Amoxicillin or Cefaclor treatment had a decreased relative risk of unilateral 
effusion in the right ear at 4 weeks (RR = 0.57) and a decreased relative risk of bilateral effusion 
at 4 weeks, p = 0.001 (RR = 0.48).  Subjects with longer duration of effusion (>8 weeks) had an 
increased relative risk of unilateral effusion in the left ear or bilateral effusion at 4 weeks (RR = 
1.95 and RR = 2.46, respectively).  Subjects who had unknown duration of effusion prior to 
entry had an increased relative risk of bilateral effusion at the 4-week timepoint (RR = 1.58).  
The relative risk of bilateral effusion at 4 weeks was decreased for those who entered during the 
summer months (RR = 0.38). 
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Table 10.  Predictors of OME at 4 Weeks Based on a Multinomial Logistic Regression Model 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Right Effusion       
Study 
AB I 0.320 0.290 1.110 0.269 -0.247 0.888
AB II -0.634 0.326 -1.950 0.052 -1.272 0.004
Treatment  
Amox/Amox D&A/Cefaclor -0.565 0.280 -2.020 0.043 -1.114 -0.017
Gender 
Male -0.053 0.202 -0.260 0.792 -0.450 0.343
Previous use of antibiotics 0.032 0.226 0.140 0.886 -0.411 0.475
Duration Group 
4-8 weeks 0.324 0.315 1.030 0.304 -0.294 0.942
Duration > 8 weeks 0.491 0.295 1.670 0.096 -0.087 1.069
unknown 0.104 0.301 0.350 0.729 -0.485 0.693
Season 
Spring 0.053 0.242 0.220 0.826 -0.421 0.528
Summer -0.246 0.297 -0.830 0.408 -0.829 0.337
Fall -0.075 0.283 -0.260 0.792 -0.629 0.480
_cons -0.731 0.358 -2.040 0.042 -1.433 -0.028
       
Left Effusion       
Study 
AB I 0.368 0.288 1.280 0.202 -0.197 0.934
AB II 0.146 0.286 0.510 0.610 -0.414 0.706
Treatment  
Amox/Amox D&A/Cefaclor -0.275 0.256 -1.070 0.283 -0.776 0.227
Gender 
Male 0.005 0.196 0.020 0.981 -0.380 0.390
Previous use of antibiotics 0.334 0.223 1.500 0.134 -0.103 0.771
Duration Group 
4-8 weeks -0.356 0.333 -1.070 0.285 -1.009 0.297
Duration > 8 weeks 0.670 0.272 2.460 0.014 0.137 1.204
unknown 0.130 0.282 0.460 0.644 -0.423 0.683
Season 
Spring 0.022 0.235 0.090 0.927 -0.439 0.482
Summer -0.106 0.282 -0.380 0.707 -0.658 0.447
Fall 0.040 0.275 0.150 0.885 -0.500 0.580
_cons -1.133 0.353 -3.210 0.001 -1.825 -0.441
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Table 10 continued 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Bilateral       
Study 
AB I 0.401 0.211 1.900 0.058 -0.013 0.815
AB II 0.184 0.207 0.890 0.375 -0.222 0.590
Treatment  
Amox/Amox D&A/Cefaclor -0.730 0.192 -3.810 0.001 -1.105 -0.354
Gender 
Male -0.225 0.142 -1.580 0.114 -0.503 0.054
Previous use of antibiotics -0.038 0.159 -0.240 0.812 -0.349 0.273
Duration Group 
4-8 weeks 0.093 0.232 0.400 0.689 -0.363 0.549
Duration > 8 weeks 0.900 0.209 4.320 0.001 0.491 1.309
unknown 0.456 0.206 2.210 0.027 0.052 0.861
Season 
Spring -0.318 0.172 -1.850 0.064 -0.655 0.019
Summer -0.975 0.220 -4.420 0.001 -1.407 -0.543
Fall 0.068 0.193 0.350 0.724 -0.310 0.446
_cons 0.670 0.250 2.680 0.007 0.180 1.160
       
Missing       
Study 
AB I 0.261 0.319 0.820 0.414 -0.364 0.886
AB II -0.252 0.330 -0.760 0.445 -0.898 0.395
Treatment  
Amox/Amox D&A/Cefaclor -0.532 0.303 -1.750 0.080 -1.126 0.063
Gender 
Male -0.751 0.215 -3.490 0.000 -1.174 -0.329
Previous use of antibiotics -0.444 0.238 -1.870 0.062 -0.910 0.022
Duration Group 
4-8 weeks -0.058 0.395 -0.150 0.882 -0.833 0.716
Duration > 8 weeks 0.768 0.328 2.340 0.019 0.125 1.410
unknown 0.315 0.330 0.960 0.339 -0.331 0.961
Season 
Spring -0.046 0.265 -0.170 0.863 -0.566 0.475
Summer -0.292 0.321 -0.910 0.362 -0.921 0.337
Fall -0.099 0.309 -0.320 0.749 -0.705 0.507
_cons -0.417 0.379 -1.100 0.272 -1.160 0.326
       
(cat1==No Effusion is reference outcome) 
Chi square test with df = 8  Study    P = 0.057 
Chi square test with df = 4  Treatment   P = 0.003 
Chi square test with df = 4  Gender   P = 0.006 
Chi square test with df = 4  Previous use of antibiotic P = 0.078 
Chi square test with df = 12                Duration of effusion  P = 0.001 
Chi square test with df = 12  Season    P = 0.002 
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4.3 TRANSITION IN LATERALITY STATUS 
Figure 1 shows the transition probabilities at 2 and 4 weeks for subjects with unilateral disease at 
baseline.  To the outer extreme of the figure is baseline status of effusion and working toward the 
center of the figure is the conditional probability of first transition in effusion status at 2 weeks, 
followed by the conditional probability of effusion at the 4-week timepoint.  There are 5 
outcomes possible at 2-weeks upon which the 4-week effusion status is conditioned.  The 
transitions in effusion status at 2 and 4 weeks were not possible using measures of prevalence.  
For example, prevalence in right ears and left ears at 2 weeks have, thus far, not reflected the 
particular changes in effusion status, i.e., unilateral cases that got better or worse and bilateral 
cases that improved. 
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Figure 1. Transition Probabilities at 2 and 4 Weeks in Subjects with Unilateral OME at Baseline 
(BL=bilateral; UR=unilateral right; UL=unilateral left) 
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The rates of unilateral cases becoming effusion-free from 2 to 4 weeks were similar to  
those from 0 to 2 weeks.  Those subjects who continued to experience effusion at 2 weeks in the 
same ear that had been diagnosed at baseline became effusion free at the 4 week timepoint at 
nearly the same rate as those who had become effusion-free from baseline to the 2-week 
timepoint (22 of 89 [24.7%] at the 4 week timepoint in those who had left-ear effusion at 
baseline and 29 of 99 [29.3%] at the 4 week timepoint in those who had right-ear effusion at 
baseline).  In accordance with the prevalence descriptives, effusion was found rarely in the 
contalateral ear if the originally affected ear had become free of effusion.  In the few instances of 
effusion in the contralateral ear only at 2 weeks, the majority became effusion free at 4 weeks (4 
of 5 subjects who had right-ear effusion at baseline and 3 of 5 subjects who had left-ear effusion 
at baseline).   
There are other similar patterns in left and right ears in the 2 to 4-week transition in 
laterality status.  The majority of unilateral ears that were effusion free at 2 weeks (49 subjects 
who had unilateral right OME and 56 subjects who had unilateral right OME) tend to remain 
effusion free at 4 weeks (73% and 61%, respectively).  Those subjects who were effusion free at 
2 weeks and experienced effusion again at 4 weeks were much more likely to have effusion in 
the ear in which effusion had been present at baseline. 
Rates of subjects with unilateral involvement whose effusion status got worse were 
nearly the same for left and right ears at 2 weeks, 30 of 202 (14.9%) who had unilateral-right 
effusion at entry and 39 of 212 (18.4%) who had unilateral-left effusion at entry.  These subjects 
were less likely to become effusion-free at 4 weeks than to remain bilateral.  Additionally, for 
those unilateral subjects who experienced a worsening of effusion status at 2 weeks, bilateral 
effusion was nearly as persistent as in those who had entered the study with bilateral effusion 
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(Fig. 2).  Overall, just over 25.4% of unilateral subjects (105 of 414) were effusion-free at 2  
weeks.   
Among bilateral cases (Figure 2), 15% experienced cure in only one ear, and 14% had no 
effusion at 2 weeks.  Those subjects experiencing an “improvement” of bilateral disease (i.e. 
experiencing the disease localized to one ear only) included 8% with right-ear effusion and 7% 
with left-ear effusion.  There is no evidence that left and right ears behave differently when 
afflicted with unilateral or bilateral disease.  
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Figure 2.Transition Probabilities at 2 and 4 Weeks in Subjects with Bilateral OME at Baseline  
(BL=bilateral; UR=unilateral right; UL=unilateral left) 
Of the 149 subjects who were effusion-free at 2 weeks, 87 (58%) remained effusion-free 
at 4 weeks.  Resistance to improvement at 2 weeks in those who entered with bilateral OME was 
not unlike that of unilateral subjects whose condition worsened at 2 weeks when observed at the 
4-week timepoint.  Those who entered with bilateral effusion experienced improvement at a 
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similarly balanced rate (84 of 1034 and 75 of 1034, respectively).  Of the bilateral cases who 
were effusion free in one ear only at the first follow-up, nearly 25% were completely effusion-
free at the end of the study—roughly the same cure rate as unilateral subjects from baseline to 2 
weeks. 
Of the 660 subjects that had bilateral effusion at 2 weeks, 475 (72%) still had bilateral 
effusion at 4 weeks.  Eight percent of the 660 bilateral children had their condition improve to 
unilateral right and 7% had their condition improve to unilateral left.  Of the 149 subjects that 
were effusion-free at 2 weeks, 12 had right-ear effusion and 14 had left-ear effusion at 4 weeks.  
Thirty subjects of the 149 (20%) who had been effusion-free at 2 weeks had bilateral effusion at 
4 weeks.  Of the 197 subjects who were effusion-free at the study’s conclusion, less than half 
(87) had been effusion-free at 2 weeks (22 had right ear effusion, 18 had left ear effusion, and 67 
had bilateral effusion).   
Modeling of the transitions was done using multinomial logistic regression.  “No 
Effusion” is the reference category for this model.  As seen in Table 11, the significant predictors 
of 2-week transitions of effusion status are previous effusion status, treatment, male gender, 
occupation of primary wage-earner, and duration of effusion.  At 2 weeks, subjects who were 
unilateral-right at baseline were much more likely to remain unilateral-right (RR = 24.8), 
subjects who were bilateral at baseline were much more likely to remain bilateral (RR = 6.3), and 
subjects who were unilateral-left at baseline were much more likely to remain unilateral-left (RR 
= 1.0, compared to RR = 0.07 for unilateral-right and RR = 0.32 for bilateral; p < 0.001 for 
each).  Treatment with Amoxicillin or Cefaclor reduced the RR of unilateral-right, unilateral-left, 
and bilateral OME at 2-weeks (p < 0.011 for each; RR = 0.58, RR = 0.49 and RR = 0.40, 
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respectively).  Overall, duration of effusion longer than 4 weeks prior to entry was associated 
with increased RR of both unilateral and bilateral effusion. 
Table 11.  Significant Predictors of OME for Baseline to 2 Week Transitions in Effusion Status 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Right Effusion       
Effusion at baseline 
Unilateral-right  3.209 0.504 6.36 0.001 2.221 4.198
Bilateral effusion  1.877 0.490 3.83 0.001 0.917 2.837
Treatment  
Amox/Amox 
D&A/Cefaclor  -0.539 0.211 -2.55 0.011 -0.953 -0.125
Gender 
Male -0.205 0.211 -0.97 0.331 -0.619 0.209
Occupation 
Clerical/semiskilled -0.463 0.284 -1.63 0.103 -1.019 0.093
Welfare/unemployed 
/other 0.134 0.234 0.57 0.566 -0.325 0.594
unknown 0.936 0.745 1.26 0.209 -0.523 2.396
Duration Group 
4-8 weeks 0.751 0.339 2.22 0.027 0.087 1.416
Duration > 8 weeks 1.065 0.308 3.46 0.001 0.461 1.668
unknown 0.491 0.300 1.64 0.102 -0.097 1.079
_cons -2.685 0.549 -4.89 0.001 -3.762 -1.608
             
Left Effusion             
Effusion at baseline 
Unilateral-right  -2.733 0.504 -5.42 0.001 -3.721 -1.745
Bilateral effusion  -1.153 0.228 -5.05 0.001 -1.601 -0.706
Treatment  
Amox/Amox 
D&A/Cefaclor  -0.718 0.217 -3.32 0.001 -1.143 -0.294
Gender 
Male -0.304 0.213 -1.43 0.152 -0.721 0.112
Occupation 
Clerical/semiskilled -0.291 0.292 -1 0.32 -0.863 0.282
Welfare/unemployed 
/other 0.311 0.239 1.3 0.193 -0.158 0.779
unknown 0.927 0.747 1.24 0.215 -0.537 2.391
Duration Group 
4-8 weeks 0.397 0.342 1.16 0.245 -0.272 1.067
Duration > 8 weeks 0.524 0.308 1.7 0.088 -0.079 1.127
unknown 0.330 0.297 1.11 0.266 -0.252 0.912
_cons 0.551 0.330 1.67 0.095 -0.097 1.198
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Table 11 continued 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Bilateral             
Effusion at baseline 
Unilateral-right  -0.086 0.320 -0.27 0.789 -0.712 0.541
Bilateral effusion  1.842 0.234 7.86 0.001 1.383 2.301
Treatment  
Amox/Amox 
D&A/Cefaclor  -0.923 0.158 -5.84 0.001 -1.233 -0.614
Gender 
Male -0.035 0.160 -0.22 0.825 -0.349 0.279
Occupation 
Clerical/semiskilled -0.026 0.201 -0.13 0.896 -0.420 0.367
Welfare/unemployed 
/other 0.167 0.181 0.92 0.356 -0.188 0.522
unknown 0.590 0.677 0.87 0.384 -0.738 1.918
Duration Group 
4-8 weeks 0.477 0.260 1.84 0.066 -0.032 0.985
Duration > 8 weeks 0.983 0.227 4.33 0.001 0.538 1.429
unknown 0.501 0.217 2.31 0.021 0.077 0.926
_cons -0.579 0.301 -1.92 0.055 -1.170 0.011
             
Missing             
Effusion at baseline 
Unilateral-right  -0.065 0.381 -0.17 0.864 -0.811 0.681
Bilateral effusion  -0.067 0.300 -0.22 0.822 -0.656 0.521
Treatment  
Amox/Amox 
D&A/Cefaclor  -0.807 0.247 -3.27 0.001 -1.291 -0.324
Gender 
Male -0.727 0.237 -3.06 0.002 -1.192 -0.261
Occupation 
Clerical/semiskilled 0.739 0.329 2.24 0.025 0.094 1.384
Welfare/unemployed 
/other 1.140 0.292 3.9 0.001 0.567 1.713
unknown 1.312 0.863 1.52 0.128 -0.379 3.004
Duration Group 
4-8 weeks 0.535 0.453 1.18 0.237 -0.352 1.423
Duration > 8 weeks 1.425 0.381 3.74 0.001 0.679 2.171
unknown 0.930 0.375 2.48 0.013 0.196 1.664
_cons -1.617 0.456 -3.55 0.001 -2.511 -0.724
       
(cat1==No Effusion  is the reference outcome) 
0-2 weeks 
Chi Square with df = 8 Previous category of effusion  P < 0.001 
Chi Square with df = 4 Treatment    P < 0.001 
Chi Square with df = 4 Gender    P = 0.013 
Chi Square with df = 12 Occupation    P = 0.014 
Chi Square with df = 12 Duration of effusion   P = 0.003 
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The comparable multinomial model for the 2-week to 4-week transition is summarized in 
Table 12.  Unilateral-right and unilateral-left subjects at 2 weeks were more likely to have 
effusion in the same ear at 4 weeks than in the contralateral ear, p = 0.001.  Unilateral-right and 
unilateral-left subjects at 2 weeks had similar probabilities of bilateral effusion at 4 weeks.  
Bilateral subjects at 2 weeks were most likely to remain bilateral at 4 weeks (RR = 29.31).  
Subjects in the AB II trial had a decreased relative risk (RR = 0.41) of unilateral-right effusion at 
4 weeks, p = 0.004.  Males had a decreased probability of bilateral effusion at 4 weeks, p = 0.05.  
Subjects who entered the study in the spring or summer months had a reduced probability of 
bilateral effusion compared to subjects who entered during the winter, p = 0.013 and p = 0.001, 
respectively.  
Table 12.  Significant Predictors of OME for 2 to 4 Week Transitions in Effusion Status 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Right Effusion             
Effusion at 2 weeks 
Unilateral Right 2.369 0.299 7.93 0.001 1.783 2.954
Unilateral Left -0.005 0.498 -0.01 0.991 -0.982 0.971
Bilateral  1.593 0.302 5.27 0.001 1.000 2.186
Missing  1.071 0.733 1.46 0.144 -0.365 2.506
Study 
AB I 0.079 0.235 0.34 0.737 -0.382 0.539
AB II -0.901 0.314 -2.87 0.004 -1.516 -0.285
Age -0.301 0.237 -1.27 0.204 -0.766 0.163
Gender 
Male -0.054 0.218 -0.25 0.805 -0.481 0.373
Previous use of 
antibiotics 0.147 0.242 0.61 0.543 -0.328 0.622
Duration Group 
4-8 weeks 0.086 0.339 0.25 0.800 -0.578 0.750
Duration > 8 
weeks 0.146 0.318 0.46 0.647 -0.478 0.769
unknown -0.148 0.325 -0.46 0.649 -0.786 0.490
Season 
Spring 0.013 0.260 0.05 0.961 -0.497 0.523
Summer -0.219 0.317 -0.69 0.490 -0.839 0.402
Fall -0.219 0.303 -0.72 0.470 -0.813 0.375
_cons -1.761 0.434 -4.06 0.001 -2.611 -0.911
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Table 12 continued 
 Log RR Std. Err. z P>|z| [95%Conf. Interval] 
Left Effusion             
Effusion at 2 weeks 
Unilateral Right 
 
-0.186 0.434 -0.43 0.668
 
-1.038 0.665
Unilateral Left 2.262 0.289 7.82 0.001 1.695 2.829
Bilateral  1.637 0.270 6.06 0.001 1.108 2.167
Missing  -0.308 1.092 -0.28 0.778 -2.448 1.833
Study 
AB I 0.488 0.237 2.06 0.039 0.024 0.953
AB II 0.235 0.265 0.89 0.376 -0.285 0.754
Age -0.198 0.227 -0.87 0.382 -0.643 0.246
Gender 
Male 0.055 0.210 0.26 0.792 -0.356 0.467
Previous use of 
antibiotics 0.367 0.236 1.55 0.121 -0.097 0.830
Duration Group 
4-8 weeks -0.575 0.357 -1.61 0.107 -1.275 0.124
Duration > 8 
weeks 0.481 0.295 1.63 0.103 -0.096 1.058
unknown -0.061 0.303 -0.2 0.840 -0.655 0.533
Season 
Spring -0.103 0.252 -0.41 0.682 -0.597 0.390
Summer -0.233 0.302 -0.77 0.442 -0.825 0.360
Fall -0.094 0.292 -0.32 0.748 -0.665 0.478
_cons -2.149 0.424 -5.07 0.001 -2.980 -1.318
       
Bilateral             
Effusion at 2 weeks 
Unilateral Right 1.194 0.279 4.28 0.001 0.647 1.741
Unilateral Left 1.449 0.288 5.04 0.001 0.885 2.013
Bilateral  3.378 0.227 14.9 0.001 2.934 3.822
Missing  2.021 0.504 4.01 0.001 1.033 3.009
Study 
AB I 0.282 0.187 1.5 0.132 -0.085 0.649
AB II 0.118 0.211 0.56 0.575 -0.295 0.531
Age 0.087 0.178 0.49 0.622 -0.261 0.435
Gender 
Male -0.324 0.165 -1.96 0.050 -0.647 -0.001
Previous use of 
antibiotics -0.089 0.184 -0.48 0.628 -0.449 0.271
Duration Group 
4-8 weeks -0.101 0.273 -0.37 0.710 -0.636 0.433
Duration > 8 
weeks 0.519 0.245 2.12 0.034 0.040 0.999
unknown 0.162 0.244 0.66 0.507 -0.316 0.641
Season 
Spring -0.497 0.200 -2.48 0.013 -0.888 -0.105
Summer -0.990 0.254 -3.9 0.001 -1.488 -0.493
Fall -0.087 0.222 -0.39 0.695 -0.523 0.349
_cons -1.230 0.338 -3.64 0.001 -1.891 -0.568
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Table 12 continued 
 Log RR Std. Err. z P>|z| [95%Conf.  Interval] 
Missing             
Effusion at 2 weeks 
Unilateral Right 0.592 0.558 1.06 0.289 -0.501 1.685
Unilateral Left 0.929 0.542 1.71 0.086 -0.133 1.992
Bilateral  1.461 0.438 3.33 0.001 0.602 2.320
Missing  5.266 0.532 9.89 0.001 4.223 6.310
Study 
AB I -0.203 0.330 -0.61 0.539 -0.849 0.443
AB II -0.305 0.395 -0.77 0.441 -1.080 0.470
Age 0.295 0.308 0.96 0.338 -0.309 0.899
Gender 
Male -0.615 0.287 -2.14 0.032 -1.178 -0.053
Previous use of 
antibiotics -0.666 0.327 -2.04 0.042 -1.307 -0.025
Duration Group 
4-8 weeks -0.308 0.511 -0.6 0.547 -1.309 0.694
Duration > 8 
weeks 0.132 0.438 0.3 0.763 -0.727 0.991
unknown -0.203 0.443 -0.46 0.647 -1.071 0.665
Season 
Spring -0.240 0.358 -0.67 0.503 -0.942 0.462
Summer -0.311 0.435 -0.72 0.474 -1.164 0.541
Fall -0.113 0.401 -0.28 0.777 -0.898 0.672
_cons -1.817 0.584 -3.11 0.002 -2.962 -0.672
(cat1==No Effusion is reference outcome) 
2-4 weeks 
Chi square test with df = 16  Previous category of effusion  P < 0.001 
Chi square test with df = 8  Study     P = 0.018 
Chi square test with df = 4  Gender    P = 0.061 
Chi square test with df = 4  Previous use of antibiotic  P = 0.043 
Chi square test with df = 12  Season     P = 0.018 
 
4.4 CONTRALATERAL EAR 
Table 13 summarizes the observed and expected numbers of subjects who experienced 
each of the 3 possible outcomes (neither ear clear, unilateral effusion, or both ears clear) at 2 and 
4 weeks. The expected counts are derived under the assumption that effusion resolves 
independently in each ear.  Subjects who had one ear or both missing were excluded.  The Chi 
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Square Goodness-of-Fit test used to test our null hypothesis of statistical independence of left 
and right ears at each timepoint.  We reject the null hypothesis of statistical independence at both 
2 and 4 weeks in (a) bilateral subjects and (b) all subjects, p < 0.001 for both.  
Table 13. Observed Versus Expected Counts of Bilateral Subjects Experiencing 1 of 3 Possible 
Outcomes at Timepoint 
a) Bilateral subjects only 
 2 weeks 4 weeks 
 
Expected 
Probability 
Expected 
Number of 
Subjects 
Observed 
Number of 
Subjects 
Expected 
Probability
Expected 
Number of 
Subjects 
Observed 
Number of 
Subjects 
Neither ear 
clear 0.584 565 660 0.491 468 580
Unilateral 0.361 349 159 0.210 200 177
Both ears 
clear 0.056 54 149 0.090 85 197
2-Week      4-Week  
ChiSquare = 287.2     ChiSquare = 174.7 
P < 0.0001      P < 0.0001 
 
b) All subjects 
 2 weeks 4 weeks 
 
Expected 
probability 
Expected 
subjects 
Observed 
Number of 
subjects 
Expected 
probability
Expected 
subjects 
Observed 
Number of 
subjects 
Neither ear 
clear 0.393 526 729 0.385 510 655
Unilateral 0.468 627 357 0.236 312 333
Both ears 
clear 0.139 187 254 0.144 191 336
2-Week      4-Week  
ChiSquare = 218.6     ChiSquare = 153.6 
P < 0.0001      P < 0.0001 
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Table 14 summarizes the GEE modeling of the prevalence of effusion in each ear at 2 and 
4 weeks, using the concurrent effusion status of the other ear as a predictor. Effusion status of a 
contralateral ear is a significant predictor of effusion in the other ear (OR = 1.44, p < 0.001).  
There is no significant effect of sidedness (p = 0.86).  Overall, the prevalence of effusion is 
decreasing over time, OR = .37 for 2 weeks and OR = .29 at 4 weeks, compared to baseline.  The 
estimated intraclass correlation coefficient is α = 0.19. 
Table 14. GEE Model for Contralateral Ear 
Predictor 
Log 
Odds 
Semi-
robust 
Std. Err. z P>|z| 
[95% 
Conf. Interval] 
Status of contralateral 
ear 0.367 0.097 3.78 0.001 0.177 0.558
2 week -1.002 0.046 -21.59 0.001 -1.093 -0.911
4 week -1.238 0.047 -26.09 0.001 -1.331 -1.145
Ear 
   Left vs. Right 0.011 0.063 0.18 0.860 -0.112 0.134
_cons 1.501 0.117 12.87 0.001 1.273 1.730
 
In summary, we have no evidence that prevalence of MEE differs by sidedness of disease 
at any timepoint.  Our investigation of baseline covariates revealed that longer duration of 
effusion is associated with increased risk of bilateral effusion rather than unilateral effusion.  
Laterality is an important prognostic factor. 
Transitions in effusion status provided information about the within subject changes over 
time.  There was no evidence that transition status of subjects were significantly different based 
on the sidedness of disease.  Baseline covariates were similarly associated with effusion both left 
and right ears. The previous state of disease has a strong association to the present state of 
disease. Bilateral OME takes longer to resolve than unilateral OME.  At 2 weeks, the rate of no 
effusion in subjects who had had unilateral OME at baseline was nearly double that of subjects 
who had entered with bilateral OME (25.4% compared to 14.0%, respectively).  Similarly, at 4 
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weeks, subjects who had entered the study with unilateral OME and continued to experience 
unilateral effusion at 2 weeks were substantially more likely to have no effusion 4 weeks than 
subjects who had entered with bilateral disease and continued to experience effusion at 2 weeks 
(29.3% compared to 10.0%, respectively). 
The descriptive analysis also offered an indication of the level of dependence between the 
ears of each subject.  A test of independence was rejected and it was concluded that the outcomes 
of the two ears are highly dependent.  Finally, a GEE model at the ear level revealed that the 
effusion status of one ear is dependent on the status of the contalateral ear, with an OR of 
effusion of 1.44 when the contralateral ear has effusion at the same timepoint). 
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5.0  DISCUSSION 
This investigation looked at 3 separate but related clinical trials in aggregate.  The D&A trial 
compared the efficacy of a standard treatment (D/A) to placebo and found no evidence that 
treatment was effective.  The ABI trial was similar to the D&A trial in design but compared an 
antibiotic (amoxicillin) with and without D/A to placebo and found that the antibiotic was 
effective at least in the short term in treating OME; D/A had no effect.  The ABII compared the 
efficacy of 2 promising antibiotics to amoxicillin but found no evidence that either was better at 
treating OME than amoxicillin.  We aggregated the various treatments used in these trials into 
two groups, based upon the effect each had on the outcome of OME.  We designated the group 
of effective medications (amoxicillin, amoxicillin/D/A, and cefaclor) as the treatment and the 
remaining medications (D/A, E-S, and placebo) as the baseline group. 
Our focus on left-right differences associated with prognosis was novel and this analysis 
has provided considerably more evidence that the bilateral ear represents a much tougher 
condition than unilateral disease in either ear.  We found no evidence that sidedness is a 
statistically significant prognostic factor in children with OME at any timepoint of the study, 
either overall or within treatment groups.  A high level of dependence between ears was first 
indicated by the transitions in effusion status.  Current effusion status in unilateral subjects is 
highly dependent upon the effusion status of the originally affected ear.  Generally, unilateral 
disease does not pass from ear to ear without an overall worsening of the subject’s condition i.e., 
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the subject begins to experience bilateral effusion.  In bilateral subjects, improvement to 
unilateral effusion occurred at similar rates in right and left ears at each timepoint. 
The multinomial regression equations provided a way to quantify the role of covariates in 
unilateral or bilateral expressions of disease.  Upper-respiratory tract infection was found to have 
a pronounced association with bilateral status of effusion at baseline.  Duration of effusion prior 
to entry seems to have been one of the most important covariates on prognosis; however, 
assignment of subjects to each duration category in the original trials was highly subjective.  One 
would expect that, if OME had a standard course over time, disease would become less severe 
during the 4-week study; however, subjects who entered with longer duration were more likely 
to continue experiencing effusion or, in the case of subjects who entered with unilateral effusion, 
may experience a worsening of their condition.  Longer duration of effusion upon entry is 
associated with increased relative risk of bilateral effusion compared to unilateral disease. 
Prevalence offers a cross-sectional description of the data at each timepoint, but it is 
difficult to assess the behavior of disease over time.  Transitional models offer a within subject 
description of disease.  Effusion status of the individual subject is tracked over time and prior 
status is linked to current effusion status.  Transitions allow one to assess the factors related to 
disease development and resolution.  Transitions are better at identifying when a treatment effect 
took place.  In our study, treatment was included in the 4-week prevalence model to account for 
possibly delayed benefits of medications that were administered for only 2 weeks. 
This study detected that certain antibiotics are effective in treating OME, in contrast to 
many other that have concluded that antibiotics are not effective.  Moreover, this study detected 
a beneficial effect associated with Cefaclor, which is not a finding of the original AB II trial.  
Our reanalysis reaffirms the importance of variables like laterality and duration of effusion on 
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prognosis.  Our reanalysis using correlated data methods augments the initial findings by further 
examining sidedness and documenting transitions over time. 
A possible limitation of this investigation is that it was a secondary data analysis on an 
existing dataset.  The original trials were not intended to address our specific questions.  The first 
study had a significant number of missing observations in upper-respiratory tract infection status 
at entry.  Because URI proved to be an important baseline covariate, those missing subjects may 
be important.  There may be measurement error in the ascertainment of effusion status, as a 
subjective criterion (otoscopy) was used as part of the determination of outcome.  For example, 
those subjects found to be effusion-free at 2 weeks and later began experiencing effusion in the 
ear initially involved may have been due to misclassification, i.e., effusion was present but 
escaped detection at 2 weeks.  Finally, treatments that were not effective were combined with the 
placebo groups; however, the placebo groups of the 3 original trials were found to be dissimilar.  
In conclusion, this investigation has reaffirmed the importance of certain antibiotic 
treatments and baseline covariates, like laterality and duration of effusion.  We used McNemar’s 
test to address aim 1) and found no evidence that left and right ears differ with respect to 
prevalence rates at 2 or 4 weeks (OR = 1.106 and OR = 0.858, respectively).  Similarly, non-
significant odds ratios were found when we accounted for treatment arms.  For aim 2), transition 
matrices suggested that OME is a continuous disease process dependent on the subject’s 
previous state.  Transitions in outcome of effusion in left and right ears at each timepoint seemed 
relatively similar in unilateral and bilateral groups.  Multinomial regression was used for each of 
the first 2 objectives to assess baseline covariates associated with prevalence and transitions of 
effusion status at each time point.  We identified statistically significant prognostic factors of 
OME, including duration of effusion.  After model selection, the tests conducted failed to show 
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any discrepancies in prevalence of OME or in transitions of effusion status attributable to 
differences in left and right ears.  Finally, to address aim 3), we conducted a Chi Square 
Goodness-Of-Fit test for the data at each timepoint and rejected our stated hypothesis of 
independence, p < 0.001.  An ear-level GEE quantified the extent of dependence one ear has 
relative to the effusion status of the other within each subject.  Effusion status of a contralateral 
ear was found to be a significant predictor of effusion in the other ear (OR = 1.44, p < 0.001).  
There was no significant effect of sidedness (p = 0.86) and bilateral disease does not resolve at 
the rate predicted by unilateral resolution. 
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APPENDIX A 
DATA STRUCTURE  
 insheet using "G:\ab4.csv", comma 
(38 vars, 1448 obs)  
.   g xoccup=occup 
.   replace xoccup=1 if occup==2 | occup==3 
(389 real changes made) 
.   replace xoccup=2 if occup==4 | occup==5  
(310 real changes made) 
.   replace xoccup=3 if occup==6 | occup==7 | occup==8 
(537 real changes made) 
.   replace xoccup=9 if occup==0 
(35 real changes made) 
.   label variable study   "Study" 
.   label variable rtrt  "Treatment" 
.   label variable gender  "Gender" 
.   label variable xrace   "Race" 
.   label variable xage   "Age @ entry" 
.   label variable durgrp  "Duration of OME @ entry" 
.   label variable xpreab "Antimicrobials rec'd in past 8 wks" 
.   label variable xhxdx   "History of ear disease" 
.   label variable season  "Season @ entry" 
.   label variable xuri1   "Upper respiratory infection @ entry" 
.   label variable xoccup   "Occupation of primary wage earner" 
.   label variable xlat    "Laterality of OME at entry" 
.   label variable sbjom11 "OME at entry visit" 
.   label variable sbjom12 "OME (subject) at 2 wk visit" 
.   label variable sbjom14 "OME (subject) at 4 wk visit" 
.   label variable ome1r1  "OME (R ear) at entry visit" 
.   label variable ome1l1  "OME (L ear) at entry visit" 
.   label variable ome1r2  "OME (R ear) at 2 wk visit" 
.   label variable ome1l2  "OME (L ear) at 2 wk visit" 
.   label variable ome1r4  "OME (R ear) at 4 wk visit" 
.   label variable ome1l4  "OME (L ear) at 4 wk visit" 
.   label variable xhear   "Avg hearing (SRT/SAT) @ entry" 
.   label variable id      "ID" 
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.   label define wssffm   1 "Winter"2 "Spring" 3 "Summer" 4 "Fall" 
.   label define occfm    1 "Exec/Sm.bus/Skld" 2 "Clerical/Semiskld" 3 
"Welfare/Unempld/Other" /// 
>   0 "Unknown" 9 "Unknown" 
.    drop preab xagegrp race hxdx xlater uri1 srtr1 srtl1 sat1 rsat1 rsrtr1 
rsrtl1 /// 
>        avgsrt1 hear1 attrib_all_la~e occup 
.   replace rtrt=0 if rtrt==2\ 
(552 real changes made) 
.   label define studyfm  1 "D & A" 2 "AB  I" 3 "AB II" 
.   label define meefm    1 "Effusion " 0 "No Effusion"   
.   label define aomfm    1 "AOM" 0 "No AOM" 
.   label define agefm    1 "< 2yrs" 0 ">=2yrs" 
.   label define dur2fm   1 "0-3 wks" 2 "4-8 wks" 3 "> 8 wks" 4 "Unknown" 
.   label define sexfm    1 "Male" 0 "Female"   
.   label define latfm    1 "Bilateral" 0 "Unilateral" 9 "Unknown"  
.   label define racefm   1 "Black" 0 "White"    
.   label define hxdxfm   1 "History" 0 "No history"  
.   label define preabfm  1 "Ab rec'd"  0 "No Ab rec'd" 
.   label define urifm    1 "(+) URI"    0 "(-) URI " 
.   label define rtrtfm   0 "Placebo" 1 "Amoxicillin" 3 "Amox/D&A" 4 "D&A" 
/// 
>                                 7 "E-S" 8 "Cefaclor" 
.   label define hrfm     1 "GE 25db" 0 "LT 25db" 9 "Unknown" 
.   label values sbjom11 meefm 
.   label values sbjom12 meefm 
.   label values sbjom14 meefm 
.   label values ome1r1 meefm 
.   label values ome1r2 meefm 
.   label values ome1r4 meefm 
.   label values ome1l1 meefm 
.   label values ome1l2 meefm 
.   label values ome1l4 meefm 
.   label values gender sexfm   
.   label values xrace racefm   
.   label values xage agefm 
.   label values season wssffm  
.   label values xpreab preabfm  
.   label values xoccup occfm 
.   label values study studyfm 
.   label values xhxdx hxdxfm  
.   label values xuri1 urifm  
.   label values xlat latfm  
.   label values xhear hrfm 
.   label values durgrp dur2fm  
.   label values rtrt rtrtfm 
. describe 
Contains data 
  obs:         1,448                           
 vars:            23                           
 size:        44,888 (95.7% of memory free) 
-----------------------------------------------------------------------------
-- 
              storage  display     value 
variable name   type   format      label      variable label 
-----------------------------------------------------------------------------
-- 
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durgrp          byte   %8.0g       dur2fm     Duration of OME @ entry 
season          byte   %8.0g       wssffm     Season @ entry 
ome1r1          byte   %11.0g      meefm      OME (R ear) at entry visit 
ome1l1          byte   %11.0g      meefm      OME (L ear) at entry visit 
sbjom11         byte   %11.0g      meefm      OME at entry visit 
ome1r2          byte   %11.0g      meefm      OME (R ear) at 2 wk visit 
ome1l2          byte   %11.0g      meefm      OME (L ear) at 2 wk visit 
sbjom12         byte   %11.0g      meefm      OME (subject) at 2 wk visit 
ome1r4          byte   %11.0g      meefm      OME (R ear) at 4 wk visit 
ome1l4          byte   %11.0g      meefm      OME (L ear) at 4 wk visit 
sbjom14         byte   %11.0g      meefm      OME (subject) at 4 wk visit 
rtrt            byte   %11.0g      rtrtfm     Treatment 
study           byte   %8.0g       studyfm    Study 
gender          byte   %8.0g       sexfm      Gender 
xlat            byte   %10.0g      latfm      Laterality of OME at entry 
xrace           byte   %8.0g       racefm     Race 
xpreab          byte   %11.0g      preabfm    Antimicrobials rec'd in past 8 
                                                wks 
xage            byte   %8.0g       agefm      Age @ entry 
xhxdx           byte   %10.0g      hxdxfm     History of ear disease 
xuri1           byte   %8.0g       urifm      Upper respiratory infection @ 
                                                entry 
xhear           byte   %8.0g       hrfm       Avg hearing (SRT/SAT) @ entry 
id              int    %8.0g                  ID 
xoccup          float  %21.0g      occfm      Occupation of primary wage 
                                                earner 
-----------------------------------------------------------------------------
-- 
Sorted by:   
     Note:  dataset has changed since last saved 
. reshape long ome1r ome1l sbjom1, i(id) j(week) 
(note: j = 1 2 4) 
 
Data                               wide   ->   long 
----------------------------------------------------------------------------- 
Number of obs.                     1448   ->    4344 
Number of variables                  25   ->      20 
j variable (3 values)                     ->   week 
xij variables: 
                   ome1r1 ome1r2 ome1r4   ->   ome1r 
                   ome1l1 ome1l2 ome1l4   ->   ome1l 
                sbjom11 sbjom12 sbjom14   ->   sbjom1 
----------------------------------------------------------------------------- 
. replace week=0 if week==1 
(1448 real changes made) 
. label variable ome1r "OME (R ear)" 
. label variable ome1l "OME (L ear)" 
. label variable sbjom1 "OME" 
. label variable week "Week" 
. g cat1=0 
. replace cat1=1 if (ome1r==1 & ome1l==0)  
(548 real changes made) 
. replace cat1=2 if (ome1r==0 & ome1l==1) 
(556 real changes made) 
. replace cat1=3 if (ome1r==1 & ome1l==1) 
(2418 real changes made) 
. replace cat1=4 if (ome1r==. | ome1l==.) 
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(232 real changes made) 
. g cat1p=cat1[_n-1] if week !=0 
(1448 missing values generated) 
. g cat1p2=cat1[_n-2] if week==4 
(2896 missing values generated) 
. g cat1l=cat1[_n+1] if week<4 
(1448 missing values generated) 
. label variable cat1 "OME at subject level" 
. label define catlab2 0 "No Effusion" 1 "R Effusion" 2 "L Effusion" 
3"Bilateral" 4 "Missing" 
. label values cat1 catlab2 
. label values cat1p catlab2 
. label values cat1p2 catlab2 
. label variable cat1p "Lag1" 
. label variable cat1p2 "Lag2" 
. label variable cat1l "Lead 1" 
. describe 
Contains data 
  obs:         4,344                           
 vars:            24                           
 size:       217,200 (79.3% of memory free) 
-----------------------------------------------------------------------------
-- 
              storage  display     value 
variable name   type   format      label      variable label 
-----------------------------------------------------------------------------
-- 
id              int    %8.0g                  ID 
week            byte   %9.0g                  Week 
durgrp          byte   %8.0g       dur2fm     Duration of OME @ entry 
season          byte   %8.0g       wssffm     Season @ entry 
ome1r           byte   %11.0g      meefm      OME (R ear) 
ome1l           byte   %11.0g      meefm      OME (L ear) 
sbjom1          byte   %11.0g      meefm      OME 
rtrt            byte   %11.0g      rtrtfm     Treatment 
study           byte   %8.0g       studyfm    Study 
gender          byte   %8.0g       sexfm      Gender 
xlat            byte   %10.0g      latfm      Laterality of OME at entry 
xrace           byte   %8.0g       racefm     Race 
xpreab          byte   %11.0g      preabfm    Antimicrobials rec'd in past 8 
                                                wks 
xage            byte   %8.0g       agefm      Age @ entry 
xhxdx           byte   %10.0g      hxdxfm     History of ear disease 
xuri1           byte   %8.0g       urifm      Upper respiratory infection @ 
                                                entry 
xhear           byte   %8.0g       hrfm       Avg hearing (SRT/SAT) @ entry 
xoccup          float  %21.0g      occfm      Occupation of primary wage 
                                                earner 
trt             float  %24.0g      trt2fm     Treatment 
xlat2           float  %12.0g      xlatfm2     
cat1            float  %11.0g      catlab2    OME at subject level 
cat1p           float  %11.0g      catlab2    Lag1 
cat1p2          float  %11.0g      catlab2    Lag2 
cat1l           float  %9.0g                  Lead 1 
-----------------------------------------------------------------------------
-- 
Sorted by:  id 
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     Note:  dataset has changed since last saved 
. g ome1e1=ome1r 
(227 missing values generated) 
 
. g ome1e2=ome1l 
(228 missing values generated) 
 
. save “G:\ab4”, replace 
. reshape long ome1e, i(id week) j(ear) 
(note: j = 1 2) 
 
Data                               wide   ->   long 
----------------------------------------------------------------------------- 
Number of obs.                     4344   ->    8688 
Number of variables                  26   ->      26 
j variable (2 values)                     ->   ear 
xij variables: 
                          ome1e1 ome1e2   ->   ome1e 
----------------------------------------------------------------------------- 
. list id week ome1e ear ome1r ome1l in 1/12 
. label variable ome1e "OME of ear" 
. label variable ear "Ear" 
. label define earlab 1 "Right" 2 "Left" 
. label value ome1e meefm 
. label value ear earlab 
 
. * Confirm treatment 
. iis id  
 
. tis week 
 
.  
. xi:xtgee ome1e i.rtrt i.week, family(binomial) corr(exch) robust 
i.rtrt            _Irtrt_0-8          (naturally coded; _Irtrt_0 omitted) 
i.week            _Iweek_0-4          (naturally coded; _Iweek_0 omitted) 
 
Iteration 1: tolerance = .04508525 
Iteration 2: tolerance = .00035624 
Iteration 3: tolerance = .00002386 
Iteration 4: tolerance = 5.003e-07 
 
GEE population-averaged model                   Number of obs     =      8233 
Group variable:                         id      Number of groups  =      1448 
Link:                                logit      Obs per group: min          2 
Family:                           binomial                     avg=       5.7 
Correlation:                  exchangeable                     max          6 
                                                Wald chi2(7)      =    560.15 
Scale parameter:                         1      Prob > chi2       =    0.0000 
 
                                     Std. Err. adjusted for clustering on id) 
----------------------------------------------------------------------------- 
             |             Semi-robust 
       ome1e |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
    _Irtrt_1 |   -.528186   .1093753    -4.83   0.000   -.7425576   -.3138143 
    _Irtrt_3 |  -.5068431    .127868    -3.96   0.000   -.7574598   -.2562264 
    _Irtrt_4 |  -.1383911   .1077881    -1.28   0.199   -.3496518    .0728696 
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    _Irtrt_7 |    -.22091   .1798446    -1.23   0.219   -.5733989    .1315789 
    _Irtrt_8 |  -.4025645   .1809581    -2.22   0.026    .7572358   -.0478932 
    _Iweek_2 |  -1.066218   .0559656   -19.05   0.000   -1.175909   -.9565273 
    _Iweek_4 |  -1.320223    .057906   -22.80   0.000    1.433717    -1.20673 
       _cons |   2.027485   .0757413    26.77   0.000    1.879035    2.175935 
----------------------------------------------------------------------------- 
 
. test _Irtrt_1=_Irtrt_3 
 
 ( 1)  _Irtrt_1 - _Irtrt_3 = 0 
 
           chi2(  1) =    0.02 
         Prob > chi2 =    0.8775 
 
. test _Irtrt_8=_Irtrt_1 
 
 ( 1) - _Irtrt_1 + _Irtrt_8 = 0 
 
           chi2(  1) =    0.44 
         Prob > chi2 =    0.5055 
 
. g trt=rtrt 
 
. replace trt=1 if rtrt==3 
(1044 real changes made) 
 
. replace trt=1 if rtrt==8 
(498 real changes made) 
 
. replace trt=0 if rtrt==4 | rtrt==7 
(2340 real changes made) 
 
.   
. label variable trt "combined treatment" 
 
. label define trtlab 0 "placebo/D&A/E-S" 1 "amoxicillin/amoxicillin and 
D&A/Cefaclor" 
. label value trt trtlab  
. save "G:\ab4treatment", replace 
file G:\ab4treatment.dta saved 
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APPENDIX B 
CODE FOR DISCRIPTIVE ANALYSIS AND MODELING 
B.1 DESCRIPTIVE ANALYSIS 
. use “G:\ab4” 
. g trt=rtrt 
. replace trt=1 if rtrt==3 
(1044 real changes made) 
. replace trt=1 if rtrt==8 
(498 real changes made) 
. replace trt=0 if rtrt==4 | rtrt==7 
(2340 real changes made) 
. label variable trt "combined treatment" 
 
. label define trtlab 0 "placebo/D&A/E-S" 1 "amoxicillin/amoxicillin and 
D&A/Cefaclor" 
. label value trt trtlab  
. iis id 
. tis week 
. *Prevalence table 
. tab cat1 if week==0 
 
     OME at | 
    subject | 
      level |      Freq.     Percent        Cum. 
------------+----------------------------------- 
 R Effusion |        202       13.95       13.95 
 L Effusion |        212       14.64       28.59 
  Bilateral |      1,034       71.41      100.00 
------------+----------------------------------- 
      Total |      1,448      100.00 
 
. sort xlat xlat2 
. by xlat: tab week cat1, row 
----------------------------------------------------------------------------- 
-> xlat = Unilateral 
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+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral   Missing |     Total 
-----------+------------------------------------------------------+--------- 
         0 |         0        202        212          0         0 |       414  
           |      0.00      48.79      51.21       0.00      0.00 |    100.00  
-----------+------------------------------------------------------+---------- 
         2 |       105        104         94         69        42 |       414  
           |     25.36      25.12      22.71      16.67     10.14 |    100.00  
-----------+------------------------------------------------------+---------- 
         4 |       139         72         84         75        44 |       414  
           |     33.57      17.39      20.29      18.12     10.63 |    100.00  
-----------+------------------------------------------------------+---------- 
     Total |       244        378        390        144        86 |     1,242  
           |     19.65      30.43      31.40      11.59      6.92 |    100.00  
-----------------------------------------------------------------------------
-----> xlat = Bilateral 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral   Missing |     Total 
-----------+------------------------------------------------------+---------- 
         0 |         0          0          0      1,034         0 |     1,034  
           |      0.00       0.00       0.00     100.00      0.00 |    100.00  
-----------+------------------------------------------------------+---------- 
         2 |       149         84         75        660        66 |     1,034  
           |     14.41       8.12       7.25      63.83      6.38 |    100.00  
-----------+------------------------------------------------------+---------- 
         4 |       197         86         91        580        80 |     1,034  
           |     19.05       8.32       8.80      56.09      7.74 |    100.00  
-----------+------------------------------------------------------+---------- 
     Total |       346        170        166      2,274       146 |     3,102  
           |     11.15       5.48       5.35      73.31      4.71 |    100.00  
 
. sort xlat2 
. by xlat2: tab week cat1 if xlat==0, row 
----------------------------------------------------------------------------- 
-> xlat2 = Unilateral R 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
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+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral   Missing |     Total 
-----------+------------------------------------------------------+---------- 
         0 |         0        202          0          0         0 |       202  
           |      0.00     100.00       0.00       0.00      0.00 |    100.00  
-----------+------------------------------------------------------+---------- 
         2 |        49         99          5         30        19 |       202  
           |     24.26      49.01       2.48      14.85      9.41 |    100.00  
-----------+------------------------------------------------------+---------- 
         4 |        71         67          7         37        20 |       202  
           |     35.15      33.17       3.47      18.32      9.90 |    100.00  
-----------+------------------------------------------------------+---------- 
     Total |       120        368         12         67        39 |       606  
           |     19.80      60.73       1.98      11.06      6.44 |    100.00  
 
 
----------------------------------------------------------------------------- 
-> xlat2 = Unilateral L 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0          0        212          0          0 |     212  
           |      0.00       0.00     100.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        56          5         89         39         23 |     212  
           |     26.42       2.36      41.98      18.40      10.85 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        68          5         77         38         24 |     212  
           |     32.08       2.36      36.32      17.92      11.32 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       124         10        378         77         47 |     636  
           |     19.50       1.57      59.43      12.11       7.39 |  100.00  
----------------------------------------------------------------------------- 
-> xlat2 = Bilateral 
no observations 
 
. sort trt xlat 
 
. by trt: tab cat1 if week==0 
 
-----------------------------------------------------------------------------
----- 
-> trt = placebo/D&A/E-S 
 
     OME at | 
    subject | 
      level |      Freq.     Percent        Cum. 
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------------+----------------------------------- 
 R Effusion |        128       13.59       13.59 
 L Effusion |        131       13.91       27.49 
  Bilateral |        683       72.51      100.00 
------------+----------------------------------- 
      Total |        942      100.00 
 
-----------------------------------------------------------------------------
----- 
-> trt = amoxicillin/amoxicillin and D&A/Cefaclor 
 
     OME at | 
    subject | 
      level |      Freq.     Percent        Cum. 
------------+----------------------------------- 
 R Effusion |         74       14.62       14.62 
 L Effusion |         81       16.01       30.63 
  Bilateral |        351       69.37      100.00 
------------+----------------------------------- 
      Total |        506      100.00 
 
 
. by trt xlat: tab week cat1, row 
 
-----------------------------------------------------------------------------
------> trt = placebo/D&A/E-S, xlat = Unilateral 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0        128        131          0          0 |     259  
           |      0.00      49.42      50.58       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        53         74         59         48         25 |     259  
           |     20.46      28.57      22.78      18.53       9.65 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        80         49         51         53         26 |     259  
           |     30.89      18.92      19.69      20.46      10.04 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       133        251        241        101         51 |     777  
           |     17.12      32.30      31.02      13.00       6.56 |  100.00  
 
-----------------------------------------------------------------------------
------> trt = placebo/D&A/E-S, xlat = Bilateral 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
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+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0          0          0        683          0 |     683  
           |      0.00       0.00       0.00     100.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        71         46         53        465         48 |     683  
           |     10.40       6.73       7.76      68.08       7.03 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |       113         59         51        401         59 |     683  
           |     16.54       8.64       7.47      58.71      8.64  |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       184        105        104      1,549        107 |   2,049  
           |      8.98       5.12       5.08      75.60       5.22 |  100.00  
 
-----------------------------------------------------------------------------
------> trt = amoxicillin/amoxicillin and D&A/Cefaclor, xlat = Unilateral 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0         74         81          0          0 |     155  
           |      0.00      47.74      52.26       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        52         30         35         21         17 |     155  
           |     33.55      19.35      22.58      13.55      10.97 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        59         23         33         22         18 |     155  
           |     38.06      14.84      21.29      14.19      11.61 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       111        127        149         43         35 |     465  
           |     23.87      27.31      32.04       9.25       7.53 |  100.00  
----------------------------------------------------------------------------- 
-> trt = amoxicillin/amoxicillin and D&A/Cefaclor, xlat = Bilateral 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0          0          0        351          0 |     351  
           |      0.00       0.00       0.00     100.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
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         2 |        78         38         22        195         18 |     351  
           |     22.22      10.83       6.27      55.56       5.13 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        84         27         40        179         21 |     351  
           |     23.93       7.69      11.40      51.00       5.98 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       162         65         62        725         39 |   1,053  
           |     15.38       6.17       5.89      68.85       3.70 |  100.00  
 
 
. sort trt xlat2 
 
. by trt xlat2: tab week cat1 if xlat==0, row 
 
-----------------------------------------------------------------------------
----- 
-> trt = placebo/D&A/E-S, xlat2 = Unilateral R 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0        128          0          0          0 |     128  
           |      0.00     100.00       0.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        27         69          3         19         10 |     128  
           |     21.09      53.91       2.34      14.84       7.81 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        41         48          2         26         11 |     128  
           |     32.03      37.50       1.56      20.31       8.59 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |        68        245          5         45         21 |     384  
           |     17.71      63.80       1.30      11.72       5.47 |  100.00  
 
-----------------------------------------------------------------------------
------> trt = placebo/D&A/E-S, xlat2 = Unilateral L 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0          0        131          0          0 |     131  
           |      0.00       0.00     100.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        26          5         56         29         15 |     131  
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           |     19.85       3.82      42.75      22.14      11.45 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        39          1         49         27         15 |     131  
           |     29.77       0.76      37.40      20.61      11.45 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |        65          6        236         56         30 |     393  
           |     16.54       1.53      60.05      14.25       7.63 |  100.00  
----------------------------------------------------------------------------- 
-> trt = placebo/D&A/E-S, xlat2 = Bilateral 
no observations 
 
----------------------------------------------------------------------------- 
-> trt = amoxicillin/amoxicillin and D&A/Cefaclor, xlat2 = Unilateral R 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0         74          0          0          0 |      74  
           |      0.00     100.00       0.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        22         30          2         11          9 |      74  
           |     29.73      40.54       2.70      14.86      12.16 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        30         19          5         11          9 |      74  
           |     40.54      25.68       6.76      14.86      12.16 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |        52        123          7         22         18 |     222  
           |     23.42      55.41       3.15       9.91       8.11 |  100.00  
----------------------------------------------------------------------------- 
-> trt = amoxicillin/amoxicillin and D&A/Cefaclor, xlat2 = Unilateral L 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |                  OME at subject level 
      Week | No Effusi  R Effusio  L Effusio  Bilateral    Missing |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |         0          0         81          0          0 |      81  
           |      0.00       0.00     100.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        30          0         33         10          8 |      81  
           |     37.04       0.00      40.74      12.35       9.88 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |        29          4         28         11          9 |      81  
           |     35.80       4.94      34.57      13.58      11.11 |  100.00  
-----------+-------------------------------------------------------+--------- 
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     Total |        59          4        142         21         17 |     243  
           |     24.28       1.65      58.44       8.64       7.00 |  100.00  
 
-----------------------------------------------------------------------------
----- 
-> trt = amoxicillin/amoxicillin and D&A/Cefaclor, xlat2 = Bilateral 
no observations 
 
 
.  
. * McNemar's test for UL vs. UR by laterality groups 
. mcc ome1r ome1l if week==2 & xlat==0 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        69         104  |        173 
       Unexposed |        94         105  |        199 
-----------------+------------------------+------------ 
           Total |       163         209  |        372 
 
McNemar's chi2(1) =      0.51    Prob > chi2 = 0.4773 
Exact McNemar significance probability       = 0.5225 
 
Proportion with factor 
        Cases       .4650538 
        Controls     .438172     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference  .0268817     -.0498936    .103657 
        ratio        1.06135      .9006011    1.25079 
        rel. diff.  .0478469     -.0809151   .1766089 
 
        odds ratio  1.106383      .8289819   1.478253   (exact) 
 
. mcc ome1r ome1l if week==4 & xlat==0 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        75          72  |        147 
       Unexposed |        84         139  |        223 
-----------------+------------------------+------------ 
           Total |       159         211  |        370 
 
McNemar's chi2(1) =      0.92    Prob > chi2 = 0.3367 
Exact McNemar significance probability       = 0.3785 
 
Proportion with factor 
        Cases       .3972973 
        Controls    .4297297     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0324324     -.1012146   .0363497 
        ratio       .9245283      .7877343   1.085077 
        rel. diff.  -.056872     -.1761442   .0624001 
 
        odds ratio  .8571429      .6168404   1.188452   (exact) 
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.  
. mcc ome1r ome1l if week==2 & xlat==1 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |       660          84  |        744 
       Unexposed |        75         149  |        224 
-----------------+------------------------+------------ 
           Total |       735         233  |        968 
 
McNemar's chi2(1) =      0.51    Prob > chi2 = 0.4754 
Exact McNemar significance probability       = 0.5259 
 
Proportion with factor 
        Cases        .768595 
        Controls    .7592975     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference  .0092975       -.01726   .0358551 
        ratio       1.012245       .978974   1.046647 
        rel. diff.  .0386266     -.0653742   .1426274 
 
        odds ratio      1.12      .8105131   1.550102   (exact) 
 
. mcc ome1r ome1l if week==4 & xlat==1 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |       580          86  |        666 
       Unexposed |        91         197  |        288 
-----------------+------------------------+------------ 
           Total |       671         283  |        954 
 
McNemar's chi2(1) =      0.14    Prob > chi2 = 0.7070 
Exact McNemar significance probability       = 0.7638 
 
Proportion with factor 
        Cases       .6981132 
        Controls    .7033543     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0052411     -.0336202    .023138 
        ratio       .9925484       .954578   1.032029 
        rel. diff. -.0176678     -.1106183   .0752826 
 
        odds ratio  .9450549      .6955118   1.283234   (exact) 
 
.  
. mcc ome1r ome1l if week==2 & trt==0 & xlat==0 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        48          74  |        122 
       Unexposed |        59          53  |        112 
-----------------+------------------------+------------ 
           Total |       107         127  |        234 
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McNemar's chi2(1) =      1.69    Prob > chi2 = 0.1934 
Exact McNemar significance probability       = 0.2246 
 
Proportion with factor 
        Cases       .5213675 
        Controls     .457265     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference  .0641026     -.0364169    .164622 
        ratio       1.140187      .9355298   1.389615 
        rel. diff.  .1181102     -.0490286   .2852491 
 
        odds ratio  1.254237      .8788323   1.796893   (exact) 
 
. mcc ome1r ome1l if week==2 & trt==1 & xlat==0 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        21          30  |         51 
       Unexposed |        35          52  |         87 
-----------------+------------------------+------------ 
           Total |        56          82  |        138 
 
McNemar's chi2(1) =      0.38    Prob > chi2 = 0.5351 
Exact McNemar significance probability       = 0.6201 
 
Proportion with factor 
        Cases       .3695652 
        Controls    .4057971     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0362319     -.1578239   .0853601 
        ratio       .9107143      .6775929    1.22404 
        rel. diff. -.0609756     -.2594679   .1375167 
 
        odds ratio  .8571429      .5083432   1.437092   (exact) 
 
. mcc ome1r ome1l if week==4 & trt==0 & xlat==0  
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        53          49  |        102 
       Unexposed |        51          80  |        131 
-----------------+------------------------+------------ 
           Total |       104         129  |        233 
 
McNemar's chi2(1) =      0.04    Prob > chi2 = 0.8415 
Exact McNemar significance probability       = 0.9204 
 
Proportion with factor 
        Cases       .4377682 
        Controls    .4463519     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0085837     -.0969869   .0798196 
        ratio       .9807692      .8108154   1.186347 
        rel. diff. -.0155039     -.1686123   .1376046 
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        odds ratio  .9607843      .6357086   1.450762   (exact) 
 
. mcc ome1r ome1l if week==4 & trt==1 & xlat==0 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |        22          23  |         45 
       Unexposed |        33          59  |         92 
-----------------+------------------------+------------ 
           Total |        55          82  |        137 
 
McNemar's chi2(1) =      1.79    Prob > chi2 = 0.1814 
Exact McNemar significance probability       = 0.2288 
 
Proportion with factor 
        Cases       .3284672 
        Controls    .4014599     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0729927     -.1866506   .0406652 
        ratio       .8181818      .6092729   1.098722 
        rel. diff. -.1219512     -.3114102   .0675078 
 
        odds ratio  .6969697      .3907655   1.223384   (exact) 
 
. * transition matrix 
. xttrans cat1 if week<4, freq 
 
    OME at | 
   subject |                  OME at subject level 
     level |         0          1          2          3          4 |    Total 
-----------+-------------------------------------------------------+--------- 
         1 |        49         99          5         30         19 |     202  
           |     24.26      49.01       2.48      14.85       9.41 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        56          5         89         39         23 |     212  
           |     26.42       2.36      41.98      18.40      10.85 |  100.00  
-----------+-------------------------------------------------------+--------- 
         3 |       149         84         75        660         66 |   1,034  
           |     14.41       8.12       7.25      63.83       6.38 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       254        188        169        729        108 |   1,448  
           |     17.54      12.98      11.67      50.35       7.46 |   00.00  
 
. xttrans cat1 if week>0, freq 
 
    OME at | 
   subject |                  OME at subject level 
     level |         0          1          2          3          4 |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |       157         21         29         38          9 |     254  
           |     61.81       8.27      11.42      14.96       3.54 |   00.00  
-----------+-------------------------------------------------------+--------- 
         1 |        54         77          8         43          6 |     188  
           |     28.72      40.96       4.26      22.87       3.19 |  100.00  
-----------+-------------------------------------------------------+--------- 
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         2 |        44          6         69         43          7 |     169  
           |     26.04       3.55      40.83      25.44       4.14 |  100.00  
-----------+-------------------------------------------------------+--------- 
         3 |        74         51         68        517         19 |     729  
           |     10.15       7.00       9.33      70.92       2.61 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |         7          3          1         14         83 |     108  
           |      6.48       2.78       0.93      12.96      76.85 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       336        158        175        655        124 |   1,448  
           |     23.20      10.91      12.09      45.23       8.56 |  100.00  
 
. sort xlat2 
 
. by xlat2: xttrans cat1 if week>0, freq  
 
---------------------------------------------------------------------------- 
-> xlat2 = Unilateral R 
 
    OME at | 
   subject |                  OME at subject level 
     level |         0          1          2          3          4 |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |        36          6          1          5          1 |      49  
           |     73.47      12.24       2.04      10.20       2.04 |  100.00  
-----------+-------------------------------------------------------+--------- 
         1 |        29         52          3         13          2 |      99  
           |     29.29      52.53       3.03      13.13       2.02 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |         4          0          1          0          0 |       5  
           |     80.00       0.00      20.00       0.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         3 |         2          6          2         18          2 |      30  
           |      6.67      20.00       6.67      60.00       6.67 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |         0          3          0          1         15 |      19  
           |      0.00      15.79       0.00       5.26      78.95 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |        71         67          7         37         20 |     202  
           |     35.15      33.17       3.47      18.32       9.90 |  100.00  
 
----------------------------------------------------------------------------- 
-> xlat2 = Unilateral L 
 
    OME at | 
   subject |                  OME at subject level 
     level |         0          1          2          3          4 |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |        34          3         14          3          2 |      56  
           |     60.71       5.36      25.00       5.36       3.57 |  100.00  
-----------+-------------------------------------------------------+--------- 
         1 |         3          0          1          1          0 |       5  
           |     60.00       0.00      20.00      20.00       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        22          1         53         10          3 |      89  
           |     24.72       1.12      59.55      11.24       3.37 |  100.00  
-----------+-------------------------------------------------------+--------- 
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         3 |         5          1          9         24          0 |      39  
           |     12.82       2.56      23.08      61.54       0.00 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |         4          0          0          0         19 |      23  
           |     17.39       0.00       0.00       0.00      82.61 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |        68          5         77         38         24 |     212  
           |     32.08       2.36      36.32      17.92      11.32 |  100.00  
 
----------------------------------------------------------------------------- 
-> xlat2 = Bilateral 
 
    OME at | 
   subject |                  OME at subject level 
     level |         0          1          2          3          4 |    Total 
-----------+-------------------------------------------------------+--------- 
         0 |        87         12         14         30          6 |     149  
           |     58.39       8.05       9.40      20.13       4.03 |  100.00  
-----------+-------------------------------------------------------+--------- 
         1 |        22         25          4         29          4 |      84  
           |     26.19      29.76       4.76      34.52       4.76 |  100.00  
-----------+-------------------------------------------------------+--------- 
         2 |        18          5         15         33          4 |      75  
           |     24.00       6.67      20.00      44.00       5.33 |  100.00  
-----------+-------------------------------------------------------+--------- 
         3 |        67         44         57        475         17 |     660  
           |     10.15       6.67       8.64      71.97       2.58 |  100.00  
-----------+-------------------------------------------------------+--------- 
         4 |         3          0          1         13         49 |      66  
           |      4.55       0.00       1.52      19.70      74.24 |  100.00  
-----------+-------------------------------------------------------+--------- 
     Total |       197         86         91        580         80 |   1,034  
           |     19.05       8.32       8.80      56.09       7.74 |  100.00  
 
B.2 MODELING 
. * Baseline 
. xi: mlogit cat1 i.study i.trt xage gender xrace i.xoccup xpreab xuri1 
i.durgrp xhxdx i.season if week==0, baseoutcome(1) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -1010.9842 
Iteration 1:   log likelihood = -981.12635 
Iteration 2:   log likelihood = -980.34357 
Iteration 3:   log likelihood = -980.34207 
Iteration 4:   log likelihood = -980.34207 
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Multinomial logistic regression                   Number of obs   =      1278 
                                                  LR chi2(36)     =     61.28 
                                                  Prob > chi2     =    0.0054 
Log likelihood = -980.34207                       Pseudo R2       =    0.0303 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+---------------------------------------------------------------
- 
L Effusion   | 
   _Istudy_2 |  -.3266058   .3173157    -1.03   0.303   -.9485332    .2953217 
   _Istudy_3 |  -.4199986   .3357981    -1.25   0.211   -1.078151    .2381536 
     _Itrt_1 |   .3094779   .2800395     1.11   0.269   -.2393895    .8583453 
        xage |  -.0417201   .2341626    -0.18   0.859    -.5006703   .4172301 
      gender |  -.0734806   .2197366    -0.33   0.738    -.5041564   .3571953 
       xrace |    .065982   .2589511     0.25   0.799    -.4415528   .5735168 
  _Ixoccup_2 |  -.2479343   .2936802    -0.84   0.399    -.8235369   .3276684 
  _Ixoccup_3 |  -.2878265   .2540586    -1.13   0.257    -.7857723   .2101193 
  _Ixoccup_9 |   .4099274   .8976054     0.46   0.648    -1.349347   2.169202 
      xpreab |   .2124063   .2624547     0.81   0.418    -.3019955   .7268081 
       xuri1 |  -.3136263    .266827    -1.18   0.240    -.8365976   .2093449 
  _Idurgrp_2 |   .1530066   .3398378     0.45   0.653    -.5130632   .8190764 
  _Idurgrp_3 |   .2940532   .3127314     0.94   0.347    -.3188891   .9069956 
  _Idurgrp_4 |   .1922431   .3194989     0.60   0.547    -.4339632   .8184494 
       xhxdx |   .0133962   .3886291     0.03   0.973    -.7483028   .7750951 
  _Iseason_2 |   -.113553    .259654    -0.44   0.662    -.6224655   .3953596 
  _Iseason_3 |  -.2747156   .3242709    -0.85   0.397    -.9102749   .3608438 
  _Iseason_4 |  -.0763674   .3159946    -0.24   0.809    -.6957053   .5429706 
       _cons |   .1213716   .5007615     0.24   0.808    -.8601028   1.102846 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Istudy_2 |  -.1295532   .2408803    -0.54   0.591      -.60167   .3425635 
   _Istudy_3 |   .0833641   .2530736     0.33   0.742    -.4126511   .5793793 
     _Itrt_1 |  -.0439525   .2107678    -0.21   0.835    -.4570498   .3691448 
        xage |  -.0867264   .1830157    -0.47   0.636    -.4454306   .2719779 
      gender |  -.1142711   .1714972    -0.67   0.505    -.4503994   .2218572 
       xrace |  -.0899433   .2032854    -0.44   0.658    -.4883752   .3084887 
  _Ixoccup_2 |   .1143291   .2264667     0.50   0.614    -.3295376   .5581957 
  _Ixoccup_3 |  -.0025196   .1994098    -0.01   0.990    -.3933556   .3883163 
  _Ixoccup_9 |   -.706426   .8508732    -0.83   0.406    -2.374107   .9612547 
      xpreab |  -.1178181   .2005835    -0.59   0.557    -.5109545   .2753183 
       xuri1 |    .438241   .1967711     2.23   0.026     .0525767   .8239053 
  _Idurgrp_2 |   .0785698   .2696718     0.29   0.771    -.4499772   .6071167 
  _Idurgrp_3 |   .7412059   .2439157     3.04   0.002     .2631399   1.219272 
  _Idurgrp_4 |   .5591364   .2452774     2.28   0.023     .0784014   1.039871 
       xhxdx |  -.3111074   .2929866    -1.06   0.288    -.8853507   .2631358 
  _Iseason_2 |  -.0286123   .2036574    -0.14   0.888    -.4277735    .370549 
  _Iseason_3 |  -.3849488   .2520488    -1.53   0.127    -.8789554   .1090578 
  _Iseason_4 |    .048414   .2447397     0.20   0.843     -.431267    .528095 
       _cons |   1.639332   .3836166     4.27   0.000     .8874568   2.391206 
----------------------------------------------------------------------------- 
(cat1==R Effusion is the base outcome) 
 
.  
. testparm _Istudy*  
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 ( 1)  [L Effusion]_Istudy_2 = 0 
 ( 2)  [Bilateral]_Istudy_2 = 0 
 ( 3)  [L Effusion]_Istudy_3 = 0 
 ( 4)  [Bilateral]_Istudy_3 = 0 
 
           chi2(  4) =    4.56 
         Prob > chi2 =    0.3360 
 
. testparm _Itrt*  
 
 ( 1)  [L Effusion]_Itrt_1 = 0 
 ( 2)  [Bilateral]_Itrt_1 = 0 
 
           chi2(  2) =    2.49 
         Prob > chi2 =    0.2880 
 
. testparm xage 
 
 ( 1)  [L Effusion]xage = 0 
 ( 2)  [Bilateral]xage = 0 
 
           chi2(  2) =    0.25 
         Prob > chi2 =    0.8829 
 
. testparm gender  
 
 ( 1)  [L Effusion]gender = 0 
 ( 2)  [Bilateral]gender = 0 
 
           chi2(  2) =    0.46 
         Prob > chi2 =    0.7951 
 
. testparm xrace  
 
 ( 1)  [L Effusion]xrace = 0 
 ( 2)  [Bilateral]xrace = 0 
 
           chi2(  2) =    0.67 
         Prob > chi2 =    0.7137 
 
. testparm _Ixoccup*  
 
 ( 1)  [L Effusion]_Ixoccup_2 = 0 
 ( 2)  [Bilateral]_Ixoccup_2 = 0 
 ( 3)  [L Effusion]_Ixoccup_3 = 0 
 ( 4)  [Bilateral]_Ixoccup_3 = 0 
 ( 5)  [L Effusion]_Ixoccup_9 = 0 
 ( 6)  [Bilateral]_Ixoccup_9 = 0 
 
           chi2(  6) =    7.12 
         Prob > chi2 =    0.3098 
 
. testparm xpreab  
 
 ( 1)  [L Effusion]xpreab = 0 
 ( 2)  [Bilateral]xpreab = 0 
 
 73 
           chi2(  2) =    2.70 
         Prob > chi2 =    0.2589 
 
. testparm xuri1  
 
 ( 1)  [L Effusion]xuri1 = 0 
 ( 2)  [Bilateral]xuri1 = 0 
 
           chi2(  2) =   15.71 
         Prob > chi2 =    0.0004 
 
. testparm _Idurgrp* 
 
 ( 1)  [L Effusion]_Idurgrp_2 = 0 
 ( 2)  [Bilateral]_Idurgrp_2 = 0 
 ( 3)  [L Effusion]_Idurgrp_3 = 0 
 ( 4)  [Bilateral]_Idurgrp_3 = 0 
 ( 5)  [L Effusion]_Idurgrp_4 = 0 
 ( 6)  [Bilateral]_Idurgrp_4 = 0 
 
           chi2(  6) =   16.35 
         Prob > chi2 =    0.0120 
 
. testparm xhxdx 
 
 ( 1)  [L Effusion]xhxdx = 0 
 ( 2)  [Bilateral]xhxdx = 0 
 
           chi2(  2) =    2.01 
         Prob > chi2 =    0.3667 
 
. testparm _Iseason*  
 
 ( 1)  [L Effusion]_Iseason_2 = 0 
 ( 2)  [Bilateral]_Iseason_2 = 0 
 ( 3)  [L Effusion]_Iseason_3 = 0 
 ( 4)  [Bilateral]_Iseason_3 = 0 
 ( 5)  [L Effusion]_Iseason_4 = 0 
 ( 6)  [Bilateral]_Iseason_4 = 0 
 
           chi2(  6) =    3.37 
         Prob > chi2 =    0.7618 
 
.  
. xi: mlogit cat1 xuri1 i.durgrp if week==0, baseoutcome(1) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
 
Iteration 0:   log likelihood = -1021.1356 
Iteration 1:   log likelihood = -1003.4503 
Iteration 2:   log likelihood = -1003.2452 
Iteration 3:   log likelihood = -1003.2451 
 
Multinomial logistic regression                   Number of obs   =      1289 
                                                  LR chi2(8)      =     35.78 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1003.2451                       Pseudo R2       =    0.0175 
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----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+---------------------------------------------------------------
- 
L Effusion   | 
       xuri1 |  -.2384627   .2610409    -0.91   0.361   -.7500934     .273168 
  _Idurgrp_2 |    .218595   .3320431     0.66   0.510   -.4321976    .8693876 
  _Idurgrp_3 |   .3496523   .3038706     1.15   0.250   -.2459232    .9452278 
  _Idurgrp_4 |   .1349241   .2988336     0.45   0.652    -.450779    .7206273 
       _cons |  -.1308602   .2400394    -0.55   0.586   -.6013287    .3396083 
-------------+--------------------------------------------------------------- 
Bilateral    | 
       xuri1 |   .4838889   .1930911     2.51   0.012    .1054372    .8623406 
  _Idurgrp_2 |   .0662502    .262331     0.25   0.801   -.4479091    .5804094 
  _Idurgrp_3 |   .7363836   .2368323     3.11   0.002    .2722008    1.200566 
  _Idurgrp_4 |   .6058358   .2292334     2.64   0.008    .1565467    1.055125 
       _cons |    1.05003   .1867319     5.62   0.000    .6840426    1.416018 
-----------------------------------------------------------------------------
- 
(cat1==R Effusion is the base outcome) 
 
.  
. testparm xuri1 
 
 ( 1)  [L Effusion]xuri1 = 0 
 ( 2)  [Bilateral]xuri1 = 0 
 
           chi2(  2) =   16.64 
         Prob > chi2 =    0.0002 
 
. testparm _Idurgrp* 
 
 ( 1)  [L Effusion]_Idurgrp_2 = 0 
 ( 2)  [Bilateral]_Idurgrp_2 = 0 
 ( 3)  [L Effusion]_Idurgrp_3 = 0 
 ( 4)  [Bilateral]_Idurgrp_3 = 0 
 ( 5)  [L Effusion]_Idurgrp_4 = 0 
 ( 6)  [Bilateral]_Idurgrp_4 = 0 
 
           chi2(  6) =   20.50 
         Prob > chi2 =    0.0023 
 
.  
. mlogit, rrr 
 
Multinomial logistic regression                   Number of obs   =      1289 
                                                  LR chi2(8)      =     35.78 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1003.2451                       Pseudo R2       =    0.0175 
 
----------------------------------------------------------------------------- 
        cat1 |        RRR   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
L Effusion   | 
       xuri1 |   .7878381    .205658    -0.91   0.361    .4723224    1.314121 
  _Idurgrp_2 |   1.244327   .4131703     0.66  0.510     .6490811     2.38545 
  _Idurgrp_3 |   1.418574   .4310631     1.15   0.250    .7819823      2.5734 
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  _Idurgrp_4 |    1.14445   .3420001     0.45   0.652    .6371316    2.055722 
-------------+--------------------------------------------------------------- 
Bilateral    | 
       xuri1 |   1.622371   .3132656     2.51   0.012    1.111196    2.368698 
  _Idurgrp_2 |   1.068494   .2802991     0.25   0.801    .6389627     1.78677 
  _Idurgrp_3 |   2.088369   .4945934     3.11   0.002    1.312851    3.321998 
  _Idurgrp_4 |   1.832783   .4201352     2.64   0.008    1.169465    2.872334 
----------------------------------------------------------------------------- 
(cat1==R Effusion is the base outcome) 
 
.  
. test ["L Effusion"] 
 
 ( 1)  [L Effusion]xuri1 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [L Effusion]_Idurgrp_3 = 0 
 ( 4)  [L Effusion]_Idurgrp_4 = 0 
 
           chi2(  4) =    2.30 
         Prob > chi2 =    0.6809 
 
. test ["Bilateral"] 
 
 ( 1)  [Bilateral]xuri1 = 0 
 ( 2)  [Bilateral]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_3 = 0 
 ( 4)  [Bilateral]_Idurgrp_4 = 0 
 
           chi2(  4) =   19.54 
         Prob > chi2 =    0.0006 
 
. test ["Bilateral"="L Effusion"] 
 
 ( 1) - [L Effusion]xuri1 + [Bilateral]xuri1 = 0 
 ( 2) - [L Effusion]_Idurgrp_2 + [Bilateral]_Idurgrp_2 = 0 
 ( 3) - [L Effusion]_Idurgrp_3 + [Bilateral]_Idurgrp_3 = 0 
 ( 4) - [L Effusion]_Idurgrp_4 + [Bilateral]_Idurgrp_4 = 0 
 
           chi2(  4) =   20.06 
         Prob > chi2 =    0.0005 
 
.  
. * 2 week prevalance 
.  
. xi: mlogit cat1 i.study i.trt xage gender xrace i.xoccup xpreab xuri1 
i.durgrp xhxdx i.season if week==2, baseoutcome(0) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -1746.2784 
Iteration 1:   log likelihood = -1677.9654 
Iteration 2:   log likelihood = -1676.1854 
Iteration 3:   log likelihood = -1676.1805 
Iteration 4:   log likelihood = -1676.1805 
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Multinomial logistic regression                   Number of obs   =      1278 
                                                  LR chi2(72)     =    140.20 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1676.1805                       Pseudo R2       =    0.0401 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Istudy_2 |  -.2666786   .3168154    -0.84   0.400   -.8876255    .3542682 
   _Istudy_3 |  -.3163391   .3268568    -0.97   0.333   -.9569667    .3242884 
     _Itrt_1 |  -.3516485    .270001    -1.30   0.193   -.8808407    .1775438 
        xage |  -.1436523   .2305428    -0.62   0.533    -.595508    .3082034 
      gender |  -.1139956   .2131241    -0.53   0.593   -.5317111      .30372 
       xrace |  -.2134859   .2559894    -0.83   0.404   -.7152158    .2882441 
  _Ixoccup_2 |  -.4677047   .2839918    -1.65   0.100   -1.024318     .088909 
  _Ixoccup_3 |   .2615856   .2476344     1.06   0.291   -.2237689      .74694 
  _Ixoccup_9 |   .4422744   .9494211     0.47   0.641   -1.418557    2.303105 
      xpreab |  -.2180859   .2472626    -0.88   0.378   -.7027116    .2665398 
       xuri1 |   .0202813   .2382512     0.09   0.932   -.4466824     .487245 
  _Idurgrp_2 |   .7943135   .3453359     2.30   0.021    .1174677    1.471159 
  _Idurgrp_3 |   .8910571   .3120621     2.86   0.004    .2794266    1.502688 
  _Idurgrp_4 |    .201098   .3135255     0.64   0.521   -.4134008    .8155967 
       xhxdx |  -.4727423   .3442505    -1.37   0.170   -1.147461    .2019763 
  _Iseason_2 |   .0701368   .2520713     0.28   0.781   -.4239138    .5641874 
  _Iseason_3 |   .1949751   .3155931     0.62   0.537   -.4235761    .8135262 
  _Iseason_4 |   .1714658   .3032769     0.57   0.572   -.4229461    .7658777 
       _cons |   .2211369   .4640584     0.48   0.634   -.6884009    1.130675 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Istudy_2 |  -.4086945   .3315987    -1.23   0.218   -1.058616    .2412269 
   _Istudy_3 |  -.2562349   .3336171    -0.77   0.442   -.9101124    .3976426 
     _Itrt_1 |  -.3701104   .2812888    -1.32   0.188   -.9214263    .1812055 
        xage |  -.0737871   .2389289    -0.31   0.757   -.5420792     .394505 
      gender |  -.2888404   .2200343    -1.31   0.189   -.7200997    .1424189 
       xrace |  -.1397552   .2658701    -0.53   0.599    -.660851    .3813407 
  _Ixoccup_2 |  -.5060425   .3027308    -1.67   0.095   -1.099384    .0872989 
  _Ixoccup_3 |   .3520906   .2568772     1.37   0.170   -.1513794    .8555605 
  _Ixoccup_9 |   .2731664   1.034307     0.26   0.792   -1.754039    2.300371 
      xpreab |  -.0688955   .2599732    -0.27   0.791   -.5784335    .4406426 
       xuri1 |  -.4288336   .2683466    -1.60   0.110   -.9547832     .097116 
  _Idurgrp_2 |   .6459045   .3551781     1.82   0.069   -.0502319    1.342041 
  _Idurgrp_3 |    .642293   .3240168     1.98   0.047    .0072318    1.277354 
  _Idurgrp_4 |   .2195487   .3198733     0.69   0.492   -.4073915    .8464889 
       xhxdx |  -.1655254   .3761734    -0.44   0.660   -.9028118    .5717609 
  _Iseason_2 |   .1658084   .2641657     0.63   0.530   -.3519468    .6835636 
  _Iseason_3 |   .3048027   .3272938     0.93   0.352   -.3366814    .9462868 
  _Iseason_4 |   .3109944   .3169119     0.98   0.326   -.3101415    .9321303 
       _cons |  -.0787156    .494065    -0.16   0.873   -1.047065     .889634 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Istudy_2 |   -.192361   .2443104    -0.79   0.431   -.6712006    .2864787 
   _Istudy_3 |  -.1579513    .249235    -0.63   0.526   -.6464428    .3305403 
     _Itrt_1 |  -.7303797   .2017792    -3.62   0.000    -1.12586   -.3348997 
        xage |  -.1689183    .175218    -0.96   0.335   -.5123392    .1745026 
      gender |  -.0620549   .1642723    -0.38   0.706   -.3840228    .2599129 
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       xrace |  -.1906943   .1974838    -0.97   0.334   -.5777553    .1963668 
  _Ixoccup_2 |   .0093937   .2024523     0.05   0.963   -.3874055    .4061928 
  _Ixoccup_3 |    .348516   .1956506     1.78   0.075   -.0349521    .7319841 
  _Ixoccup_9 |  -.8877551    .948797    -0.94   0.349   -2.747363    .9718528 
      xpreab |  -.0247227   .1919914    -0.13   0.898    -.401019    .3515736 
       xuri1 |   .2913974   .1811195     1.61   0.108   -.0635903    .6463851 
  _Idurgrp_2 |   .3659574   .2699976     1.36   0.175   -.1632281     .895143 
  _Idurgrp_3 |   1.081087   .2343069     4.61   0.000    .6218536     1.54032 
  _Idurgrp_4 |   .5429701   .2286121     2.38   0.018    .0948986    .9910416 
       xhxdx |  -.2696527    .281476    -0.96   0.338   -.8213355      .28203 
  _Iseason_2 |   .0969818   .1910517     0.51   0.612   -.2774726    .4714363 
  _Iseason_3 |  -.2287067   .2534924    -0.90   0.367   -.7255427    .2681292 
  _Iseason_4 |   .2233055   .2320258     0.96   0.336   -.2314567    .6780678 
       _cons |   1.024077   .3663569     2.80   0.005    .3060307    1.742123 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Istudy_2 |   .1470763   .3625824     0.41   0.685    -.563572    .8577247 
   _Istudy_3 |   -.312565    .395095    -0.79   0.429   -1.086937    .4618069 
     _Itrt_1 |  -.8479389   .3212027    -2.64   0.008   -1.477485   -.2183932 
        xage |    .076687   .2763242     0.28   0.781   -.4648986    .6182725 
      gender |  -.7612529   .2538164    -3.00   0.003   -1.258724   -.2637818 
       xrace |   -.025847   .2992943    -0.09   0.931    -.612453     .560759 
  _Ixoccup_2 |   .7147196   .3478763     2.05   0.040    .0328946    1.396545 
  _Ixoccup_3 |    1.06024   .3274765     3.24   0.001    .4183977    1.702082 
  _Ixoccup_9 |   1.281759   1.070631     1.20   0.231   -.8166396    3.380158 
      xpreab |  -.2446252   .2978151    -0.82   0.411   -.8283322    .3390817 
       xuri1 |  -.1142923   .2924275    -0.39   0.696   -.6874396    .4588551 
  _Idurgrp_2 |    .771939   .4920167     1.57   0.117   -.1923961    1.736274 
  _Idurgrp_3 |   1.530271   .4196545     3.65   0.000     .707763    2.352779 
  _Idurgrp_4 |   .9135816    .417099     2.19   0.029    .0960826    1.731081 
       xhxdx |  -.3557718   .4058132    -0.88   0.381   -1.151151    .4396076 
  _Iseason_2 |   .1457251   .3007787     0.48   0.628   -.4437904    .7352405 
  _Iseason_3 |  -.0308465    .398575    -0.08   0.938   -.8120392    .7503462 
  _Iseason_4 |   .0279763   .3731991     0.07   0.940   -.7034805    .7594332 
       _cons |  -1.245374   .5904962    -2.11   0.035   -2.402725   -.0880221 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Istudy*  
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =    4.80 
         Prob > chi2 =    0.7791 
 
. testparm _Itrt*  
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
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 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   15.58 
         Prob > chi2 =    0.0036 
 
. testparm xage 
 
 ( 1)  [R Effusion]xage = 0 
 ( 2)  [L Effusion]xage = 0 
 ( 3)  [Bilateral]xage = 0 
 ( 4)  [Missing]xage = 0 
 
           chi2(  4) =    1.68 
         Prob > chi2 =    0.7950 
 
. testparm gender  
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   11.39 
         Prob > chi2 =    0.0226 
 
. testparm xrace  
 
 ( 1)  [R Effusion]xrace = 0 
 ( 2)  [L Effusion]xrace = 0 
 ( 3)  [Bilateral]xrace = 0 
 ( 4)  [Missing]xrace = 0 
 
           chi2(  4) =    1.30 
         Prob > chi2 =    0.8608 
 
. testparm _Ixoccup*  
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =   25.47 
         Prob > chi2 =    0.0127 
 
. testparm xpreab  
 
 ( 1)  [R Effusion]xpreab = 0 
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 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    1.56 
         Prob > chi2 =    0.8163 
 
. testparm xuri1  
 
 ( 1)  [R Effusion]xuri1 = 0 
 ( 2)  [L Effusion]xuri1 = 0 
 ( 3)  [Bilateral]xuri1 = 0 
 ( 4)  [Missing]xuri1 = 0 
 
           chi2(  4) =   11.82 
         Prob > chi2 =    0.0187 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   37.32 
         Prob > chi2 =    0.0002 
 
. testparm xhxdx 
 
 ( 1)  [R Effusion]xhxdx = 0 
 ( 2)  [L Effusion]xhxdx = 0 
 ( 3)  [Bilateral]xhxdx = 0 
 ( 4)  [Missing]xhxdx = 0 
 
           chi2(  4) =    2.10 
         Prob > chi2 =    0.7174 
 
. testparm _Iseason*  
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
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 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =    7.27 
         Prob > chi2 =    0.8390 
 
.  
. xi: mlogit cat1 i.trt gender i.xoccup xuri1 i.durgrp if week==2, 
baseoutcome(0) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
 
Iteration 0:   log likelihood = -1765.6059 
Iteration 1:   log likelihood = -1708.0461 
Iteration 2:   log likelihood =  -1706.773 
Iteration 3:   log likelihood = -1706.7711 
Iteration 4:   log likelihood = -1706.7711 
 
Multinomial logistic regression                   Number of obs   =      1289 
                                                  LR chi2(36)     =    117.67 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1706.7711                       Pseudo R2       =    0.0333 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
     _Itrt_1 |  -.6031388   .2063041    -2.92   0.003   -1.007487   -.1987901 
      gender |  -.0917704    .209794    -0.44   0.662   -.5029591    .3194184 
  _Ixoccup_2 |  -.4884226   .2813728    -1.74   0.083   -1.039903    .0630579 
  _Ixoccup_3 |    .217727   .2308118     0.94   0.346   -.2346559    .6701098 
  _Ixoccup_9 |   .5142936   .9425162     0.55   0.585   -1.333004    2.361591 
       xuri1 |   .0293513   .2323613     0.13   0.899   -.4260685    .4847711 
  _Idurgrp_2 |   .6726568   .3334342     2.02   0.044    .0191377    1.326176 
  _Idurgrp_3 |   .8052972   .3026036     2.66   0.008    .2122051    1.398389 
  _Idurgrp_4 |   .2975909   .2954263     1.01   0.314   -.2814339    .8766157 
       _cons |  -.4196105   .3136685    -1.34   0.181   -1.034389    .1951684 
-------------+--------------------------------------------------------------- 
L Effusion   | 
     _Itrt_1 |  -.6212685   .2166741    -2.87   0.004    -1.045942   -.196595 
      gender |  -.2875832   .2176747    -1.32   0.186   -.7142178    .1390514 
  _Ixoccup_2 |   -.510772   .3006108    -1.70   0.089   -1.099958    .0784144 
  _Ixoccup_3 |   .2707202    .240702     1.12   0.261    -.201047    .7424875 
  _Ixoccup_9 |   .2991354   1.027285     0.29   0.771   -1.714307    2.312578 
       xuri1 |  -.4472464   .2641429    -1.69   0.090    -.964957    .0704643 
  _Idurgrp_2 |   .5732574   .3475399     1.65   0.099   -.1079084    1.254423 
  _Idurgrp_3 |   .6018009   .3175614     1.90   0.058    -.020608     1.22421 
  _Idurgrp_4 |   .2601769   .3037005     0.86   0.392   -.3350653     .855419 
       _cons |  -.2726923   .3197654    -0.85   0.394    -.899421    .3540364 
-------------+--------------------------------------------------------------- 
Bilateral    | 
     _Itrt_1 |  -.8713042   .1580383    -5.51   0.000   -1.181054   -.5615547 
      gender |  -.0834276   .1621589    -0.51   0.607   -.4012533    .2343981 
  _Ixoccup_2 |   .0018624   .2004758     0.01   0.993   -.3910629    .3947877 
  _Ixoccup_3 |   .2619508   .1831986     1.43   0.153   -.0971119    .6210135 
  _Ixoccup_9 |  -.5214347    .900103    -0.58   0.562   -2.285604    1.242735 
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       xuri1 |   .2954098   .1775371     1.66   0.096   -.0525566    .6433761 
  _Idurgrp_2 |   .3260269   .2632685     1.24   0.216   -.1899698    .8420236 
  _Idurgrp_3 |   1.065826   .2293075     4.65   0.000    .6163913     1.51526 
  _Idurgrp_4 |   .5963474   .2169385     2.75   0.006    .1711557    1.021539 
       _cons |   .6705327   .2388081     2.81   0.005    .2024774    1.138588 
-------------+--------------------------------------------------------------- 
Missing      | 
     _Itrt_1 |  -.8152927   .2544209    -3.20   0.001   -1.313948   -.3166369 
      gender |  -.7702711   .2482571    -3.10   0.002   -1.256846   -.2836961 
  _Ixoccup_2 |   .6795027   .3383971     2.01   0.045    .0162565    1.342749 
  _Ixoccup_3 |   1.064437   .3052617     3.49   0.000    .4661347    1.662739 
  _Ixoccup_9 |   1.204511   1.057181     1.14   0.255   -.8675254    3.276547 
       xuri1 |    -.00443    .280201    -0.02   0.987   -.5536138    .5447539 
  _Idurgrp_2 |   .5250913   .4725949     1.11   0.267   -.4011777     1.45136 
  _Idurgrp_3 |   1.354882   .3984125     3.40   0.001    .5740077    2.135756 
  _Idurgrp_4 |   .8898677   .3880606     2.29   0.022     .129283    1.650452 
       _cons |     -1.552   .4290825    -3.62   0.000   -2.392987    -.711014 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Itrt* 
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   31.10 
         Prob > chi2 =    0.0000 
 
. testparm gender  
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   11.80 
         Prob > chi2 =    0.0189 
 
. testparm _Ixoccup* 
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =   25.24 
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         Prob > chi2 =    0.0137 
 
. testparm xuri1  
 
 ( 1)  [R Effusion]xuri1 = 0 
 ( 2)  [L Effusion]xuri1 = 0 
 ( 3)  [Bilateral]xuri1 = 0 
 ( 4)  [Missing]xuri1 = 0 
 
           chi2(  4) =   12.14 
         Prob > chi2 =    0.0163 
 
. testparm _Idurgrp*  
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   35.80 
         Prob > chi2 =    0.0003 
 
.  
. mlogit, rrr 
 
Multinomial logistic regression                   Number of obs   =      1289 
                                                  LR chi2(36)     =    117.67 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1706.7711                       Pseudo R2       =    0.0333 
 
----------------------------------------------------------------------------- 
        cat1 |        RRR   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
     _Itrt_1 |   .5470917   .1128673    -2.92   0.003    .3651352    .8197219 
      gender |   .9123146   .1913982    -0.44   0.662    .6047385    1.376327 
  _Ixoccup_2 |   .6135935   .1726485    -1.74   0.083    .3534889    1.065088 
  _Ixoccup_3 |   1.243248   .2869562     0.94   0.346    .7908429    1.954452 
  _Ixoccup_9 |   1.672457   1.576317     0.55   0.585    .2636839    10.60782 
       xuri1 |   1.029786   .2392825     0.13   0.899    .6530716    1.623803 
  _Idurgrp_2 |   1.959436   .6533431     2.02   0.044    1.019322    3.766612 
  _Idurgrp_3 |   2.237361   .6770336     2.66   0.008    1.236401    4.048674 
  _Idurgrp_4 |   1.346611   .3978242     1.01   0.314    .7547008    2.402754 
-------------+--------------------------------------------------------------- 
L Effusion   | 
     _Itrt_1 |   .5372625   .1164109    -2.87   0.004    .3513607    .8215233 
      gender |   .7500742   .1632722    -1.32   0.186    .4895749    1.149183 
  _Ixoccup_2 |   .6000322   .1803762    -1.70   0.089    .3328849    1.081571 
  _Ixoccup_3 |   1.310908   .3155382     1.12   0.261     .817874    2.101156 
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  _Ixoccup_9 |   1.348692   1.385492     0.29   0.771    .1800885    10.10043 
       xuri1 |   .6393864   .1688894    -1.69   0.090    .3809996    1.073006 
  _Idurgrp_2 |   1.774036   .6165485     1.65   0.099    .8977098    3.505816 
  _Idurgrp_3 |   1.825403   .5796776     1.90   0.058    .9796029    3.401477 
  _Idurgrp_4 |   1.297159    .393948     0.86   0.392    .7152914     2.35236 
-------------+--------------------------------------------------------------- 
Bilateral    | 
     _Itrt_1 |   .4184055   .0661241    -5.51   0.000    .3069552    .5703217 
      gender |   .9199577   .1491794    -0.51   0.607    .6694805    1.264148 
  _Ixoccup_2 |   1.001864   .2008495     0.01   0.993    .6763376    1.484069 
  _Ixoccup_3 |   1.299463   .2380598     1.43   0.153    .9074545    1.860813 
  _Ixoccup_9 |   .5936682   .5343625    -0.58   0.562    .1017126    3.465077 
       xuri1 |   1.343677   .2385525     1.66   0.096    .9488006    1.902894 
  _Idurgrp_2 |   1.385453    .364746     1.24   0.216    .8269841    2.321059 
  _Idurgrp_3 |   2.903236   .6657337     4.65   0.000    1.852232    4.550605 
  _Idurgrp_4 |   1.815475   .3938465     2.75   0.006    1.186676    2.777466 
-------------+--------------------------------------------------------------- 
Missing      | 
     _Itrt_1 |   .4425098   .1125837    -3.20   0.001    .2687568    .7285952 
      gender |   .4628876   .1149151    -3.10   0.002    .2845501    .7529954 
  _Ixoccup_2 |   1.972896   .6676225     2.01   0.045    1.016389    3.829556 
  _Ixoccup_3 |   2.899205   .8850165     3.49   0.000    1.593822    5.273734 
  _Ixoccup_9 |   3.335126   3.525831     1.14   0.255    .4199896    26.48415 
       xuri1 |   .9955798   .2789625    -0.02   0.987    .5748686    1.724184 
  _Idurgrp_2 |   1.690613   .7989752     1.11   0.267    .6695311    4.268918 
  _Idurgrp_3 |   3.876303   1.544367     3.40   0.001    1.775368    8.463442 
  _Idurgrp_4 |   2.434808   .9448528     2.29   0.022    1.138012    5.209336 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. test ["R Effusion"="L Effusion"] 
 
 ( 1)  [R Effusion]_Itrt_1 - [L Effusion]_Itrt_1 = 0 
 ( 2)  [R Effusion]gender - [L Effusion]gender = 0 
 ( 3)  [R Effusion]_Ixoccup_2 - [L Effusion]_Ixoccup_2 = 0 
 ( 4)  [R Effusion]_Ixoccup_3 - [L Effusion]_Ixoccup_3 = 0 
 ( 5)  [R Effusion]_Ixoccup_9 - [L Effusion]_Ixoccup_9 = 0 
 ( 6)  [R Effusion]xuri1 - [L Effusion]xuri1 = 0 
 ( 7)  [R Effusion]_Idurgrp_2 - [L Effusion]_Idurgrp_2 = 0 
 ( 8)  [R Effusion]_Idurgrp_3 - [L Effusion]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 - [L Effusion]_Idurgrp_4 = 0 
 
           chi2(  9) =    4.43 
         Prob > chi2 =    0.8808 
 
.  
. * 4 week prevalance 
.  
. xi: mlogit cat1 i.study i.trt xage gender xrace i.xoccup xpreab xuri1 
i.durgrp xhxdx i.season if week==4, baseoutcome(0) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
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Iteration 0:   log likelihood =  -1798.418 
Iteration 1:   log likelihood = -1719.6928 
Iteration 2:   log likelihood = -1718.1626 
Iteration 3:   log likelihood = -1718.1594 
Iteration 4:   log likelihood = -1718.1594 
 
Multinomial logistic regression                   Number of obs   =      1278 
                                                  LR chi2(72)     =    160.52 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1718.1594                       Pseudo R2       =    0.0446 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|     95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Istudy_2 |   .1951617   .3062143     0.64   0.524   -.4050073    .7953307 
   _Istudy_3 |  -.7610933   .3413166    -2.23   0.026   -1.430062    -.092125 
     _Itrt_1 |   -.548281    .285136    -1.92   0.054   -1.107137    .0105753 
        xage |  -.3068702   .2374475    -1.29   0.196   -.7722587    .1585183 
      gender |  -.0812659   .2158054    -0.38   0.706   -.5042367    .3417049 
       xrace |   -.258948   .2578933    -1.00   0.315   -.7644096    .2465136 
  _Ixoccup_2 |  -.3221918   .2827519    -1.14   0.255   -.8763754    .2319918 
  _Ixoccup_3 |  -.0364199   .2453153    -0.15   0.882    -.517229    .4443892 
  _Ixoccup_9 |  -1.106282   1.142828    -0.97   0.333   -3.346183    1.133619 
      xpreab |   .0422876   .2464108     0.17   0.864   -.4406687    .5252439 
       xuri1 |   -.010055   .2375433    -0.04   0.966   -.4756314    .4555213 
  _Idurgrp_2 |   .2053585   .3383606     0.61   0.544   -.4578161    .8685331 
  _Idurgrp_3 |   .5220581   .3147353     1.66   0.097   -.0948117    1.138928 
  _Idurgrp_4 |   -.096572   .3199535    -0.30   0.763   -.7236693    .5305253 
       xhxdx |  -.2134335   .3258737    -0.65   0.512   -.8521343    .4252672 
  _Iseason_2 |   .0350658   .2493702     0.14   0.888   -.4536908    .5238224 
  _Iseason_3 |  -.2071401   .3144187    -0.66   0.510   -.8233893    .4091092 
  _Iseason_4 |  -.1318095   .3182243    -0.41   0.679   -.7555178    .4918987 
       _cons |  -.0892839   .4557021    -0.20   0.845   -.9824436    .8038757 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Istudy_2 |   .5560416   .3143087     1.77   0.077   -.0599922    1.172075 
   _Istudy_3 |   .3173566   .3154421     1.01   0.314   -.3008987    .9356118 
     _Itrt_1 |  -.3040333   .2597039    -1.17   0.242   -.8130436     .204977 
        xage |  -.0607895   .2284526    -0.27   0.790   -.5085485    .3869694 
      gender |  -.0516811   .2132771    -0.24   0.809   -.4696965    .3663343 
       xrace |  -.1439865   .2610353    -0.55   0.581   -.6556064    .3676333 
  _Ixoccup_2 |  -.7213614   .2904292    -2.48   0.013   -1.290592   -.1521307 
  _Ixoccup_3 |  -.1382339   .2413278    -0.57   0.567   -.6112277      .33476 
  _Ixoccup_9 |   .0033671    .903775     0.00   0.997   -1.767999    1.774733 
      xpreab |   .3128424    .248642     1.26   0.208   -.1744869    .8001717 
       xuri1 |   -.062667   .2415703    -0.26   0.795   -.5361362    .4108021 
  _Idurgrp_2 |  -.5555795   .3712449    -1.50   0.135   -1.283206    .1720472 
  _Idurgrp_3 |   .6503567   .2973743     2.19   0.029    .0675138      1.2332 
  _Idurgrp_4 |   .0450227   .3071523     0.15   0.883   -.5569848    .6470303 
       xhxdx |   .4720987   .4085883     1.16   0.248   -.3287196    1.272917 
  _Iseason_2 |   .0223646   .2473207     0.09   0.928   -.4623751    .5071043 
  _Iseason_3 |  -.1257183   .3055165    -0.41   0.681   -.7245196    .4730831 
  _Iseason_4 |   .0125948   .3150946     0.04   0.968   -.6049793    .6301689 
       _cons |   -1.34485   .5226188    -2.57   0.010   -2.369164   -.3205355 
-------------+--------------------------------------------------------------- 
Bilateral    | 
 85 
   _Istudy_2 |   .4420491   .2250553     1.96   0.050    .0009489    .8831493 
   _Istudy_3 |   .2279728   .2238416     1.02   0.308   -.2107487    .6666943 
     _Itrt_1 |  -.7080764   .1938629    -3.65   0.000   -1.088041   -.3281121 
        xage |  -.0233333   .1646464    -0.14   0.887   -.3460344    .2993677 
      gender |  -.2605757   .1524461    -1.71   0.087   -.5593646    .0382132 
       xrace |  -.0336177   .1818595    -0.18   0.853   -.3900558    .3228205 
  _Ixoccup_2 |   -.030945   .1928741    -0.16   0.873   -.4089714    .3470814 
  _Ixoccup_3 |   .0948915   .1796877     0.53   0.597     -.25729     .447073 
  _Ixoccup_9 |  -1.131758   .7893724    -1.43   0.152   -2.678899    .4153835 
      xpreab |   .0106409    .176443     0.06   0.952    -.335181    .3564628 
       xuri1 |   .2082541   .1679953     1.24   0.215   -.1210106    .5375188 
  _Idurgrp_2 |  -.0711794   .2513081    -0.28   0.777   -.5637343    .4213754 
  _Idurgrp_3 |   .9053314   .2264268     4.00   0.000    .4615429     1.34912 
  _Idurgrp_4 |   .3902808   .2208506     1.77   0.077   -.0425784    .8231399 
       xhxdx |  -.0352536    .239992    -0.15   0.883   -.5056293    .4351222 
  _Iseason_2 |  -.3066437   .1786813    -1.72   0.086   -.6568527    .0435653 
  _Iseason_3 |  -.9662009   .2375143    -4.07   0.000    -1.43172   -.5006813 
  _Iseason_4 |   .1034584   .2140859     0.48   0.629   -.3161423     .523059 
       _cons |   .6280943   .3334631     1.88   0.060   -.0254814     1.28167 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Istudy_2 |   .2974053   .3398492     0.88   0.382   -.3686869    .9634975 
   _Istudy_3 |  -.1131057   .3563445    -0.32   0.751   -.8115281    .5853167 
     _Itrt_1 |  -.5899203   .3099201    -1.90   0.057   -1.197353    .0175119 
        xage |   .2585245   .2540088     1.02   0.309   -.2393236    .7563725 
      gender |  -.8576556   .2331468    -3.68   0.000   -1.314615   -.4006962 
       xrace |   .2078907   .2726068     0.76   0.446   -.3264089    .7421903 
  _Ixoccup_2 |   .0476085   .3163709     0.15   0.880   -.5724671    .6676841 
  _Ixoccup_3 |    .263818    .284772     0.93   0.354   -.2943248    .8219608 
  _Ixoccup_9 |   .2434752   .9217532     0.26   0.792   -1.563128    2.050078 
      xpreab |  -.5269033   .2702844    -1.95   0.051   -1.056651    .0028444 
       xuri1 |   .0306737   .2625626     0.12   0.907   -.4839394    .5452869 
  _Idurgrp_2 |   .1197822   .4283175     0.28   0.780   -.7197047    .9592691 
  _Idurgrp_3 |   .9626344   .3669064     2.62   0.009     .243511    1.681758 
  _Idurgrp_4 |   .3822149   .3600921     1.06   0.288   -.3235527    1.087983 
       xhxdx |  -.1571468   .3412917    -0.46   0.645   -.8260662    .5117727 
  _Iseason_2 |  -.0774872   .2809064    -0.28   0.783   -.6280537    .4730792 
  _Iseason_3 |   -.293638    .350196    -0.84   0.402   -.9800095    .3927335 
  _Iseason_4 |   .0055277   .3417465     0.02   0.987   -.6642831    .6753386 
       _cons |  -.6194064   .4972471    -1.25   0.213   -1.593993    .3551799 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Istudy*  
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =   16.51 
         Prob > chi2 =    0.0356 
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. testparm _Itrt*  
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   14.30 
         Prob > chi2 =    0.0064 
 
. testparm xage 
 
 ( 1)  [R Effusion]xage = 0 
 ( 2)  [L Effusion]xage = 0 
 ( 3)  [Bilateral]xage = 0 
 ( 4)  [Missing]xage = 0 
 
           chi2(  4) =    3.80 
         Prob > chi2 =    0.4338 
 
. testparm gender  
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   15.22 
         Prob > chi2 =    0.0043 
 
. testparm xrace  
 
 ( 1)  [R Effusion]xrace = 0 
 ( 2)  [L Effusion]xrace = 0 
 ( 3)  [Bilateral]xrace = 0 
 ( 4)  [Missing]xrace = 0 
 
           chi2(  4) =    2.52 
         Prob > chi2 =    0.6415 
 
. testparm _Ixoccup*  
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =   13.05 
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         Prob > chi2 =    0.3654 
 
. testparm xpreab  
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    7.70 
         Prob > chi2 =    0.1034 
 
. testparm xuri1  
 
 ( 1)  [R Effusion]xuri1 = 0 
 ( 2)  [L Effusion]xuri1 = 0 
 ( 3)  [Bilateral]xuri1 = 0 
 ( 4)  [Missing]xuri1 = 0 
 
           chi2(  4) =    2.91 
         Prob > chi2 =    0.5730 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   34.12 
         Prob > chi2 =    0.0006 
 
. testparm xhxdx 
 
 ( 1)  [R Effusion]xhxdx = 0 
 ( 2)  [L Effusion]xhxdx = 0 
 ( 3)  [Bilateral]xhxdx = 0 
 ( 4)  [Missing]xhxdx = 0 
 
           chi2(  4) =    2.67 
         Prob > chi2 =    0.6142 
 
. testparm _Iseason*  
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
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 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =   26.60 
         Prob > chi2 =    0.0088 
 
.  
. xi: mlogit cat1 i.study i.trt gender xpreab i.durgrp i.season if week==4, 
baseoutcome(0) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -2033.5652 
Iteration 1:   log likelihood =  -1970.776 
Iteration 2:   log likelihood = -1970.1764 
Iteration 3:   log likelihood = -1970.1761 
 
Multinomial logistic regression                   Number of obs   =      1447 
                                                  LR chi2(44)     =    126.78 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1970.1761                       Pseudo R2       =    0.0312 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Istudy_2 |   .3204294   .2897053     1.11   0.269   -.2473826    .8882413 
   _Istudy_3 |  -.6339116   .3256641    -1.95   0.052   -1.272202    .0043784 
     _Itrt_1 |  -.5653623   .2799959    -2.02   0.043   -1.114144   -.0165804 
      gender |   -.053475   .2024629    -0.26   0.792    -.450295     .343345 
      xpreab |   .0324947   .2260265     0.14   0.886   -.4105092    .4754986 
  _Idurgrp_2 |   .3239877   .3153306     1.03   0.304   -.2940488    .9420243 
  _Idurgrp_3 |   .4911009   .2949424     1.67   0.096   -.0869755    1.069177 
  _Idurgrp_4 |   .1041938   .3005717     0.35   0.729   -.4849159    .6933035 
  _Iseason_2 |   .0533525   .2422445     0.22   0.826    -.421438     .528143 
  _Iseason_3 |  -.2461952   .2974723    -0.83   0.408   -.8292303    .3368398 
  _Iseason_4 |  -.0746118   .2829233    -0.26   0.792   -.6291313    .4799077 
       _cons |  -.7305878   .3584198    -2.04   0.042   -1.433078   -.0280979 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Istudy_2 |   .3682657   .2884373     1.28   0.202   -.1970609    .9335924 
   _Istudy_3 |   .1458801   .2856768     0.51   0.610   -.4140362    .7057963 
     _Itrt_1 |   -.274636   .2560479    -1.07   0.283   -.7764806    .2272086 
      gender |   .0048001   .1964401     0.02   0.981   -.3802154    .3898157 
      xpreab |   .3339904   .2230053     1.50   0.134    -.103092    .7710728 
  _Idurgrp_2 |  -.3561894   .3332918    -1.07   0.285   -1.009429    .2970505 
  _Idurgrp_3 |   .6704794   .2720631     2.46   0.014    .1372456    1.203713 
  _Idurgrp_4 |   .1303494   .2821896     0.46   0.644   -.4227321    .6834308 
  _Iseason_2 |   .0216623   .2348704     0.09   0.927   -.4386752    .4819999 
  _Iseason_3 |  -.1058932   .2818412    -0.38   0.707   -.6582917    .4465054 
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  _Iseason_4 |   .0399995   .2754321     0.15   0.885   -.4998375    .5798365 
       _cons |  -1.133116   .3532477    -3.21   0.001   -1.825469   -.4407632 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Istudy_2 |   .4012663    .211297     1.90   0.058   -.0128681    .8154008 
   _Istudy_3 |   .1838344   .2070339     0.89   0.375   -.2219445    .5896133 
     _Itrt_1 |  -.7298874   .1915311    -3.81   0.000   -1.105282   -.3544933 
      gender |  -.2246491   .1420977    -1.58   0.114   -.5031553    .0538572 
      xpreab |  -.0377255    .158605    -0.24   0.812   -.3485855    .2731345 
  _Idurgrp_2 |   .0930868   .2324927     0.40   0.689   -.3625906    .5487641 
  _Idurgrp_3 |   .9000117   .2085019     4.32   0.000    .4913555    1.308668 
  _Idurgrp_4 |   .4564431   .2064398     2.21   0.027    .0518285    .8610576 
  _Iseason_2 |  -.3182565   .1718704    -1.85   0.064   -.6551164    .0186033 
  _Iseason_3 |  -.9746243   .2204031    -4.42   0.000   -1.406606    -.542642 
  _Iseason_4 |   .0681364    .192727     0.35   0.724   -.3096015    .4458743 
       _cons |   .6700936    .250041     2.68   0.007    .1800222    1.160165 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Istudy_2 |   .2606257    .318916     0.82   0.414   -.3644382    .8856897 
   _Istudy_3 |  -.2516273    .329679    -0.76   0.445   -.8977861    .3945316 
     _Itrt_1 |  -.5315543   .3031693    -1.75   0.080   -1.125755    .0626465 
      gender |  -.7512688   .2154735    -3.49   0.000   -1.173589   -.3289484 
      xpreab |  -.4438642    .237903    -1.87   0.062   -.9101454    .0224171 
  _Idurgrp_2 |  -.0584642   .3952548    -0.15   0.882   -.8331493     .716221 
  _Idurgrp_3 |   .7675294   .3279405     2.34   0.019    .1247778    1.410281 
  _Idurgrp_4 |   .3152641   .3295921     0.96   0.339   -.3307246    .9612528 
  _Iseason_2 |  -.0457499   .2654894    -0.17   0.863   -.5660996    .4745997 
  _Iseason_3 |  -.2922473   .3209323    -0.91   0.362    -.921263    .3367684 
  _Iseason_4 |  -.0990324   .3091151    -0.32   0.749   -.7048867     .506822 
       _cons |   -.416881   .3791642    -1.10   0.272   -1.160029    .3262672 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Istudy*  
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =   15.12 
         Prob > chi2 =    0.0569 
 
. testparm _Itrt*  
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   15.74 
         Prob > chi2 =    0.0034 
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. testparm gender  
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   14.47 
         Prob > chi2 =    0.0059 
 
. testparm xpreab  
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    8.41 
         Prob > chi2 =    0.0776 
 
. testparm _Idurgrp*  
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   32.63 
         Prob > chi2 =    0.0011 
 
. testparm _Iseason*  
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =   31.61 
         Prob > chi2 =    0.0016 
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.  
. mlogit, rrr 
 
Multinomial logistic regression                   Number of obs   =      1447 
                                                  LR chi2(44)     =    126.78 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1970.1761                       Pseudo R2       =    0.0312 
 
----------------------------------------------------------------------------- 
        cat1 |        RRR   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Istudy_2 |   1.377719   .3991325     1.11   0.269    .7808419    2.430851 
   _Istudy_3 |   .5305126   .1727689    -1.95   0.052     .280214    1.004388 
     _Itrt_1 |   .5681543   .1590809    -2.02   0.043    .3281961    .9835563 
      gender |   .9479296   .1919206    -0.26   0.792    .6374401    1.409655 
      xpreab |   1.033028   .2334918     0.14   0.886    .6633124    1.608816 
  _Idurgrp_2 |    1.38263   .4359856     1.03   0.304    .7452401    2.565169 
  _Idurgrp_3 |   1.634114   .4819695     1.67   0.096    .9166995    2.912982 
  _Idurgrp_4 |   1.109816   .3335791     0.35   0.729     .615749    2.000313 
  _Iseason_2 |   1.054801   .2555198     0.22   0.826    .6561027     1.69578 
  _Iseason_3 |   .7817696   .2325548    -0.83   0.408     .436385    1.400515 
  _Iseason_4 |   .9281037   .2625822    -0.26   0.792    .5330547    1.615925 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Istudy_2 |   1.445226    .416857     1.28   0.202    .8211406     2.54363 
   _Istudy_3 |   1.157057   .3305445     0.51   0.610     .660977    2.025459 
     _Itrt_1 |   .7598486   .1945576    -1.07   0.283    .4600222    1.255092 
      gender |   1.004812   .1973853     0.02   0.981    .6837141    1.476709 
      xpreab |    1.39653   .3114336     1.50   0.134     .902044    2.162085 
  _Idurgrp_2 |     .70034   .2334176    -1.07   0.285    .3644269    1.345883 
  _Idurgrp_3 |   1.955174   .5319307     2.46   0.014     1.14711    3.332468 
  _Idurgrp_4 |   1.139226   .3214778     0.46   0.644    .6552541    1.980661 
  _Iseason_2 |   1.021899   .2400138     0.09   0.927    .6448902     1.61931 
  _Iseason_3 |   .8995207    .253522    -0.38   0.707     .517735    1.562841 
  _Iseason_4 |    1.04081   .2866725     0.15   0.885    .6066292    1.785746 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Istudy_2 |   1.493715   .3156175     1.90   0.058    .9872143    2.260081 
   _Istudy_3 |   1.201817   .2488168     0.89   0.375    .8009598    1.803291 
     _Itrt_1 |   .4819633    .092311    -3.81   0.000    .3311177    .7015288 
      gender |   .7987965   .1135071    -1.58   0.114    .6046199    1.055334 
      xpreab |   .9629772    .152733    -0.24   0.812    .7056855    1.314077 
  _Idurgrp_2 |   1.097557    .255174     0.40   0.689    .6958713    1.731112 
  _Idurgrp_3 |   2.459632   .5128378     4.32   0.000     1.63453     3.70124 
  _Idurgrp_4 |    1.57845   .3258548     2.21   0.027    1.053195    2.365661 
  _Iseason_2 |   .7274161   .1250213    -1.85   0.064    .5193816    1.018777 
  _Iseason_3 |   .3773341   .0831656    -4.42   0.000    .2449732    .5812106 
  _Iseason_4 |   1.070511   .2063164     0.35   0.724    .7337393    1.561855 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Istudy_2 |   1.297742   .4138707     0.82   0.414    .6945868    2.424656 
   _Istudy_3 |   .7775345   .2563368    -0.76   0.445    .4074708    1.483689 
     _Itrt_1 |   .5876908   .1781698    -1.75   0.080    .3244074     1.06465 
      gender |   .4717676   .1016534    -3.49   0.000     .309255    .7196801 
      xpreab |   .6415526   .1526273    -1.87   0.062    .4024657     1.02267 
  _Idurgrp_2 |    .943212   .3728091    -0.15   0.882    .4346782    2.046684 
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  _Idurgrp_3 |   2.154437   .7065272     2.34   0.019    1.132897    4.097107 
  _Idurgrp_4 |   1.370621    .451746     0.96   0.339     .718403    2.614971 
  _Iseason_2 |   .9552808   .2536169    -0.17   0.863    .5677355    1.607371 
  _Iseason_3 |   .7465839   .2396029    -0.91   0.362     .398016    1.400415 
  _Iseason_4 |   .9057134   .2799697    -0.32   0.749    .4941645    1.660007 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
.  
. test ["L Effusion"="R Effusion"] 
 
 ( 1) - [R Effusion]_Istudy_2 + [L Effusion]_Istudy_2 = 0 
 ( 2) - [R Effusion]_Istudy_3 + [L Effusion]_Istudy_3 = 0 
 ( 3) - [R Effusion]_Itrt_1 + [L Effusion]_Itrt_1 = 0 
 ( 4) - [R Effusion]gender + [L Effusion]gender = 0 
 ( 5) - [R Effusion]xpreab + [L Effusion]xpreab = 0 
 ( 6) - [R Effusion]_Idurgrp_2 + [L Effusion]_Idurgrp_2 = 0 
 ( 7) - [R Effusion]_Idurgrp_3 + [L Effusion]_Idurgrp_3 = 0 
 ( 8) - [R Effusion]_Idurgrp_4 + [L Effusion]_Idurgrp_4 = 0 
 ( 9) - [R Effusion]_Iseason_2 + [L Effusion]_Iseason_2 = 0 
 (10) - [R Effusion]_Iseason_3 + [L Effusion]_Iseason_3 = 0 
 (11) - [R Effusion]_Iseason_4 + [L Effusion]_Iseason_4 = 0 
 
           chi2( 11) =   18.24 
         Prob > chi2 =    0.0762 
 
.  
. * 0-2 week regression 
. xi: mlogit cat1 i.cat1p i.study i.trt xage gender i.xoccup xpreab xuri1 
i.durgrp xhxdx i.season /// 
> if week==2, baseoutcome(0)  
i.cat1p           _Icat1p_0-4         (naturally coded; _Icat1p_0 omitted) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
note: _Icat1p_1 dropped due to collinearity 
note: _Icat1p_4 dropped due to collinearity 
Iteration 0:   log likelihood = -1762.1827 
Iteration 1:   log likelihood = -1537.5732 
Iteration 2:   log likelihood = -1483.2296 
Iteration 3:   log likelihood =  -1479.113 
Iteration 4:   log likelihood =  -1479.105 
Iteration 5:   log likelihood =  -1479.105 
 
Multinomial logistic regression                   Number of obs   =      1286 
                                                  LR chi2(76)     =    566.16 
                                                  Prob > chi2     =    0.0000 
Log likelihood =  -1479.105                       Pseudo R2       =    0.1606 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Icat1p_2 |  -3.091649   .5122849    -6.04   0.000   -4.095709    -2.08759 
   _Icat1p_3 |  -1.413134   .2446118    -5.78   0.000   -1.892564   -.9337038 
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   _Istudy_2 |  -.3238264   .3326766    -0.97   0.330   -.9758606    .3282078 
   _Istudy_3 |  -.3476495   .3378664    -1.03   0.304   -1.009855    .3145564 
     _Itrt_1 |    -.28178   .2849347    -0.99   0.323   -.8402417    .2766817 
        xage |  -.1869932   .2399912    -0.78   0.436   -.6573673     .283381 
      gender |  -.1277665    .224583    -0.57   0.569    -.567941     .312408 
  _Ixoccup_2 |  -.5443306   .2998862    -1.82   0.070   -1.132097    .0434356 
  _Ixoccup_3 |   .0937043   .2496967     0.38   0.707   -.3956922    .5831008 
  _Ixoccup_9 |   .5783531   1.008537     0.57   0.566   -1.398343    2.555049 
      xpreab |  -.2319092   .2607808    -0.89   0.374   -.7430303    .2792118 
       xuri1 |   .0814888   .2499278     0.33   0.744   -.4083608    .5713384 
  _Idurgrp_2 |    .918852   .3667337     2.51   0.012    .2000672    1.637637 
  _Idurgrp_3 |   1.118998   .3346236     3.34   0.001    .4631482    1.774849 
  _Idurgrp_4 |   .3664098   .3335983     1.10   0.272   -.2874308     1.02025 
       xhxdx |  -.5877235   .3589794    -1.64   0.102    -1.29131    .1158632 
  _Iseason_2 |   .0070403   .2665801     0.03   0.979    -.515447    .5295276 
  _Iseason_3 |   .0458532    .329758     0.14   0.889   -.6004606     .692167 
  _Iseason_4 |   .1655286   .3157119     0.52   0.600   -.4532555    .7843126 
       _cons |   1.335876   .5123235     2.61   0.009    .3317398    2.340011 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Icat1p_2 |   3.567228   .7498237     4.76   0.000    2.097601    5.036856 
   _Icat1p_3 |   2.362657   .7409887     3.19   0.001    .9103461    3.814968 
   _Istudy_2 |  -.2716505   .3462544    -0.78   0.433   -.9502967    .4069957 
   _Istudy_3 |     -.0615   .3477672    -0.18   0.860   -.7431112    .6201111 
     _Itrt_1 |  -.5048956   .2942708    -1.72   0.086   -1.081656    .0718646 
        xage |  -.0571605   .2468351    -0.23   0.817   -.5409484    .4266273 
      gender |  -.2887381    .229365    -1.26   0.208   -.7382852     .160809 
  _Ixoccup_2 |  -.4108015   .3153065    -1.30   0.193   -1.028791    .2071879 
  _Ixoccup_3 |     .39989   .2570329     1.56   0.120   -.1038852    .9036651 
  _Ixoccup_9 |  -.1100874   1.086169    -0.10   0.919    -2.23894    2.018765 
      xpreab |  -.1446101   .2741305    -0.53   0.598    -.681896    .3926758 
       xuri1 |  -.3643427   .2782302    -1.31   0.190   -.9096638    .1809784 
  _Idurgrp_2 |   .5431039   .3717434     1.46   0.144   -.1854997    1.271707 
  _Idurgrp_3 |   .5395238   .3397585     1.59   0.112   -.1263906    1.205438 
  _Idurgrp_4 |   .2058679   .3366821     0.61   0.541   -.4540169    .8657527 
       xhxdx |  -.1642768   .3913225    -0.42   0.675   -.9312548    .6027012 
  _Iseason_2 |   .2096597   .2751864     0.76   0.446   -.3296957     .749015 
  _Iseason_3 |   .3460709   .3425005     1.01   0.312   -.3252178     1.01736 
  _Iseason_4 |   .2983292    .328818     0.91   0.364   -.3461423    .9428007 
       _cons |  -2.782093   .8846482    -3.14   0.002   -4.515972   -1.048215 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Icat1p_2 |   .0135859   .3430502     0.04   0.968   -.6587802    .6859519 
   _Icat1p_3 |   1.839287   .2682262     6.86   0.000    1.313573       2.365 
   _Istudy_2 |  -.1641133   .2518639    -0.65   0.515   -.6577576    .3295309 
   _Istudy_3 |  -.2085184   .2542674    -0.82   0.412   -.7068734    .2898365 
     _Itrt_1 |  -.7567701   .2088836    -3.62   0.000   -1.166174   -.3473658 
        xage |  -.1785835   .1794015    -1.00   0.320    -.530204     .173037 
      gender |  -.0035659   .1691146    -0.02   0.983   -.3350244    .3278925 
  _Ixoccup_2 |  -.0442819   .2100544    -0.21   0.833   -.4559809    .3674171 
  _Ixoccup_3 |    .224813   .1927345     1.17   0.243   -.1529397    .6025657 
  _Ixoccup_9 |  -.7798662    .987827    -0.79   0.430   -2.715971    1.156239 
      xpreab |   .0677697   .1974441     0.34   0.731   -.3192137     .454753 
       xuri1 |   .1206184   .1862066     0.65   0.517   -.2443398    .4855766 
  _Idurgrp_2 |   .2881116   .2808737     1.03   0.305   -.2623907    .8386139 
  _Idurgrp_3 |   .9207919   .2430027     3.79   0.000    .4445154    1.397068 
  _Idurgrp_4 |   .4271835   .2379389     1.80   0.073   -.0391681    .8935351 
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       xhxdx |  -.1791647    .286609    -0.63   0.532    -.740908    .3825785 
  _Iseason_2 |   .0761671   .1976465     0.39   0.700   -.3112128    .4635471 
  _Iseason_3 |  -.2677244   .2598567    -1.03   0.303   -.7770341    .2415854 
  _Iseason_4 |   .1715427   .2376294     0.72   0.470   -.2942025    .6372878 
       _cons |  -.4057563   .4442725    -0.91   0.361   -1.276514    .4650018 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Icat1p_2 |  -.0039921   .4023393    -0.01   0.992   -.7925627    .7845784 
   _Icat1p_3 |  -.1081183    .332719    -0.32   0.745   -.7602356     .543999 
   _Istudy_2 |   .1505917   .3623048     0.42   0.678   -.5595127    .8606961 
   _Istudy_3 |  -.2790215   .3876966    -0.72   0.472   -1.038893    .4808499 
     _Itrt_1 |  -.8217846   .3200116    -2.57   0.010   -1.448996   -.1945735 
        xage |   .1446808   .2668658     0.54   0.588   -.3783664    .6677281 
      gender |   -.782679   .2514989    -3.11   0.002   -1.275608   -.2897502 
  _Ixoccup_2 |   .7314016   .3433201     2.13   0.033    .0585066    1.404296 
  _Ixoccup_3 |   .9965457   .3114546     3.20   0.001     .386106    1.606985 
  _Ixoccup_9 |   1.207186   1.068909     1.13   0.259   -.8878361    3.302208 
      xpreab |  -.2990878   .2964256    -1.01   0.313   -.8800714    .2818958 
       xuri1 |  -.0609462    .286367    -0.21   0.831   -.6222151    .5003228 
  _Idurgrp_2 |   .6834427   .4822077     1.42   0.156   -.2616672    1.628552 
  _Idurgrp_3 |   1.481166   .4099627     3.61   0.000    .6776535    2.284678 
  _Idurgrp_4 |   .8638829   .4069985     2.12   0.034    .0661804    1.661585 
       xhxdx |  -.3542509   .3994781    -0.89   0.375   -1.137214    .4287117 
  _Iseason_2 |   .1538368   .2989305     0.51   0.607   -.4320562    .7397297 
  _Iseason_3 |   .0011961   .3888124     0.00   0.998   -.7608623    .7632544 
  _Iseason_4 |   .0637964    .366671     0.17   0.862   -.6548654    .7824583 
       _cons |  -1.114068   .6320335    -1.76   0.078   -2.352831     .124695 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Icat1p* 
 
 ( 1)  [R Effusion]_Icat1p_2 = 0 
 ( 2)  [L Effusion]_Icat1p_2 = 0 
 ( 3)  [Bilateral]_Icat1p_2 = 0 
 ( 4)  [Missing]_Icat1p_2 = 0 
 ( 5)  [R Effusion]_Icat1p_3 = 0 
 ( 6)  [L Effusion]_Icat1p_3 = 0 
 ( 7)  [Bilateral]_Icat1p_3 = 0 
 ( 8)  [Missing]_Icat1p_3 = 0 
 
           chi2(  8) =  335.85 
         Prob > chi2 =    0.0000 
 
. testparm _Istudy* 
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =    4.46 
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         Prob > chi2 =    0.8130 
 
. testparm _Itrt* 
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   15.15 
         Prob > chi2 =    0.0044 
 
. testparm xage 
 
 ( 1)  [R Effusion]xage = 0 
 ( 2)  [L Effusion]xage = 0 
 ( 3)  [Bilateral]xage = 0 
 ( 4)  [Missing]xage = 0 
 
           chi2(  4) =    2.55 
         Prob > chi2 =    0.6360 
 
. testparm gender 
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   13.15 
         Prob > chi2 =    0.0106 
 
. testparm _Ixoccup* 
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =   24.21 
         Prob > chi2 =    0.0190 
 
. testparm xpreab* 
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
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           chi2(  4) =    3.29 
         Prob > chi2 =    0.5110 
 
. testparm xuri1 
 
 ( 1)  [R Effusion]xuri1 = 0 
 ( 2)  [L Effusion]xuri1 = 0 
 ( 3)  [Bilateral]xuri1 = 0 
 ( 4)  [Missing]xuri1 = 0 
 
           chi2(  4) =    3.84 
         Prob > chi2 =    0.4280 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   30.51 
         Prob > chi2 =    0.0023 
 
. testparm xhxdx 
 
 ( 1)  [R Effusion]xhxdx = 0 
 ( 2)  [L Effusion]xhxdx = 0 
 ( 3)  [Bilateral]xhxdx = 0 
 ( 4)  [Missing]xhxdx = 0 
 
           chi2(  4) =    3.02 
         Prob > chi2 =    0.5537 
 
. testparm _Iseason* 
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =    6.07 
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         Prob > chi2 =    0.9125 
 
.  
. xi: mlogit cat1 i.cat1p i.trt gender i.xoccup i.durgrp if week==2, 
baseoutcome(0)  
i.cat1p           _Icat1p_0-4         (naturally coded; _Icat1p_0 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
 
note: _Icat1p_2 dropped due to collinearity 
note: _Icat1p_4 dropped due to collinearity 
Iteration 0:   log likelihood = -1969.5679 
Iteration 1:   log likelihood = -1733.3463 
Iteration 2:   log likelihood = -1674.3622 
Iteration 3:   log likelihood = -1669.2657 
Iteration 4:   log likelihood = -1669.2533 
Iteration 5:   log likelihood = -1669.2533 
 
Multinomial logistic regression                   Number of obs   =      1448 
                                                  LR chi2(40)     =    600.63 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1669.2533                       Pseudo R2       =    0.1525 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Icat1p_1 |   3.209223   .5044244     6.36   0.000     2.22057    4.197877 
   _Icat1p_3 |   1.876855   .4897517     3.83   0.000    .9169594    2.836751 
     _Itrt_1 |  -.5389933    .211031    -2.55   0.011   -.9526064   -.1253802 
      gender |  -.2051607   .2111177    -0.97   0.331   -.6189439    .2086224 
  _Ixoccup_2 |  -.4626786   .2837351    -1.63   0.103   -1.018789     .093432 
  _Ixoccup_3 |   .1344073   .2344131     0.57   0.566   -.3250339    .5938484 
  _Ixoccup_9 |   .9364645   .7446758     1.26   0.209   -.5230733    2.396002 
  _Idurgrp_2 |   .7511859   .3390763     2.22   0.027    .0866085    1.415763 
  _Idurgrp_3 |   1.064738   .3080126     3.46   0.001    .4610444    1.668432 
  _Idurgrp_4 |    .491136   .3001896     1.64   0.102   -.0972247    1.079497 
       _cons |  -2.685066   .5494036    -4.89   0.000   -3.761877   -1.608255 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Icat1p_1 |  -2.732991   .5038685    -5.42   0.000   -3.720556   -1.745427 
   _Icat1p_3 |   -1.15307   .2283029    -5.05   0.000   -1.600536   -.7056047 
     _Itrt_1 |  -.7180981    .216539    -3.32   0.001   -1.142507   -.2936895 
      gender |  -.3043876   .2126122    -1.43   0.152   -.7210998    .1123246 
  _Ixoccup_2 |  -.2906234    .292072    -1.00   0.320   -.8630739    .2818272 
  _Ixoccup_3 |   .3105628   .2388346     1.30   0.193   -.1575443    .7786699 
  _Ixoccup_9 |   .9269062   .7467481     1.24   0.215   -.5366931    2.390506 
  _Idurgrp_2 |   .3974794   .3415447     1.16   0.245   -.2719359    1.066895 
  _Idurgrp_3 |    .523926   .3075754     1.70   0.088   -.0789108    1.126763 
  _Idurgrp_4 |   .3301976   .2969062     1.11   0.266   -.2517279     .912123 
       _cons |   .5509157   .3303727     1.67   0.095    -.096603    1.198434 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Icat1p_1 |  -.0856942   .3197428    -0.27   0.789   -.7123785    .5409901 
   _Icat1p_3 |    1.84193   .2342932     7.86   0.000    1.382724    2.301137 
     _Itrt_1 |  -.9233898   .1580113    -5.84   0.000   -1.233086   -.6136933 
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      gender |  -.0354319   .1602126    -0.22   0.825   -.3494428    .2785791 
  _Ixoccup_2 |  -.0263115   .2009141    -0.13   0.896   -.4200958    .3674729 
  _Ixoccup_3 |   .1669297    .180977     0.92   0.356   -.1877786    .5216381 
  _Ixoccup_9 |   .5900157    .677356     0.87   0.384   -.7375777    1.917609 
  _Idurgrp_2 |   .4765016   .2595987     1.84   0.066   -.0323025    .9853056 
  _Idurgrp_3 |   .9833777    .227147     4.33   0.000    .5381779    1.428578 
  _Idurgrp_4 |   .5013901    .216711     2.31   0.021    .0766443    .9261358 
       _cons |  -.5793969   .3013995    -1.92   0.055   -1.170129    .0113352 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Icat1p_1 |  -.0654157   .3806498    -0.17   0.864   -.8114756    .6806443 
   _Icat1p_3 |  -.0674927   .3003521    -0.22   0.822    -.656172    .5211865 
     _Itrt_1 |  -.8073753   .2467513    -3.27   0.001   -1.290999   -.3237516 
      gender |  -.7267657   .2374155    -3.06   0.002   -1.192091   -.2614399 
  _Ixoccup_2 |   .7390479   .3293024     2.24   0.025    .0936271    1.384469 
  _Ixoccup_3 |   1.139851   .2922156     3.90   0.000    .5671193    1.712583 
  _Ixoccup_9 |   1.312396   .8628383     1.52   0.128   -.3787361    3.003528 
  _Idurgrp_2 |   .5352739   .4527959     1.18   0.237   -.3521898    1.422738 
  _Idurgrp_3 |   1.424968   .3806664     3.74   0.000    .6788761    2.171061 
  _Idurgrp_4 |   .9298691   .3746815     2.48   0.013    .1955069    1.664231 
       _cons |  -1.617493   .4559075    -3.55   0.000   -2.511056   -.7239312 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Icat1p* 
 
 ( 1)  [R Effusion]_Icat1p_1 = 0 
 ( 2)  [L Effusion]_Icat1p_1 = 0 
 ( 3)  [Bilateral]_Icat1p_1 = 0 
 ( 4)  [Missing]_Icat1p_1 = 0 
 ( 5)  [R Effusion]_Icat1p_3 = 0 
 ( 6)  [L Effusion]_Icat1p_3 = 0 
 ( 7)  [Bilateral]_Icat1p_3 = 0 
 ( 8)  [Missing]_Icat1p_3 = 0 
 
           chi2(  8) =  396.12 
         Prob > chi2 =    0.0000 
 
. testparm _Itrt* 
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =   35.45 
         Prob > chi2 =    0.0000 
 
. testparm gender 
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =   12.60 
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         Prob > chi2 =    0.0134 
 
. testparm _Ixoccup* 
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =   25.20 
         Prob > chi2 =    0.0139 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   29.95 
         Prob > chi2 =    0.0028 
 
.  
. * 2-4 week regression 
.  
. xi: mlogit cat1 i.cat1p i.study i.trt xage gender i.xoccup xpreab xuri1 
i.durgrp xhxdx i.season /// 
> if week==4, baseoutcome(0)  
i.cat1p           _Icat1p_0-4         (naturally coded; _Icat1p_0 omitted) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.xoccup          _Ixoccup_1-9        (naturally coded; _Ixoccup_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -1814.5434 
Iteration 1:   log likelihood = -1500.9165 
Iteration 2:   log likelihood = -1421.1014 
Iteration 3:   log likelihood = -1369.3757 
Iteration 4:   log likelihood = -1345.2005 
Iteration 5:   log likelihood = -1343.7113 
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Iteration 6:   log likelihood = -1343.4929 
Iteration 7:   log likelihood = -1343.4813 
Iteration 8:   log likelihood = -1343.4812 
Iteration 9:   log likelihood = -1343.4812 
 
Multinomial logistic regression                   Number of obs   =      1286 
                                                  LR chi2(84)     =    942.12 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1343.4812                       Pseudo R2       =    0.2596 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Icat1p_1 |   2.288146   .3112502     7.35   0.000    1.678106    2.898185 
   _Icat1p_2 |  -.1498757   .5395384    -0.28   0.781   -1.207351    .9076002 
   _Icat1p_3 |   1.550533   .3162887     4.90   0.000    .9306185    2.170447 
   _Icat1p_4 |    .987764   .7397527     1.34   0.182   -.4621248    2.437653 
   _Istudy_2 |   .3225392   .3248918     0.99   0.321   -.3142371    .9593154 
   _Istudy_3 |  -.7357696   .3608922    -2.04   0.041   -1.443105    -.028434 
     _Itrt_1 |  -.5159671   .3047631    -1.69   0.090   -1.113292    .0813577 
        xage |  -.2899996   .2481513    -1.17   0.243   -.7763673    .1963681 
      gender |   -.057505   .2305678    -0.25   0.803   -.5094096    .3943996 
  _Ixoccup_2 |  -.1979239    .304281    -0.65   0.515   -.7943037     .398456 
  _Ixoccup_3 |  -.1369444   .2518787    -0.54   0.587   -.6306177    .3567288 
  _Ixoccup_9 |  -1.315533   1.180781    -1.11   0.265   -3.629822    .9987563 
      xpreab |   .1587111   .2629193     0.60   0.546   -.3566013    .6740234 
       xuri1 |  -.1328421   .2531992    -0.52   0.600   -.6291035    .3634193 
  _Idurgrp_2 |   .0620224   .3632875     0.17   0.864    -.650008    .7740528 
  _Idurgrp_3 |   .2724687    .337183     0.81   0.419   -.3883978    .9333352 
  _Idurgrp_4 |  -.1878812   .3419935    -0.55   0.583   -.8581761    .4824138 
       xhxdx |    -.14192    .344351    -0.41   0.680   -.8168355    .5329955 
  _Iseason_2 |   .0132177   .2685544     0.05   0.961   -.5131392    .5395745 
  _Iseason_3 |  -.2884107   .3323442    -0.87   0.385   -.9397935     .362972 
  _Iseason_4 |  -.1311436   .3335596    -0.39   0.694   -.7849084    .5226213 
       _cons |  -1.366333   .5194085    -2.63   0.009   -2.384355   -.3483112 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Icat1p_1 |  -.0397517   .4459431    -0.09   0.929   -.9137841    .8342806 
   _Icat1p_2 |   2.332793    .316346     7.37   0.000    1.712766     2.95282 
   _Icat1p_3 |   1.745633   .2926938     5.96   0.000    1.171963    2.319302 
   _Icat1p_4 |  -.1502465   1.098755    -0.14   0.891   -2.303767    2.003274 
   _Istudy_2 |   .7214573   .3363497     2.14   0.032    .0622239    1.380691 
   _Istudy_3 |   .4800981   .3318384     1.45   0.148   -.1702931    1.130489 
     _Itrt_1 |  -.1436574   .2809098    -0.51   0.609   -.6942306    .4069157 
        xage |  -.0103309   .2407784    -0.04   0.966   -.4822479     .461586 
      gender |   .0338294   .2274263     0.15   0.882   -.4119181    .4795768 
  _Ixoccup_2 |  -.6262258   .3064443    -2.04   0.041   -1.226846   -.0256061 
  _Ixoccup_3 |  -.2698547   .2454375    -1.10   0.272   -.7509034     .211194 
  _Ixoccup_9 |   .0738135   .9919642     0.07   0.941   -1.870401    2.018028 
      xpreab |   .3309318   .2635978     1.26   0.209   -.1857103    .8475739 
       xuri1 |  -.0415228   .2565192    -0.16   0.871   -.5442913    .4612456 
  _Idurgrp_2 |  -.7128329   .3923623    -1.82   0.069   -1.481849    .0561832 
  _Idurgrp_3 |   .4875304   .3199054     1.52   0.128   -.1394726    1.114533 
  _Idurgrp_4 |  -.0658253   .3274445    -0.20   0.841   -.7076047    .5759541 
       xhxdx |    .510912   .4281914     1.19   0.233   -.3283276    1.350152 
  _Iseason_2 |  -.1106914   .2659062    -0.42   0.677    -.631858    .4104753 
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  _Iseason_3 |  -.3062549   .3262167    -0.94   0.348   -.9456279    .3331182 
  _Iseason_4 |  -.0116153   .3301493    -0.04   0.972    -.658696    .6354653 
       _cons |   -2.58981   .5837273    -4.44   0.000   -3.733895   -1.445726 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Icat1p_1 |   1.047359   .2928496     3.58   0.000     .473384    1.621333 
   _Icat1p_2 |    1.40061   .3032023     4.62   0.000     .806344    1.994875 
   _Icat1p_3 |   3.280354   .2356332    13.92   0.000    2.818521    3.742186 
   _Icat1p_4 |   1.920825   .5115963     3.75   0.000    .9181145    2.923535 
   _Istudy_2 |   .6497764   .2588621     2.51   0.012    .1424159    1.157137 
   _Istudy_3 |   .4029986   .2562192     1.57   0.116   -.0991817    .9051789 
     _Itrt_1 |  -.4774405   .2258545    -2.11   0.035   -.9201073   -.0347737 
        xage |   .1117674   .1881827     0.59   0.553   -.2570638    .4805986 
      gender |  -.3372479   .1761128    -1.91   0.055   -.6824225    .0079268 
  _Ixoccup_2 |  -.0894852   .2276562    -0.39   0.694   -.5356831    .3567126 
  _Ixoccup_3 |  -.0062195   .1975066    -0.03   0.975   -.3933254    .3808864 
  _Ixoccup_9 |  -.7423434   .8800361    -0.84   0.399   -2.467183    .9824957 
      xpreab |  -.0025114   .2025971    -0.01   0.990   -.3995944    .3945717 
       xuri1 |   .0249182   .1939424     0.13   0.898   -.3552019    .4050383 
  _Idurgrp_2 |  -.2176496   .2937891    -0.74   0.459   -.7934655    .3581664 
  _Idurgrp_3 |   .5468629   .2621033     2.09   0.037    .0331499    1.060576 
  _Idurgrp_4 |   .1415532   .2570176     0.55   0.582   -.3621919    .6452984 
       xhxdx |   .0393669   .2763091     0.14   0.887   -.5021889    .5809227 
  _Iseason_2 |  -.4765435   .2077472    -2.29   0.022   -.8837205   -.0693664 
  _Iseason_3 |  -1.094269   .2702837    -4.05   0.000   -1.624015   -.5645222 
  _Iseason_4 |   .0336318   .2471475     0.14   0.892   -.4507684     .518032 
       _cons |   -1.22861   .4169334    -2.95   0.003   -2.045784   -.4114351 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Icat1p_1 |   .6660998   .5782874     1.15   0.249   -.4673227    1.799522 
   _Icat1p_2 |   .9360831   .5870627     1.59   0.111   -.2145387    2.086705 
   _Icat1p_3 |   1.598806   .4657563     3.43   0.001    .6859404    2.511671 
   _Icat1p_4 |   5.298002   .5637875     9.40   0.000    4.192998    6.403005 
   _Istudy_2 |  -.0442759   .4497384    -0.10   0.922    -.925747    .8371952 
   _Istudy_3 |  -.1163372   .4700364    -0.25   0.805   -1.037592    .8049172 
     _Itrt_1 |   -.063007   .4065763    -0.15   0.877   -.8598818    .7338679 
        xage |   .4354618   .3234858     1.35   0.178   -.1985588    1.069482 
      gender |  -.7439679   .3024459    -2.46   0.014   -1.336751   -.1511848 
  _Ixoccup_2 |   -.615647   .4169964    -1.48   0.140   -1.432945     .201651 
  _Ixoccup_3 |  -.3661642    .356141    -1.03   0.304   -1.064188    .3318593 
  _Ixoccup_9 |  -.6209991   1.311372    -0.47   0.636   -3.191241    1.949242 
      xpreab |   -.835165   .3588664    -2.33   0.020    -1.53853   -.1317997 
       xuri1 |    .132896   .3423436     0.39   0.698    -.538085    .8038771 
  _Idurgrp_2 |  -.1085202   .5348923    -0.20   0.839    -1.15689    .9398494 
  _Idurgrp_3 |   .2593767    .467594     0.55   0.579   -.6570906    1.175844 
  _Idurgrp_4 |  -.2359329   .4634232    -0.51   0.611   -1.144226    .6723598 
       xhxdx |  -.1698088   .4406823    -0.39   0.700    -1.03353    .6939126 
  _Iseason_2 |   -.223143   .3705197    -0.60   0.547   -.9493483    .5030623 
  _Iseason_3 |  -.2110105   .4507144    -0.47   0.640   -1.094394    .6723735 
  _Iseason_4 |   .0995606   .4338464     0.23   0.818   -.7507626    .9498839 
       _cons |  -1.550166   .6998451    -2.22   0.027   -2.921837   -.1784945 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Icat1p* 
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 ( 1)  [R Effusion]_Icat1p_1 = 0 
 ( 2)  [L Effusion]_Icat1p_1 = 0 
 ( 3)  [Bilateral]_Icat1p_1 = 0 
 ( 4)  [Missing]_Icat1p_1 = 0 
 ( 5)  [R Effusion]_Icat1p_2 = 0 
 ( 6)  [L Effusion]_Icat1p_2 = 0 
 ( 7)  [Bilateral]_Icat1p_2 = 0 
 ( 8)  [Missing]_Icat1p_2 = 0 
 ( 9)  [R Effusion]_Icat1p_3 = 0 
 (10)  [L Effusion]_Icat1p_3 = 0 
 (11)  [Bilateral]_Icat1p_3 = 0 
 (12)  [Missing]_Icat1p_3 = 0 
 (13)  [R Effusion]_Icat1p_4 = 0 
 (14)  [L Effusion]_Icat1p_4 = 0 
 (15)  [Bilateral]_Icat1p_4 = 0 
 (16)  [Missing]_Icat1p_4 = 0 
 
           chi2( 16) =  668.34 
         Prob > chi2 =    0.0000 
 
. testparm _Istudy* 
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =   20.27 
         Prob > chi2 =    0.0094 
 
. testparm _Itrt* 
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =    6.30 
         Prob > chi2 =    0.1779 
 
. testparm xage 
 
 ( 1)  [R Effusion]xage = 0 
 ( 2)  [L Effusion]xage = 0 
 ( 3)  [Bilateral]xage = 0 
 ( 4)  [Missing]xage = 0 
 
           chi2(  4) =    4.82 
         Prob > chi2 =    0.3064 
 
. testparm gender 
 
 ( 1)  [R Effusion]gender = 0 
 103 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =    9.67 
         Prob > chi2 =    0.0463 
 
. testparm _Ixoccup* 
 
 ( 1)  [R Effusion]_Ixoccup_2 = 0 
 ( 2)  [L Effusion]_Ixoccup_2 = 0 
 ( 3)  [Bilateral]_Ixoccup_2 = 0 
 ( 4)  [Missing]_Ixoccup_2 = 0 
 ( 5)  [R Effusion]_Ixoccup_3 = 0 
 ( 6)  [L Effusion]_Ixoccup_3 = 0 
 ( 7)  [Bilateral]_Ixoccup_3 = 0 
 ( 8)  [Missing]_Ixoccup_3 = 0 
 ( 9)  [R Effusion]_Ixoccup_9 = 0 
 (10)  [L Effusion]_Ixoccup_9 = 0 
 (11)  [Bilateral]_Ixoccup_9 = 0 
 (12)  [Missing]_Ixoccup_9 = 0 
 
           chi2( 12) =    8.87 
         Prob > chi2 =    0.7140 
 
. testparm xpreab* 
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    9.41 
         Prob > chi2 =    0.0516 
 
. testparm xuri1 
 
 ( 1)  [R Effusion]xuri1 = 0 
 ( 2)  [L Effusion]xuri1 = 0 
 ( 3)  [Bilateral]xuri1 = 0 
 ( 4)  [Missing]xuri1 = 0 
 
           chi2(  4) =    0.68 
         Prob > chi2 =    0.9536 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
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 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   18.36 
         Prob > chi2 =    0.1053 
 
. testparm xhxdx 
 
 ( 1)  [R Effusion]xhxdx = 0 
 ( 2)  [L Effusion]xhxdx = 0 
 ( 3)  [Bilateral]xhxdx = 0 
 ( 4)  [Missing]xhxdx = 0 
 
           chi2(  4) =    2.26 
         Prob > chi2 =    0.6873 
 
. testparm _Iseason* 
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =   25.02 
         Prob > chi2 =    0.0147 
 
.  
. xi: mlogit cat1 i.cat1p i.study i.trt gender xpreab i.durgrp i.season /// 
> if week==4, baseoutcome(0)  
i.cat1p           _Icat1p_0-4         (naturally coded; _Icat1p_0 omitted) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.trt             _Itrt_0-1           (naturally coded; _Itrt_0 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -2033.5652 
Iteration 1:   log likelihood = -1689.4859 
Iteration 2:   log likelihood = -1592.7834 
Iteration 3:   log likelihood = -1548.6245 
Iteration 4:   log likelihood = -1518.9505 
Iteration 5:   log likelihood = -1515.0547 
Iteration 6:   log likelihood = -1514.2083 
Iteration 7:   log likelihood =    -1514.1 
Iteration 8:   log likelihood = -1514.0966 
Iteration 9:   log likelihood = -1514.0966 
 
Multinomial logistic regression                   Number of obs   =      1447 
                                                  LR chi2(60)     =   1038.94 
                                                  Prob > chi2     =    0.0000 
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Log likelihood = -1514.0966                       Pseudo R2       =    0.2554 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Icat1p_1 |   2.349943   .2990258     7.86   0.000    1.763863    2.936022 
   _Icat1p_2 |  -.0332155   .4985454    -0.07   0.947   -1.010347    .9439156 
   _Icat1p_3 |   1.561644   .3031183     5.15   0.000    .9675426    2.155744 
   _Icat1p_4 |   1.026793   .7333825     1.40   0.161   -.4106103    2.464196 
   _Istudy_2 |   .4078761   .3127889     1.30   0.192   -.2051789    1.020931 
   _Istudy_3 |  -.6185018   .3458133    -1.79   0.074   -1.296283    .0592799 
     _Itrt_1 |  -.4894066   .3019528    -1.62   0.105   -1.081223    .1024101 
      gender |  -.0678529   .2175112    -0.31   0.755    -.494167    .3584612 
      xpreab |   .1305204   .2418819     0.54   0.589   -.3435595    .6046003 
  _Idurgrp_2 |   .1194865   .3391043     0.35   0.725   -.5451457    .7841187 
  _Idurgrp_3 |   .2066771   .3170785     0.65   0.515   -.4147854    .8281397 
  _Idurgrp_4 |  -.0711004   .3242195    -0.22   0.826    -.706559    .5643583 
  _Iseason_2 |   .0212802   .2604504     0.08   0.935   -.4891933    .5317536 
  _Iseason_3 |  -.2044459   .3172216    -0.64   0.519   -.8261889    .4172971 
  _Iseason_4 |  -.2125607   .3029517    -0.70   0.483   -.8063351    .3812136 
       _cons |  -1.860587    .430654    -4.32   0.000   -2.704653    -1.01652 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Icat1p_1 |   -.187028   .4345216    -0.43   0.667   -1.038675    .6646187 
   _Icat1p_2 |   2.258533   .2898187     7.79   0.000    1.690499    2.826567 
   _Icat1p_3 |   1.638277   .2711368     6.04   0.000    1.106859    2.169696 
   _Icat1p_4 |  -.3162962     1.0923    -0.29   0.772   -2.457165    1.824572 
   _Istudy_2 |   .5692573    .310547     1.83   0.067   -.0394037    1.177918 
   _Istudy_3 |   .3156129   .3028151     1.04   0.297   -.2778938    .9091195 
     _Itrt_1 |  -.1140144    .276054    -0.41   0.680   -.6550702    .4270414 
      gender |   .0567206   .2100062     0.27   0.787    -.354884    .4683253 
      xpreab |   .3481582     .23551     1.48   0.139    -.113433    .8097493 
  _Idurgrp_2 |  -.5483059   .3557557    -1.54   0.123   -1.245574    .1489625 
  _Idurgrp_3 |   .5171038   .2925971     1.77   0.077   -.0563761    1.090584 
  _Idurgrp_4 |  -.0168018   .3001382    -0.06   0.955   -.6050618    .5714583 
  _Iseason_2 |  -.1207573   .2509226    -0.48   0.630   -.6125565     .371042 
  _Iseason_3 |  -.2360193   .3020982    -0.78   0.435   -.8281209    .3560823 
  _Iseason_4 |  -.0981538   .2914014    -0.34   0.736   -.6692901    .4729825 
       _cons |  -2.221479   .4187749    -5.30   0.000   -3.042263   -1.400695 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Icat1p_1 |   1.170552    .279826     4.18   0.000    .6221028    1.719001 
   _Icat1p_2 |   1.423294   .2879054     4.94   0.000      .85901    1.987579 
   _Icat1p_3 |   3.338708   .2270463    14.70   0.000    2.893705     3.78371 
   _Icat1p_4 |   1.967681   .5058517     3.89   0.000    .9762296    2.959132 
   _Istudy_2 |   .6058366   .2451726     2.47   0.013    .1253071    1.086366 
   _Istudy_3 |   .3500485   .2400893     1.46   0.145    -.120518    .8206149 
     _Itrt_1 |  -.4679239   .2235191    -2.09   0.036   -.9060132   -.0298345 
      gender |  -.3196497   .1648646    -1.94   0.053   -.6427785    .0034791 
      xpreab |  -.0585738     .18258    -0.32   0.748    -.416424    .2992764 
  _Idurgrp_2 |  -.1055591   .2720952    -0.39   0.698   -.6388558    .4277376 
  _Idurgrp_3 |   .5112517   .2430423     2.10   0.035    .0348976    .9876058 
  _Idurgrp_4 |   .1528332   .2417044     0.63   0.527   -.3208988    .6265652 
  _Iseason_2 |  -.4803751   .2002225    -2.40   0.016    -.872804   -.0879462 
  _Iseason_3 |  -.9748663   .2538136    -3.84   0.000   -1.472332   -.4774007 
  _Iseason_4 |  -.0917672   .2224969    -0.41   0.680   -.5278532    .3443188 
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       _cons |  -1.192402   .3317557    -3.59   0.000   -1.842631   -.5421725 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Icat1p_1 |   .5983444   .5577694     1.07   0.283   -.4948636    1.691552 
   _Icat1p_2 |    .940097   .5417407     1.74   0.083   -.1216953    2.001889 
   _Icat1p_3 |   1.456276   .4393617     3.31   0.001     .595143    2.317409 
   _Icat1p_4 |   5.272293    .533648     9.88   0.000    4.226363    6.318224 
   _Istudy_2 |   -.119238   .4301379    -0.28   0.782   -.9622928    .7238168 
   _Istudy_3 |  -.2719842    .449607    -0.60   0.545   -1.153198    .6092293 
     _Itrt_1 |  -.0821821   .4085096    -0.20   0.841   -.8828462     .718482 
      gender |  -.6177598   .2870602    -2.15   0.031   -1.180387   -.0551322 
      xpreab |  -.6239173   .3227849    -1.93   0.053   -1.256564    .0087295 
  _Idurgrp_2 |  -.3608199   .5077002    -0.71   0.477   -1.355894    .6342541 
  _Idurgrp_3 |   .0809435   .4320736     0.19   0.851   -.7659052    .9277923 
  _Idurgrp_4 |  -.2591885   .4373931    -0.59   0.553   -1.116463    .5980863 
  _Iseason_2 |  -.2341736   .3589195    -0.65   0.514    -.937643    .4692957 
  _Iseason_3 |  -.2979656   .4332548    -0.69   0.492   -1.147129    .5511983 
  _Iseason_4 |  -.1104768   .3993371    -0.28   0.782   -.8931632    .6722095 
       _cons |  -1.710224   .5685727    -3.01   0.003   -2.824606   -.5958422 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Icat1p* 
 
 ( 1)  [R Effusion]_Icat1p_1 = 0 
 ( 2)  [L Effusion]_Icat1p_1 = 0 
 ( 3)  [Bilateral]_Icat1p_1 = 0 
 ( 4)  [Missing]_Icat1p_1 = 0 
 ( 5)  [R Effusion]_Icat1p_2 = 0 
 ( 6)  [L Effusion]_Icat1p_2 = 0 
 ( 7)  [Bilateral]_Icat1p_2 = 0 
 ( 8)  [Missing]_Icat1p_2 = 0 
 ( 9)  [R Effusion]_Icat1p_3 = 0 
 (10)  [L Effusion]_Icat1p_3 = 0 
 (11)  [Bilateral]_Icat1p_3 = 0 
 (12)  [Missing]_Icat1p_3 = 0 
 (13)  [R Effusion]_Icat1p_4 = 0 
 (14)  [L Effusion]_Icat1p_4 = 0 
 (15)  [Bilateral]_Icat1p_4 = 0 
 (16)  [Missing]_Icat1p_4 = 0 
 
           chi2( 16) =  783.60 
         Prob > chi2 =    0.0000 
 
. testparm _Istudy* 
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =   18.57 
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         Prob > chi2 =    0.0173 
 
. testparm _Itrt* 
 
 ( 1)  [R Effusion]_Itrt_1 = 0 
 ( 2)  [L Effusion]_Itrt_1 = 0 
 ( 3)  [Bilateral]_Itrt_1 = 0 
 ( 4)  [Missing]_Itrt_1 = 0 
 
           chi2(  4) =    6.10 
         Prob > chi2 =    0.1921 
 
. testparm gender 
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =    8.87 
         Prob > chi2 =    0.0645 
 
. testparm xpreab* 
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    8.54 
         Prob > chi2 =    0.0737 
 
. testparm _Idurgrp* 
 
 ( 1)  [R Effusion]_Idurgrp_2 = 0 
 ( 2)  [L Effusion]_Idurgrp_2 = 0 
 ( 3)  [Bilateral]_Idurgrp_2 = 0 
 ( 4)  [Missing]_Idurgrp_2 = 0 
 ( 5)  [R Effusion]_Idurgrp_3 = 0 
 ( 6)  [L Effusion]_Idurgrp_3 = 0 
 ( 7)  [Bilateral]_Idurgrp_3 = 0 
 ( 8)  [Missing]_Idurgrp_3 = 0 
 ( 9)  [R Effusion]_Idurgrp_4 = 0 
 (10)  [L Effusion]_Idurgrp_4 = 0 
 (11)  [Bilateral]_Idurgrp_4 = 0 
 (12)  [Missing]_Idurgrp_4 = 0 
 
           chi2( 12) =   17.01 
         Prob > chi2 =    0.1491 
 
. testparm _Iseason* 
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
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 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =   23.30 
         Prob > chi2 =    0.0253 
 
.xi: mlogit cat1 i.cat1p i.study xage gender xpreab i.durgrp i.season /// 
> if week==4, baseoutcome(0)  
i.cat1p           _Icat1p_0-4         (naturally coded; _Icat1p_0 omitted) 
i.study           _Istudy_1-3         (naturally coded; _Istudy_1 omitted) 
i.durgrp          _Idurgrp_1-4        (naturally coded; _Idurgrp_1 omitted) 
i.season          _Iseason_1-4        (naturally coded; _Iseason_1 omitted) 
 
Iteration 0:   log likelihood = -2033.5652 
Iteration 1:   log likelihood =   -1689.74 
Iteration 2:   log likelihood = -1593.1771 
Iteration 3:   log likelihood = -1549.5486 
Iteration 4:   log likelihood = -1519.4673 
Iteration 5:   log likelihood = -1515.4733 
Iteration 6:   log likelihood = -1514.6068 
Iteration 7:   log likelihood = -1514.4949 
Iteration 8:   log likelihood = -1514.4913 
Iteration 9:   log likelihood = -1514.4913 
 
Multinomial logistic regression                   Number of obs   =      1447 
                                                  LR chi2(60)     =   1038.15 
                                                  Prob > chi2     =    0.0000 
Log likelihood = -1514.4913                       Pseudo R2       =    0.2553 
 
----------------------------------------------------------------------------- 
        cat1 |      Coef.   Std. Err.      z    P>|z|    [95% Conf. Interval] 
-------------+--------------------------------------------------------------- 
R Effusion   | 
   _Icat1p_1 |   2.368623    .298807     7.93   0.000    1.782972    2.954274 
   _Icat1p_2 |  -.0053832   .4984058    -0.01   0.991   -.9822407    .9714743 
   _Icat1p_3 |   1.592778   .3024302     5.27   0.000    1.000025     2.18553 
   _Icat1p_4 |   1.070592   .7325532     1.46   0.144   -.3651859     2.50637 
   _Istudy_2 |   .0787384   .2348973     0.34   0.737   -.3816519    .5391287 
   _Istudy_3 |  -.9005529   .3138897    -2.87   0.004   -1.515765   -.2853404 
        xage |   -.301118   .2370292    -1.27   0.204   -.7656868    .1634507 
      gender |  -.0539218   .2178761    -0.25   0.805   -.4809511    .3731075 
      xpreab |   .1472656   .2422429     0.61   0.543   -.3275217    .6220528 
  _Idurgrp_2 |   .0860492   .3389239     0.25   0.800   -.5782295    .7503279 
  _Idurgrp_3 |   .1456515   .3180196     0.46   0.647   -.4776554    .7689584 
  _Idurgrp_4 |  -.1480511   .3253231    -0.46   0.649   -.7856727    .4895704 
  _Iseason_2 |   .0128645   .2601749     0.05   0.961   -.4970689    .5227978 
  _Iseason_3 |  -.2185165   .3168047    -0.69   0.490   -.8394424    .4024094 
  _Iseason_4 |  -.2190234   .3028582    -0.72   0.470   -.8126145    .3745678 
       _cons |  -1.760977    .433575    -4.06   0.000   -2.610768   -.9111852 
-------------+--------------------------------------------------------------- 
L Effusion   | 
   _Icat1p_1 |  -.1864645   .4343755    -0.43   0.668   -1.037825    .6648959 
 109 
   _Icat1p_2 |   2.261833   .2892583     7.82   0.000    1.694898    2.828769 
   _Icat1p_3 |   1.637469   .2703773     6.06   0.000     1.10754    2.167399 
   _Icat1p_4 |  -.3076539   1.092057    -0.28   0.778   -2.448046    1.832738 
   _Istudy_2 |   .4883885   .2368908     2.06   0.039    .0240911     .952686 
   _Istudy_3 |   .2347662   .2650381     0.89   0.376   -.2846989    .7542313 
        xage |  -.1981233   .2267353    -0.87   0.382   -.6425163    .2462697 
      gender |   .0552331   .2099052     0.26   0.792   -.3561735    .4666396 
      xpreab |     .36658    .236305     1.55   0.121   -.0965692    .8297293 
  _Idurgrp_2 |   -.575457   .3569811    -1.61   0.107   -1.275127    .1242132 
  _Idurgrp_3 |   .4807646   .2945192     1.63   0.103   -.0964824    1.058012 
  _Idurgrp_4 |  -.0613362   .3031316    -0.20   0.840   -.6554632    .5327907 
  _Iseason_2 |  -.1032537   .2518917    -0.41   0.682   -.5969524    .3904449 
  _Iseason_3 |  -.2325702   .3024779    -0.77   0.442   -.8254159    .3602756 
  _Iseason_4 |  -.0938249   .2915356    -0.32   0.748   -.6652241    .4775744 
       _cons |  -2.148777   .4239244    -5.07   0.000   -2.979653     -1.3179 
-------------+--------------------------------------------------------------- 
Bilateral    | 
   _Icat1p_1 |   1.193787   .2791339     4.28   0.000    .6466941    1.740879 
   _Icat1p_2 |   1.449235   .2877659     5.04   0.000    .8852247    2.013246 
   _Icat1p_3 |   3.378048   .2267198    14.90   0.000    2.933686    3.822411 
   _Icat1p_4 |   2.021219   .5042094     4.01   0.000    1.032987    3.009451 
   _Istudy_2 |   .2817901   .1872478     1.50   0.132   -.0852089    .6487891 
   _Istudy_3 |   .1180993   .2106875     0.56   0.575   -.2948405    .5310391 
        xage |   .0874295    .177537     0.49   0.622   -.2605366    .4353955 
      gender |  -.3236468   .1647806    -1.96   0.050   -.6466109   -.0006827 
      xpreab |  -.0888231   .1835628    -0.48   0.628   -.4485996    .2709533 
  _Idurgrp_2 |  -.1014669   .2727452    -0.37   0.710   -.6360376    .4331038 
  _Idurgrp_3 |   .5190673   .2446265     2.12   0.034    .0396082    .9985264 
  _Idurgrp_4 |   .1621039   .2441855     0.66   0.507   -.3164908    .6406987 
  _Iseason_2 |  -.4966469   .1998848    -2.48   0.013   -.8884139   -.1048799 
  _Iseason_3 |  -.9901613   .2538968    -3.90   0.000    -1.48779   -.4925328 
  _Iseason_4 |  -.0872239    .222462    -0.39   0.695   -.5232415    .3487937 
       _cons |  -1.229651   .3375827    -3.64   0.000   -1.891301    -.568001 
-------------+--------------------------------------------------------------- 
Missing      | 
   _Icat1p_1 |   .5919823   .5577892     1.06   0.289   -.5012645    1.685229 
   _Icat1p_2 |   .9292975    .542082     1.71   0.086   -.1331636    1.991759 
   _Icat1p_3 |   1.461075   .4382597     3.33   0.001    .6021019    2.320048 
   _Icat1p_4 |    5.26634   .5323215     9.89   0.000    4.223009    6.309671 
   _Istudy_2 |  -.2026391    .329631    -0.61   0.539   -.8487041    .4434258 
   _Istudy_3 |  -.3048928   .3952816    -0.77   0.441   -1.079631    .4698449 
        xage |    .295155   .3081298     0.96   0.338   -.3087683    .8990784 
      gender |   -.615353   .2870371    -2.14   0.032   -1.177935   -.0527705 
      xpreab |  -.6659993   .3269659    -2.04   0.042   -1.306841   -.0251579 
  _Idurgrp_2 |  -.3076001   .5107884    -0.60   0.547   -1.308727    .6935267 
  _Idurgrp_3 |   .1319428    .438083     0.30   0.763   -.7266841    .9905698 
  _Idurgrp_4 |  -.2026095   .4429051    -0.46   0.647   -1.070688    .6654686 
  _Iseason_2 |  -.2399404   .3581509    -0.67   0.503   -.9419033    .4620226 
  _Iseason_3 |   -.311406   .4348247    -0.72   0.474   -1.163647    .5408348 
  _Iseason_4 |  -.1132277   .4005313    -0.28   0.777   -.8982546    .6717991 
       _cons |  -1.816873   .5843497    -3.11   0.002   -2.962178    -.671569 
----------------------------------------------------------------------------- 
(cat1==No Effusion is the base outcome) 
 
.  
. testparm _Icat1p* 
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 ( 1)  [R Effusion]_Icat1p_1 = 0 
 ( 2)  [L Effusion]_Icat1p_1 = 0 
 ( 3)  [Bilateral]_Icat1p_1 = 0 
 ( 4)  [Missing]_Icat1p_1 = 0 
 ( 5)  [R Effusion]_Icat1p_2 = 0 
 ( 6)  [L Effusion]_Icat1p_2 = 0 
 ( 7)  [Bilateral]_Icat1p_2 = 0 
 ( 8)  [Missing]_Icat1p_2 = 0 
 ( 9)  [R Effusion]_Icat1p_3 = 0 
 (10)  [L Effusion]_Icat1p_3 = 0 
 (11)  [Bilateral]_Icat1p_3 = 0 
 (12)  [Missing]_Icat1p_3 = 0 
 (13)  [R Effusion]_Icat1p_4 = 0 
 (14)  [L Effusion]_Icat1p_4 = 0 
 (15)  [Bilateral]_Icat1p_4 = 0 
 (16)  [Missing]_Icat1p_4 = 0 
 
           chi2( 16) =  790.37 
         Prob > chi2 =    0.0000 
 
. testparm _Istudy* 
 
 ( 1)  [R Effusion]_Istudy_2 = 0 
 ( 2)  [L Effusion]_Istudy_2 = 0 
 ( 3)  [Bilateral]_Istudy_2 = 0 
 ( 4)  [Missing]_Istudy_2 = 0 
 ( 5)  [R Effusion]_Istudy_3 = 0 
 ( 6)  [L Effusion]_Istudy_3 = 0 
 ( 7)  [Bilateral]_Istudy_3 = 0 
 ( 8)  [Missing]_Istudy_3 = 0 
 
           chi2(  8) =   18.46 
         Prob > chi2 =    0.0180 
 
. testparm gender 
 
 ( 1)  [R Effusion]gender = 0 
 ( 2)  [L Effusion]gender = 0 
 ( 3)  [Bilateral]gender = 0 
 ( 4)  [Missing]gender = 0 
 
           chi2(  4) =    9.02 
         Prob > chi2 =    0.0607 
 
. testparm xpreab* 
 
 ( 1)  [R Effusion]xpreab = 0 
 ( 2)  [L Effusion]xpreab = 0 
 ( 3)  [Bilateral]xpreab = 0 
 ( 4)  [Missing]xpreab = 0 
 
           chi2(  4) =    9.83 
         Prob > chi2 =    0.0433 
 
. testparm _Iseason* 
 
 ( 1)  [R Effusion]_Iseason_2 = 0 
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 ( 2)  [L Effusion]_Iseason_2 = 0 
 ( 3)  [Bilateral]_Iseason_2 = 0 
 ( 4)  [Missing]_Iseason_2 = 0 
 ( 5)  [R Effusion]_Iseason_3 = 0 
 ( 6)  [L Effusion]_Iseason_3 = 0 
 ( 7)  [Bilateral]_Iseason_3 = 0 
 ( 8)  [Missing]_Iseason_3 = 0 
 ( 9)  [R Effusion]_Iseason_4 = 0 
 (10)  [L Effusion]_Iseason_4 = 0 
 (11)  [Bilateral]_Iseason_4 = 0 
 (12)  [Missing]_Iseason_4 = 0 
 
           chi2( 12) =   24.35 
         Prob > chi2 =    0.0182 
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